Note: Descriptions are shown in the official language in which they were submitted.
IP190597
ANTI-CD73-ANTI-PD-1 BISPECIFIC ANTIBODY AND USE
THEREOF
TECHNICAL FIELD
The present invention relates to the fields of tumor treatment and molecular
immunology, and particularly to an anti-CD73/anti-PD-1 bispecific antibody, a
pharmaceutical composition thereof, and use thereof
BACKGROUND
Ecto-5'-nucleotidase, namely CD73 protein, is a multifunctional glycoprotein
encoded by NT5E gene and having a molecular weight of 70 KD, which is
anchored on a cell membrane by glyocsyl phosphatidy linositol (GPI)
(Zimmermann H., 5'-Nucleotidase: molecular structure and functional aspects.,
Biocheml, 1992; 285:345-365).
CD73 is widely distributed on the surface of human tissue cells, and it has
been
found in research that CD73 is highly expressed in various solid tumors,
specifically in cancer cells, dendritic cells, regulatory T cells (Tregs),
natural
killer cells (NK cells), myeloid-derived suppressor cells (MDSCs),
tumor-associated macrophages (TAMs) and the like in a tumor micro
environment. The expression of CD73 is regulated by TGF-p, EGFR, AKT,
r3-catenin and other molecules, especially HIF-1, which exerts the function of
a
transcription factor, is the most critical. An important feature of the tumor
microenvironment is hypoxia, which induces the up-regulation of
hypoxia-inducible factor-1 (HIF-1) and other molecules, thereby leading to the
widespread expression of CD73 in the tumor micro environment (Synnestvedt
K, et al., Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-
1
mediates permeability changes in intestinal epithelia. J Clin Invest., 2002;
110:993-1002.). Analysis of clinical tumor samples has shown that high
expression of CD73 is a potential biomarker and is closely related to adverse
prognosis of various types of tumors, including breast cancer, lung cancer,
ovarian cancer, kidney cancer, gastric cancer, head and neck cancer and the
1
CA 03176321 2022- 10- 20
IP190597
like.
CD73 has hydrolase activity and non-hydrolase activity. The enzyme and
non-enzyme functions of CD73 simultaneously work in the related process in
tumors, and mutually promote and maintain the progression of tumors. More
and more studies have found that CD73 is a key regulatory molecule for tumor
cell proliferation, metastasis and invasion in vitro, and tumor angiogenesis
and
tumor immune escape mechanism in vivo, wherein an important mechanism of
immune suppression is mediated by CD73-adenosine metabolic signaling
pathway. CD39 at the upstream of CD73 can catalyze ATP to generate
adenosine monophosphate (AMP), the generated AMP is converted into
adenosine by CD73, and adenosine binds to a downstream adenosine receptor
(A2AR). A2AR inhibits a series of signaling pathways related to immune
activation, such as LCK, MAPK, PKC, and inhibits the immune killing effect
of T cells by activating protein kinase A (PKA) and Csk kinase, thereby
playing an immune suppression role to enable the tumor to achieve immune
escape (Antonioli L, et al., Immunity, inflammation and cancer: a leading role
for adenosine. Nat Rev Cancer., 2013; 13:842-857). Preclinical animal model
studies have shown that CD73 expressed in immune cells and non-immune
cells can promote the immune escape, development and metastasis of tumors,
wherein the inhibition of cytotoxic T cell (CTL) and NK cell functions by Treg
cell-related CD73-adenosine signals is the most significant.
For the treatment of solid tumors, one important aspect of overcoming drug
resistance and improving the therapeutic effect is to relieve the inhibition
effect
of the tumor micro environment (TME) on immune effector cells. TME is a
very complex system composed of various cells, intercellular matrix, enzymes,
cytokines, metabolites, etc. It features significant low hydrogen, low pH and
high pressure, and is greatly different from normal tissues. Hypoxia or ATP
enrichment caused by chemoradiotherapy for killing tumor cells promotes the
cascade reaction of CD39-CD73 adenosine signals, which is beneficial to the
proliferation and function of various cancer-promoting cells, but is not
2
CA 03176321 2022- 10- 20
IP190597
beneficial to cancer-inhibiting cells. (Regateiro, F. S., Cobbold, S. P. &
Waldmann, H., CD73 and adenosine generation in the creation of regulatory
microenvironments. Clin. Exp. Immunol., 2013;171:1-7).
The use of antibodies targeting CD73 or gene knock-out of CD73 in animal
models can effectively block the growth and metastasis of tumors. Recently,
the use of CD73 monoclonal antibody, small interfering RNA technology,
specific inhibitor APCP and the like has achieved remarkable therapeutic
effect
in anti-tumor treatment of animal experiments, providing a new way for
anti-tumor treatment. Evidence from in vivo studies has shown that targeted
blockade of CD73 will be an effective treatment means for tumor patients.
The relation between CD73 overexpression and tumor subtype, prognosis and
response in patients has shown that CD73 can be an important marker for
future tumor treatment and detection of individuals. Therefore, the study of
the
CD73 target is indispensable.
The transmembrane receptor PD-1 (programmed cell death protein 1) is a
member of the CD28 family, and is expressed in activated T cells, B cells and
myeloid cells. The receptors of PD-1, PDL1 and PDL2, are members of the B7
superfamily. PDL1 is expressed in a variety of cells including T cells, B
cells,
endothelial cells and epithelial cells, and PDL2 is expressed only in antigen
presenting cells such as dendritic cells and macrophages.
PD-1 plays a very important role in down-regulating the activation of T cells,
and the PD-1-mediated down-regulation of T cells is one of the important
mechanisms of tumor immune escape. PDL-1 expressed on the surface of
tumors can bind to PD-1 on the surface of immune cells, thereby inhibiting the
killing of tumor tissues by the immune cells through the PD-1/PDL-1 signaling
pathway, and tumors with high expression of PD-Li are associated with
cancers that are difficult to detect (Hamanishi et al., Proc. Natl. Acad. Sci.
USA, 2007; 104:3360-5). An effective way to antagonize PD-1 and thus inhibit
PD-1/PDL-1 signaling pathway is injection of anti-PDL-1 antibody.
Due to the broad anti-tumor prospect and surprising efficacy of PD-1
3
CA 03176321 2022- 10- 20
IP190597
antibodies, it is widely accepted that antibodies targeting the PD-1 pathway
will bring about breakthroughs in the treatment of a variety of tumors:
non-small cell lung cancer, renal cell carcinoma, ovarian cancer and melanoma
(Homet M. B., Parisi G., et al., Anti-PD-1 therapy in melanoma. Semin Oncol.,
2015 Jun; 42(3):466-473), and hematological tumor and anemia (Held SA,
Heine A, et al., Advances in immunotherapy of chronic myeloid leukemia
CML. Curr Cancer Drug Targets, 2013 Sep; 13(7):768-74).
Bifunctional antibodies, also known as bispecific antibodies, are specific
antibody drugs that target two different antigens simultaneously, and can be
produced by immunosorting and purification, or can be obtained by genetic
engineering. The genetic engineering has flexibility in aspects of binding
site
optimization, synthetic form, yield and the like, thus having certain
advantages.
Currently, over 45 forms of the bispecific antibody have been demonstrated
(Muller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy:
current perspectives. BioDrugs 2010; 24:89-98). The IgG-ScFv form, namely
the Morrison form (Coloma MJ, Morrison SL. Design and production of novel
tetravalent bispecific antibodies. Nat Biotechnol. Nature Biotechnology, 1997;
15:159-163), has been demonstrated to be an ideal form of the bifunctional
antibody due to its similarity to the naturally existing IgG form and
advantages
in antibody engineering, expression and purification (Miller BR, Demarest SJ,
et al., Stability engineering of scFvs for the development of bispecific and
multivalent antibodies. Protein Eng Des Sel 2010; 23:549-57; Fitzgerald J,
Lugovskoy A. Rational engineering of antibody therapeutics targeting multiple
oncogene pathways. MAbs 2011;3 :299-309).
ADCC (antibody-dependent cell-mediated cytotoxicity) refers to killing of a
target cell by a killer cell (NK cell, macrophage, etc.) that is mediated by
binding of the Fab fragment of an antibody to an epitope of a virus-infected
cell or a tumor cell and binding of the Fc fragment of the antibody to an Fc
receptor (FcR) on the surface of the killer cell.
CDC (complement dependent cytotoxicity) refers to a lytic effect on target
4
CA 03176321 2022- 10- 20
IP190597
cells by a membrane-attacking complex that is formed by the bindings of an
antibody to a corresponding antigen on a cell membrane surface and later to
the
complement Clq and activation of C2¨C9.
The IgG family comprises four members, IgG1 , IgG2, IgG3 and IgG4, which
differ in amino acids in the fragment crystallizable (Fc) region of the heavy
chain constant region, resulting in their varying affinities for FcyRs. Wild-
type
IgG1 can bind to various FcyRs and elicit ADCC and CDC effects. Zhang et al.
(Zhang T et al, Cancer Immunol Immunother., 2018; 67(7):1079-1090.) and
Dahan et al. (Dahan R et al., Cancer cell, 2015, 28(3):285-95.) reported that
the binding of Fc fragments of antibodies targeting immune checkpoints such
as PD-1 to Fc receptors negatively affects antibody-mediated anti-cancer
activity, possibly because Fc-dependent effector function-induced immune cell
damage, including antibody-dependent cell-mediated cytotoxicity, is an
important mechanism leading to immune cell damage.
Interleukin-8 (IL-8) is a chemotactic cytokine and is mainly secreted by
monocytes and the like. IL-8 plays an important role in the proliferation of
normal cells and tumor cells, especially in promoting the development and
progression of tumors. Studies have shown that IL-8 can promote the
development of tumors; and the tumor cells themselves also secrete IL-8 to
promote tumor growth and metastasis (Lo MC et al., Cancer letters, 2013,
335(1):81-92). Therefore, IL-8 has become an important inflammatory factor
indispensable in the tumor micro environment.
As a pro-inflammatory factor, IL-8 is closely related to the development and
progression of tumors. During the methylarsonate-induced malignant
transformation of non-renal cancer cells, the expression of IL-8 gene is
increased. Gene silencing of IL-8 can significantly inhibit the growth of
transplanted tumors in mice, and in addition, the reduction of IL-8 level can
inhibit the expression of matrix metalloproteinase-9, cyclin D1, pro-apoptotic
protein Bc1-2 and vascular endothelial growth factor (VEGF), which are related
to the growth and metastasis of tumors (Escudero-Lourdes C et al., Toxicology
CA 03176321 2022- 10- 20
IP190597
and applied pharmacology, 2012, 258(1):10-18). Inoue et al. found that IL-8
can induce malignant transformation of non-neoplastic bladder cell line
(233JP) and increases its aggressiveness, while the incidence of malignant
transformation of 233JP cells is significantly reduced in IL-8 knock-out mice
(Inoue K et al., Cancer Res, 2000, 60(8):2290-2299). Furthermore, in prostate
cancer, IL-8 can promote the development of castration-resistant prostate
cancer (CRPC) in patients (Chen K et al., Cancer research, 2015,
75(10):1992-2004), and is associated with drug resistance to tumor treatment
(Araki S et al., Cancer Res, 2007, 67(14):6854-6862), gene silencing of IL-8
or its receptor can induce cell cycle arrest in tumor cells and inhibit tumor
proliferation (Singh RK, Lokeshwar BL., Molecul Cancer, 2009, 8:57). The
above studies have shown that the level of IL-8 is closely related to the
development and progression of tumors. Further studies (Mian BM et al. Clin
Cancer Res, 2003, 9(8):3167-3175) have shown that IL-8 can be a novel target
for tumor treatment. In a tumor model of bladder cancer, the use of anti-IL-8
antibodies can significantly inhibit the growth of tumors.
IL-6 is mainly produced rapidly by macrophages in response to
pathogen-associated molecular patterns (PAMPs) or damage-associated
molecular patterns (DAMPs), and plays a protective role by removing
infectious agents and inducing acute phase and immune responses to cure the
damaged tissues. Although IL-6 plays an important role in infection and the
resistance to and repair of tissue damage, a high level of IL-6 can activate
the
coagulation pathway and vascular endothelial cells, thereby inhibiting
myocardial function, and can even cause a "cytokine storm", resulting in
severe acute systemic inflammatory responses. Cytokine storm is a fatal
complication and adverse effect in viral infection, tumor immunotherapy and
the like.
Immune-related adverse effect is a common and dangerous adverse effect in
the anti-tumor treatment with immune checkpoint inhibitors (ICIs) (Spain L et
al., Cancer Treat Rev., 2016; 44:51-60). In recent years, immune checkpoint
6
CA 03176321 2022- 10- 20
IP190597
inhibitors have achieved great success in tumor immunotherapy, but also led to
a brand-new toxicity profile due to off-target effects, among which the severe
immune-related adverse events (irAEs) in major organs (including heart, lung
and brain) are especially life-threatening (Bergqvist V, et al., Cancer
Immunol
Immunother., 2017; 66(5):581-592, Gomatou G et al., Respiration., 2020;
1:1-11; Joshi MN et al., Clin Endocrinol (0Ø, 2016; 85(3):331-9,
Prieux-Klotz C et al., Target Oncol., 2017; 12(3):301-308, Tajiri K et al.,
Jpn
J Clin Oncol., 2018; 48(1):7-12). Existing data have shown that ICIs can
induce off-target effects by 4 mechanisms, including direct binding to immune
checkpoint molecules expressed on the surface of normal cells, and activating
complement hypersensitivity; the presence of homologous antigens/epitopes in
normal tissues and tumor cells; producing autoantibodies, increasing the level
of pro-inflammatory cytokines, such as IL-6 and the like (Martins F et al.,
The
Lancet Oncology, 20(1), e54¨e64).
Currently, anti-IL-6 therapy, such as tocilizumab, a recombinant humanized
anti-IL-6R monoclonal antibody, has been used to treat severe irAEs, severe or
refractory arthritis, large vessel vasculitis, uveitis, myocarditis,
pneumonia,
myasthenia gravis and the like in the acute phase (Martins F et al., The
Lancet
Oncology, 20(1), e54¨e64).
Binding of FcyRIa on macrophages to wild-type IgG1 or IgG4 antibodies can
induce the macrophages to secrete IL-8 and IL-6 (Kinder M et al., mAbs.,
2015), while inducing mutations in the Fc segments of antibodies and
eliminating their binding to FcyRIa can effectively inhibit the secretion of
IL-8,
thereby improving the safety and efficacy of the antibodies.
SUMMARY
The inventors used mammalian cell expression systems to express recombinant
human CD73 and PD-1 as antigens to immunize mice, and obtained hybridoma
cells by fusion of mouse spleen cells and myeloma cells. The inventors
obtained the following hybridoma cell lines by screening a large number of the
7
CA 03176321 2022- 10- 20
IP190597
samples:
hybridoma cell line LT014 (also called CD73-19F3) deposited at China Center
for Type Culture Collection (CCTCC) on June 19, 2018 with an accession
number of CCTCC NO: C2018137; and
hybridoma cell line LT003 (also called PD-1-14C12) deposited at China
Center for Type Culture Collection (CCTCC) on June 16, 2015 with an
accession number of CCTCC NO: C2015105.
The inventors surprisingly found that:
the hybridoma cell line LT014 can secrete a specific monoclonal antibody
(named as 19F3) specifically binding to human CD73, and the monoclonal
antibody can effectively inhibit the enzyme activity reaction of CD73 in a
non-substrate competition mode, reduce the production of adenosine, and
promote the activity and the tumor inhibitory effect of T cells; and
the hybridoma cell line LT003 may secrete a specific monoclonal antibody
(named as 14C12) specifically binding to PD-1, and the monoclonal antibody
can effectively block the binding of PD-1 to PDLl.
Furthermore, the inventors creatively prepared humanized anti-CD73
antibodies (named as 19F3H2L2, 19F3H2L3, 19F3H2L3(hG1M) and
19F3H2L3(hG1TM), respectively) and humanized anti-PD-1 antibodies
(named as 14C12H1L1 and 14C12H1L1(hG1TM)).
Furthermore, the inventors creatively fused two types of humanized antibodies
into new antibodies through protein recombination, and obtained humanized
bifunctional antibodies (named as P1D7V01, P1D7V03, NTPDV1, NTPDV2,
NTPDV3 and NTPDV4, respectively (also written as NTPDV1(hG1TM),
NTPDV2(hG1TM), NTPDV3(hG1TM) and NTPDV4(hG1TM) herein and in
the Chinese Patent Application NO. 202110270671.X)) capable of binding to
CD73 and PD-1, inhibiting the activity of CD73 and blocking the binding of
PD-1 to PDL1, and having the potential for use in preparing a medicament for
preventing and treating of solid tumors and hematological tumors.
The present invention is detailed below.
8
CA 03176321 2022- 10- 20
IP190597
One aspect of the present invention relates to an anti-CD73/anti-PD-1
bispecific antibody comprising:
a first protein functional region targeting PD-1, and
a second protein functional region targeting CD73.
In one embodiment of the present invention, in the bispecific antibody,
the first protein functional region comprises: HCDR1, HCDR2 and HCDR3
contained in a heavy chain variable region having an amino acid sequence set
forth in SEQ ID NO: 44, wherein preferably the amino acid sequences of
HCDR1, HCDR2 and HCDR3 are sequences set forth in SEQ ID NOs: 45-47,
respectively, or sequences having at least 80%, 81%, 82%, 83%, 84%, 85%,
86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98% or 99% sequence identity to the sequences set forth in SEQ ID
NOs: 45-47, or amino acid sequences having one or more (preferably 1,2 or 3)
conservative amino acid mutations (preferably substitutions, insertions or
deletions) compared with the sequences set forth in SEQ ID NOs: 45-47; and
LCDR1, LCDR2 and LCDR3 contained in a light chain variable region having
an amino acid sequence set forth in SEQ ID NO: 49, wherein preferably the
amino acid sequences of LCDR1, LCDR2 and LCDR3 are sequences set forth
in SEQ ID NOs: 50-52, respectively, or sequences having at least 80%, 81%,
82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the
sequences set forth in SEQ ID NOs: 50-52, or amino acid sequences having
one or more (preferably 1, 2 or 3) conservative amino acid mutations
(preferably substitutions, insertions or deletions) compared with the
sequences
set forth in SEQ ID NOs: 50-52;
the second protein functional region comprises: HCDR1, HCDR2 and HCDR3
contained in a heavy chain variable region having an amino acid sequence set
forth in SEQ ID NO: 2, wherein preferably the amino acid sequences of
HCDR1, HCDR2 and HCDR3 are sequences set forth in SEQ ID NOs: 3-5, or
sequences having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%,
9
CA 03176321 2022- 10- 20
IP190597
89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%
or 99% sequence identity to the sequences set forth in SEQ ID NOs: 3-5, or
amino acid sequences having one or more (preferably 1, 2 or 3) conservative
amino acid mutations (preferably substitutions, insertions or deletions)
compared with the sequences set forth in SEQ ID NOs: 3-5; and
LCDR1, LCDR2 and LCDR3 contained in a light chain variable region having
an amino acid sequence set forth in SEQ ID NO: 7, wherein preferably the
amino acid sequences of LCDR1, LCDR2 and LCDR3 are sequences set forth
in SEQ ID NOs: 8-10, respectively, or sequences having at least 80%, 81%,
82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the
sequences set forth in SEQ ID NOs: 8-10, or amino acid sequences having one
or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably
substitutions, insertions or deletions) compared with the sequences set forth
in
SEQ ID NOs: 8-10.
In one embodiment of the present invention, in the anti-CD73/anti-PD-1
bispecific antibody,
the first protein functional region comprises:
a sequence having an amino acid sequence set forth in SEQ ID NO: 44 or SEQ
ID NO: 62, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%,
86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98% or 99% sequence identity to the sequence set forth in SEQ ID
NO: 44 or 62, or an amino acid sequence having one or more (preferably 1, 2
or 3) conservative amino acid mutations (preferably substitutions, insertions
or
deletions) compared with the sequences set forth in SEQ ID NO: 44 or 62; and
a sequence having an amino acid sequence correspondingly set forth in SEQ
ID NO: 49 or SEQ ID NO: 64, or a sequence having at least 80%, 81%, 82%,
83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence set
forth in SEQ ID NO: 49 or 64, or an amino acid sequence having one or more
I0
CA 03176321 2022- 10- 20
IP190597
(preferably 1, 2 or 3) conservative amino acid mutations (preferably
substitutions, insertions or deletions) compared with the sequences set forth
in
SEQ ID NO: 49 or 64;
and/or,
the second protein functional region comprises a sequence having an amino
acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 20, or a sequence
having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or
90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%
sequence identity to the sequence set forth in SEQ ID NO: 2 or 20, or an amino
acid sequence having one or more (preferably 1, 2 or 3) conservative amino
acid mutations (preferably substitutions, insertions or deletions) compared
with
the sequences set forth in SEQ ID NO: 2 or 20; and
a sequence having an amino acid sequence correspondingly set forth in SEQ
ID NO: 7 or SEQ ID NO: 22, or a sequence having at least 80%, 81%, 82%,
83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence set
forth in SEQ ID NO: 7 or 22, or an amino acid sequence having one or more
(preferably 1, 2 or 3) conservative amino acid mutations (preferably
substitutions, insertions or deletions) compared with the sequences set forth
in
SEQ ID NO: 7 or 22;
or
the second protein functional region comprises a sequence having an amino
acid sequence set forth in SEQ ID NO: 20, or a sequence having at least 80%,
81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the
sequence set forth in SEQ ID NO: 20, or an amino acid sequence having one or
more (preferably 1, 2 or 3) conservative amino acid mutations (preferably
substitutions, insertions or deletions) compared with the sequences set forth
in
SEQ ID NO: 20; and
a sequence having an amino acid sequence set forth in SEQ ID NO: 24, or a
II
CA 03176321 2022- 10- 20
IP190597
sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%,
89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%
or 99% sequence identity to the sequence set forth in SEQ ID NO: 24, or an
amino acid sequence having one or more (preferably 1, 2 or 3) conservative
amino acid mutations (preferably substitutions, insertions or deletions)
compared with the sequences set forth in SEQ ID NO: 24.
One aspect of the present invention relates to an anti-CD73/anti-PD-1
bispecific antibody comprising:
a first protein functional region targeting CD73, and
a second protein functional region targeting PD-1.
In one embodiment of the present invention, in the bispecific antibody,
the first protein functional region comprises: HCDR1, HCDR2 and HCDR3
contained in a heavy chain variable region having an amino acid sequence set
forth in SEQ ID NO: 2, wherein preferably the amino acid sequences of
HCDR1, HCDR2 and HCDR3 are sequences set forth in SEQ ID NOs: 3-5,
respectively, or sequences having at least 80%, 81%, 82%, 83%, 84%, 85%,
86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98% or 99% sequence identity to the sequences set forth in SEQ ID
NOs: 3-5, or amino acid sequences having one or more (preferably 1, 2 or 3)
conservative amino acid mutations (preferably substitutions, insertions or
deletions) compared with the sequences set forth in SEQ ID NOs: 3-5; and
LCDR1, LCDR2 and LCDR3 contained in a light chain variable region having
an amino acid sequence set forth in SEQ ID NO: 7, wherein preferably the
amino acid sequences of LCDR1, LCDR2 and LCDR3 are sequences set forth
in SEQ ID NOs: 8-10, respectively, or sequences having at least 80%, 81%,
82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the
sequences set forth in SEQ ID NOs: 8-10, or amino acid sequences having one
or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably
substitutions, insertions or deletions) compared with the sequences set forth
in
12
CA 03176321 2022- 10- 20
IP190597
SEQ ID NOs: 8-10;
the second protein functional region comprises: HCDR1, HCDR2 and HCDR3
contained in a heavy chain variable region having an amino acid sequence set
forth in SEQ ID NO: 44, wherein preferably the amino acid sequences of
HCDR1, HCDR2 and HCDR3 are sequences set forth in SEQ ID NOs: 45-47,
respectively, or sequences having at least 80%, 81%, 82%, 83%, 84%, 85%,
86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98% or 99% sequence identity to the sequences set forth in SEQ ID
NOs: 45-47, or amino acid sequences having one or more (preferably 1,2 or 3)
conservative amino acid mutations (preferably substitutions, insertions or
deletions) compared with the sequences set forth in SEQ ID NOs: 45-47; and
LCDR1, LCDR2 and LCDR3 contained in a light chain variable region having
an amino acid sequence set forth in SEQ ID NO: 49, wherein preferably the
amino acid sequences of LCDR1, LCDR2 and LCDR3 are sequences set forth
in SEQ ID NOs: 50-52, respectively, or sequences having at least 80%, 81%,
82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the
sequences set forth in SEQ ID NOs: 50-52, or amino acid sequences having
one or more (preferably 1, 2 or 3) conservative amino acid mutations
(preferably substitutions, insertions or deletions) compared with the
sequences
set forth in SEQ ID NOs: 50-52.
In one embodiment of the present invention, in the anti-CD73/anti-PD-1
bispecific antibody,
the first protein functional region comprises:
a sequence having an amino acid sequence set forth in SEQ ID NO: 2 or SEQ
ID NO: 20, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%,
86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98% or 99% sequence identity to the sequence set forth in SEQ ID
NO: 2 or 20, or an amino acid sequence having one or more (preferably 1,2 or
3) conservative amino acid mutations (preferably substitutions, insertions or
13
CA 03176321 2022- 10- 20
IP190597
deletions) compared with the sequences set forth in SEQ ID NO: 2 or 20; and
a sequence having an amino acid sequence correspondingly set forth in SEQ
ID NO: 7, SEQ ID NO: 22 or SEQ ID NO: 24, or a sequence having at least
80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at
least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to
the sequence set forth in SEQ ID NO: 7, SEQ ID NO: 22 or SEQ ID NO: 24,
or an amino acid sequence having one or more (preferably 1, 2 or 3)
conservative amino acid mutations (preferably substitutions, insertions or
deletions) compared with the sequences set forth in SEQ ID NO: 7, 22 or 24;
and/or,
the second protein functional region comprises a sequence having an amino
acid sequence set forth in SEQ ID NO: 44 or SEQ ID NO: 62, or a sequence
having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or
90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%
sequence identity to the sequence set forth in SEQ ID NO: 44 or SEQ ID NO:
62, or an amino acid sequence having one or more (preferably 1, 2 or 3)
conservative amino acid mutations (preferably substitutions, insertions or
deletions) compared with the sequences set forth in SEQ ID NO: 44 or SEQ ID
NO: 62; and
a sequence having an amino acid sequence correspondingly set forth in SEQ
ID NO: 49 or 64, or a sequence having at least 80%, 81%, 82%, 83%, 84%,
85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98% or 99% sequence identity to the sequence set forth in
SEQ ID NO: 49 or 64, or an amino acid sequence having one or more
(preferably 1, 2 or 3) conservative amino acid mutations (preferably
substitutions, insertions or deletions) compared with the sequences set forth
in
SEQ ID NO: 49 or 64.
In one embodiment of the present invention, in the anti-CD73/anti-PD-1
bispecific antibody, the first protein functional region and the second
protein
functional region are linked directly or via a linker; preferably, the linker
is
14
CA 03176321 2022- 10- 20
IP190597
(GGGGS)n, and n is a positive integer, e.g., 1, 2, 3, 4, 5 or 6.
In one embodiment of the present invention, the first protein functional
region
and the second protein functional region in the anti-CD73/anti-PD-1 bispecific
antibody are independently an immunoglobulin or an antigen-binding
fragment, such as a half-antibody, Fab, F(abi)2 or a single chain fragment
variable, preferably, the first protein functional region is an immunoglobulin
and the second protein functional region is an antigen-binding fragment; or
the
first protein functional region is an antigen-binding fragment and the second
protein functional region is an immunoglobulin.
In one embodiment of the present invention, the N terminus of the heavy chain
variable region of the antigen-binding fragment is linked directly (or via a
linker) to the C terminus of CH1 of the immunoglobulin, and the N terminus of
the light chain variable region of the antigen-binding fragment is linked
directly (or via a linker) to the C terminus of the light chain variable
region CL
of the immunoglobulin, or the N terminus of the heavy chain variable region of
the antigen-binding fragment is linked directly (or via a linker) to the C
terminus of the light chain variable region CL of the immunoglobulin, and the
N terminus of the light chain variable region of the antigen-binding fragment
is
linked directly (or via a linker) to the C terminus of the heavy chain
variable
region CH1 of the immunoglobulin.
In one embodiment of the present invention, the C terminus of the heavy chain
variable region of the antigen-binding fragment is linked directly (or via a
linker) to the N terminus of the heavy chain of the immunoglobulin, and the C
terminus of the light chain variable region of the antigen-binding fragment is
linked directly (or via a linker) to the N terminus of the light chain of the
immunoglobulin, or the C terminus of the heavy chain variable region of the
antigen-binding fragment is linked directly (or via a linker) to the N
terminus
of the light chain of the immunoglobulin, and the C terminus of the light
chain
variable region of the antigen-binding fragment is linked directly (or via a
linker) to the N terminus of the heavy chain of the immunoglobulin.
CA 03176321 2022- 10- 20
IP190597
In one embodiment of the present invention, the antigen-binding fragment is a
single chain fragment variable; preferably, the first protein functional
region is
an immunoglobulin and the second protein functional region is a single chain
fragment variable; or the first protein functional region is a single chain
fragment variable and the second protein functional region is an
immunoglobulin.
In one embodiment of the present invention, the bispecific antibody is
provided, wherein the numbers of the first protein functional region and the
second protein functional region are each independently 1,2 or more.
In one embodiment of the present invention, in the anti-CD73/anti-PD-1
bispecific antibody, the single chain fragment variable is a molecule formed
by
connecting an antibody heavy chain variable region (VH) and an antibody light
chain variable region (VL) via a linker; preferably, the single chain fragment
variable may have a general structure: NH2-VL-linker-VH-COOH or
NH2-VH-linker-VL-COOH.
In one embodiment of the present invention, in the anti-CD73/anti-PD-1
bispecific antibody, when the single chain fragment variable is linked to the
C
terminus of the heavy chain of the immunoglobulin (CH) (or the N terminus of
the heavy chain, the C terminal of CH1 of the heavy chain variable region) by
a linker, the antibody heavy chain variable region (VH) of the single chain
fragment variable may be firstly linked, or the antibody light chain variable
region (VL) of the single chain fragment variable may be firstly linked;
preferably, the single chain fragment variable may have a general structure:
CH-linker-VH-linker-VL-COOH, or CH-linker-VL-linker-VH-COOH,
preferably,
the heavy chain variable region of the immunoglobulin comprises CDRs
having amino acid sequences set forth in SEQ ID NOs: 3-5, and the light chain
variable region of the immunoglobulin comprises CDRs having amino acid
sequences set forth in SEQ ID NOs: 8-10;
the heavy chain variable region of the single chain fragment variable
comprises
16
CA 03176321 2022- 10- 20
IP190597
CDRs having amino acid sequences set forth in SEQ ID NOs: 45-47, and the
light chain variable region of the single chain fragment variable comprises
CDRs having amino acid sequences set forth in SEQ ID NOs: 50-52,
preferably, when the single chain fragment variable (such as
NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH)is linked to the C
terminus of the heavy chain of the immunoglobulin via a linker, the antibody
heavy chain variable region (VH) of the single chain fragment variable
comprising CDRs having amino acid sequences set forth in SEQ ID NOs:
45-47 may be firstly linked, or the antibody light chain variable region (VI)
of
the single chain fragment variable comprising CDRs having amino acid
sequences set forth in SEQ ID NOs: 50-52 may be firstly linked,
or preferably,
the heavy chain variable region of the immunoglobulin comprises CDRs
having amino acid sequences set forth in SEQ ID NOs: 45-47, and the light
chain variable region of the immunoglobulin comprises CDRs having amino
acid sequences set forth in SEQ ID NOs: 50-52; and/or,
the heavy chain variable region of the single chain fragment variable
comprises
CDRs having amino acid sequences set forth in SEQ ID NOs: 3-5, and the
light chain variable region of the single chain fragment variable comprises
CDRs having amino acid sequences set forth in SEQ ID NOs: 8-10,
wherein, when the single chain fragment variable (such as
NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH)is linked to the C
terminus of the heavy chain of the immunoglobulin via a linker, the antibody
heavy chain variable region (VH) of the single chain fragment variable
comprising CDRs having amino acid sequences set forth in SEQ ID NOs: 3-5
may be firstly linked, or the antibody light chain variable region (VI) of the
single chain fragment variable comprising CDRs having amino acid sequences
set forth in SEQ ID NOs: 8-10 may be firstly linked,
preferably,
one immunoglobulin molecule is linked to two single chain fragment variable
17
CA 03176321 2022- 10- 20
IP190597
molecules, and more preferably, the two single chain fragment variable
molecules are identical.
In one embodiment of the present invention, in the anti-CD73/anti-PD-1
bispecific antibody, the immunoglobulin is IgG, IgA, IgD, IgE or IgM,
preferably IgG, e.g., IgG1 , IgG2, IgG3 or IgG4.
In one embodiment of the present invention, in the anti-CD73/anti-PD-1
bispecific antibody, the single chain fragment variable is linked to the C
terminus of the heavy chain of the immunoglobulin. Since an immunoglobulin
consists of two heavy chains, two single chain fragment variable molecules are
linked to one immunoglobulin molecule. Preferably, the two single chain
fragment variable molecules are identical.
In one embodiment of the present invention, in the anti-CD73/anti-PD-1
bispecific antibody,
the heavy chain variable region of the immunoglobulin comprises CDRs
having amino acid sequences set forth in SEQ ID NOs: 3-5, and the light chain
variable region of the immunoglobulin comprises CDRs having amino acid
sequences set forth in SEQ ID NOs: 8-10;
and/or,
the heavy chain variable region of the single chain fragment variable
comprises
CDRs having amino acid sequences set forth in SEQ ID NOs: 45-47, and the
light chain variable region of the single chain fragment variable comprises
CDRs having amino acid sequences set forth in SEQ ID NOs: 50-52,
preferably, when the single chain fragment variable (such as
NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH)is linked to the C
terminus of the heavy chain of the immunoglobulin via a linker, the antibody
heavy chain variable region (VH) of the single chain fragment variable
comprising CDRs having amino acid sequences set forth in SEQ ID NOs:
45-47 may be firstly linked, or the antibody light chain variable region (VI)
of
the single chain fragment variable comprising CDRs having amino acid
sequences set forth in SEQ ID NOs: 50-52 may be firstly linked.
18
CA 03176321 2022- 10- 20
IP190597
In another embodiment of the present invention, in the anti-CD73/anti-PD-1
bispecific antibody,
the heavy chain variable region of the immunoglobulin comprises CDRs
having amino acid sequences set forth in SEQ ID NOs: 45-47, and the light
chain variable region of the immunoglobulin comprises CDRs having amino
acid sequences set forth in SEQ ID NOs: 50-52; and/or,
the heavy chain variable region of the single chain fragment variable
comprises
CDRs having amino acid sequences set forth in SEQ ID NOs: 3-5, and the
light chain variable region of the single chain fragment variable comprises
CDRs having amino acid sequences set forth in SEQ ID NOs: 8-10,
wherein, when the single chain fragment variable (such as
NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH)is linked to the C
terminus of the heavy chain of the immunoglobulin via a linker, the antibody
heavy chain variable region (VH) of the single chain fragment variable
comprising CDRs having amino acid sequences set forth in SEQ ID NOs: 3-5
may be firstly linked, or the antibody light chain variable region (VI) of the
single chain fragment variable comprising CDRs having amino acid sequences
set forth in SEQ ID NOs: 8-10 may be firstly linked.
In one embodiment of the present invention, in the anti-CD73/anti-PD-1
bispecific antibody,
the heavy chain variable region of the immunoglobulin has an amino acid
sequence selected from SEQ ID NO: 2 and SEQ ID NO: 20, and the light chain
variable region of the immunoglobulin has an amino acid sequence
correspondingly selected from SEQ ID NO: 7 and SEQ ID NO: 22; or the
heavy chain variable region of the immunoglobulin has an amino acid
sequence set forth in SEQ ID NO. 20, and the light chain variable region of
the
immunoglobulin has an amino acid sequence set forth in SEQ ID NO. 24;
and/or,
the heavy chain variable region of the single chain fragment variable has an
amino acid sequence selected from SEQ ID NO: 44 and SEQ ID NO: 62, and
19
CA 03176321 2022- 10- 20
IP190597
the light chain variable region of the single chain fragment variable has an
amino acid sequence correspondingly selected from SEQ ID NO: 49 and SEQ
ID NO: 64;
wherein, when the single chain fragment variable is linked to the C terminus
of
the heavy chain of the immunoglobulin via a linker, the antibody heavy chain
variable region (VH) of the single chain fragment variable may be firstly
linked, or the antibody light chain variable region (VI) of the single chain
fragment variable may be firstly linked.
In another embodiment of the present invention, in the anti-CD73/anti-PD-1
bispecific antibody,
the heavy chain variable region of the immunoglobulin has an amino acid
sequence selected from SEQ ID NO: 44 and SEQ ID NO: 62; the light chain
variable region of the immunoglobulin has an amino acid sequence
correspondingly selected from SEQ ID NO: 49 and SEQ ID NO: 64, or the
heavy chain variable region of the single chain fragment variable has an amino
acid sequence selected from SEQ ID NO: 2 and SEQ ID NO: 20, the light
chain variable region of the single chain fragment variable has an amino acid
sequence correspondingly selected from SEQ ID NO: 7 and SEQ ID NO: 22,
or the heavy chain variable region of the single- chain antibody has an amino
acid sequence set forth in SEQ ID NO: 20, and the light chain variable region
of the single chain fragment variable has an amino acid sequence set forth in
SEQ ID NO: 24.
Another aspect of the present invention relates to an isolated nucleic acid
molecule comprising a nucleotide sequence capable of encoding a heavy chain
variable region of a bispecific antibody, wherein,
the heavy chain variable region of the antibody comprises:
a CDR having an amino acid sequence of SEQ ID NOs: 3-5, a CDR having an
amino acid sequence of SEQ ID NOs: 45-47, and a CDR having an amino acid
sequence of SEQ ID NOs: 50-52;
and the heavy chain variable region of the bispecific antibody specifically
CA 03176321 2022- 10- 20
IP190597
binds to CD73 and PD-1 antigens as a part of the bispecific antibody, and the
bispecific antibody further comprises a light chain variable region
comprising:
a CDR having an amino acid sequence of SEQ ID NOs: 8-10;
preferably, the CDRs of the light chain variable region are different from the
CDRs of the heavy chain variable region.
In one embodiment of the present invention, in the bispecific antibody,
the immunoglobulin comprises a non-CDR region derived from a species other
than murine, such as from a human antibody.
In one embodiment of the present invention, the constant regions of the
immunoglobulin are humanized. For example, the heavy chain constant region
is Ig gamma-1 chain C region, ACCESSION: P01857, and the light chain
constant region is Ig kappa chain C region, ACCESSION: P01834.
In one embodiment of the present invention, the constant regions of the
immunoglobulin are humanized. For example, the heavy chain constant region
is Ig gamma-1 chain C region, ACCESSION: P01857, and the light chain
constant region is Ig kappa chain C region, ACCESSION: P01834, wherein,
according to the EU numbering system, the heavy chain constant region of the
immunoglobulin comprises mutations at any 2 or 3 of positions 234, 235 and
237, and the affinity constant of the bispecific antibody for FcyRIa, FcyRIIIa
and/or Cl q is reduced after the mutations as compared to that before the
mutations; preferably, the affinity constants are measured by a Fortebio Octet
system.
In one or more embodiments of the present invention, for the bispecific
antibody, according to the EU numbering system, the heavy chain constant
region of the immunoglobulin has the following mutations at positions 234,
235 and/or 237:
L234A and L235A,
L234A and G237A,
L235A and G237A,
or
21
CA 03176321 2022- 10- 20
IP190597
L234A, L235A and G237A.
In the present invention, letters before the position number represent amino
acids before mutation, and letters after the position number represent amino
acids after mutation, unless otherwise specified.
In one or more embodiments of the present invention, for the bispecific
antibody, according to the EU numbering system, the heavy chain constant
region of the immunoglobulin has one or more mutations selected from:
N297A, D265A, D270A, P238D, L328E, E233D, H268D, P271G, A330R,
C226S, C229S, E233P, P33 1S, S267E, L328F, A330L, M252Y, S254T,
T256E, N297Q, P238S, P238A, A327Q, A327G, P329A, K322A, T394D,
G236R, G236A, L328R, A330S, P33 1S, H268A, E318A and K320A.
In a specific embodiment, the anti-CD73/anti-PD-1 bispecific antibody has a
structure shown as heavy chain-light chain-linker 1-scFv, and the scFv is
selected from 14C12H1V-linker 2-14C12L1V, 14C12H1V-linker
1-14C12L1V, 14C12H1V-linker 2-14C12L1V and 14C12H1V-linker
1-14C12L1V, particularly selected from the group consisting of:
(1) NTPDV1, of which the heavy chain has an amino acid sequence set forth in
SEQ ID NO: 85, the light chain has an amino acid sequence set forth in SEQ
ID NO: 28, the linker 1 has an amino acid sequence set forth in SEQ ID NO:
79, 14C12H1V has an amino acid sequence set forth in SEQ ID NO: 66, the
linker 2 has an amino acid sequence set forth in SEQ ID NO: 81, and
14C12L1V has an amino acid sequence set forth in SEQ ID NO: 68;
(2) NTPDV2, of which the heavy chain has an amino acid sequence set forth in
SEQ ID NO: 85, the light chain has an amino acid sequence set forth in SEQ
ID NO: 28, the linker 1 has an amino acid sequence set forth in SEQ ID NO:
79, 14C12H1V has an amino acid sequence set forth in SEQ ID NO: 66, the
linker 1 has an amino acid sequence set forth in SEQ ID NO: 79, and
14C12L1V has an amino acid sequence set forth in SEQ ID NO: 68;
(3) NTPDV3, of which the heavy chain has an amino acid sequence set forth in
SEQ ID NO: 85, the light chain has an amino acid sequence set forth in SEQ
22
CA 03176321 2022- 10- 20
IP190597
ID NO: 96, the linker 1 has an amino acid sequence set forth in SEQ ID NO:
79, 14C12H1V has an amino acid sequence set forth in SEQ ID NO: 66, the
linker 2 has an amino acid sequence set forth in SEQ ID NO: 81, and
14C12L1V has an amino acid sequence set forth in SEQ ID NO: 68; and
(4) NTPDV4, of which the heavy chain has an amino acid sequence set forth in
SEQ ID NO: 85, the light chain has an amino acid sequence set forth in SEQ
ID NO: 96, the linker 1 has an amino acid sequence set forth in SEQ ID NO:
79, 14C12H1V has an amino acid sequence set forth in SEQ ID NO: 66, the
linker 1 has an amino acid sequence set forth in SEQ ID NO: 79, and
14C12L1V has an amino acid sequence set forth in SEQ ID NO: 68.
In one embodiment of the present invention, the bispecific antibody binds to
CD73 protein and /or PD-1 protein with a KD of less than about 10-5 M, e.g.,
less than about 10-6 M, 10-7 M, 10-8 M, 10-9 M, 10-10 M or less.
Yet another aspect of the present invention relates to a vector comprising the
isolated nucleic acid molecule disclosed herein.
Yet another aspect of the present invention relates to a host cell comprising
the
isolated nucleic acid molecule or the vector disclosed herein.
Yet another aspect of the present invention relates to a method for preparing
the bispecific antibody disclosed herein, comprising culturing the host cell
disclosed herein in a suitable condition and isolating the bispecific antibody
from the cell cultures.
Yet another aspect of the present invention relates to a conjugate comprising
a
bispecific antibody and a conjugated moiety, wherein the bispecific antibody
is
the bispecific antibody disclosed herein and the conjugated moiety is a
detectable label; specifically, the conjugated moiety is a radioisotope, a
fluorescent substance, a chemiluminescent substance, a colored substance or an
enzyme.
Yet another aspect of the present invention relates to a kit comprising the
bispecific antibody disclosed herein or comprising the conjugate disclosed
herein; preferably, the kit further comprises a secondary antibody that
23
CA 03176321 2022- 10- 20
IP190597
specifically recognizes the bispecific antibody; optionally, the secondary
antibody further comprises a detectable label, e.g., a radioisotope, a
fluorescent
substance, a chemiluminescent substance, a colored substance or an enzyme.
Yet another aspect of the present invention relates to use of the bispecific
antibody disclosed herein in preparing a kit for detecting the presence or
level
of CD73 and/or PD-1 in a sample.
Yet another aspect of the present invention relates to a pharmaceutical
composition comprising the bispecific antibody disclosed herein or the
conjugate disclosed herein; optionally, the pharmaceutical composition further
comprises a pharmaceutically acceptable carrier and/or excipient.
Yet another aspect of the present invention relates to use of the bispecific
antibody disclosed herein or the conjugate disclosed herein in preventing
and/or treating a tumor or anemia, or in diagnosing a tumor or anemia.
Yet another aspect of the present invention relates to use of the bispecific
antibody disclosed herein or the conjugate disclosed herein in preparing a
medicament for preventing and/or treating a tumor or anemia, or in preparing a
medicament for diagnosing a tumor or anemia.
Yet another aspect of the present invention relates to use of the bispecific
antibody disclosed herein or the conjugate disclosed herein in preparing:
a medicament for detecting the level of CD73 in a sample,
a medicament for inhibiting the enzyme activity reaction of CD73,
and/or
a medicament for blocking the binding of PD-1 to PD-L1,
a medicament for down-regulating (e.g., down-regulating) the activity or level
of PD-1,
a medicament for relieving the immunosuppression of PD-1 in an organism,
a medicament for elevating IL-2 expression in T lymphocytes, or
a medicament for elevating IFN-yexpression in T lymphocytes.
Yet another aspect of the present invention relates to an in vivo or in vitro
method comprising administering to a cell or administering to a subject in
need
24
CA 03176321 2022- 10- 20
IP190597
an effective amount of the bispecific antibody disclosed herein or the
conjugate
disclosed herein.
The anti-CD73/anti-PD-1 bispecific antibodies disclosed herein can inhibit the
enzyme activity of CD73 a cell membrane surface, and can induce the
secretion of IFNy and IL-2 to activate the immune response.
The variable regions of the light chain and the heavy chain determine the
binding of the antigen; the variable region of each chain contains three
hypervariable regions called complementarity determining regions (CDRs)
(CDRs of the heavy chain (H) comprise HCDR1, HCDR2 and HCDR3, and
CDRs of the light chain (L) comprise LCDR1, LCDR2 and LCDR3, which are
named by Kabat et al., see Bethesda M.d., Sequences of Proteins of
Immunological Interest, Fifth Edition, NIH Publication 1991; 1-3:91-3242.
Preferably, CDRs may also be defined by the IMGT numbering system, see
Ehrenmann F, Kaas Q, and Lefranc M P., IMGT/3Dstructure-DB and
IMGT/DomainGapAlign: a database and a tool for immunoglobulins or
antibodies, T cell receptors, MHC, IgSF and MhcSF[J]. Nucleic acids research
2009; 38(suppl_1): D301¨D307.
The amino acid sequences of the CDRs of the monoclonal antibody in (1) to
(11) below are analyzed by technical means well known to those skilled in the
art, for example, according to the IMGT definition, and the results are as
follows:
(1) 19F3
The heavy chain variable region has an amino acid sequence set forth in SEQ
ID NO: 2, and the light chain variable region has an amino acid sequence set
forth in SEQ ID NO: 7.
The 3 CDRs of the heavy chain variable region have the following amino acid
sequences:
HCDR1: GYSFTGYT (SEQ ID NO: 3),
HCDR2: INPYNAGT (SEQ ID NO: 4), and
HCDR3: ARSEYRYGGDYFDY (SEQ ID NO: 5);
CA 03176321 2022- 10- 20
IP190597
the 3 CDRs of the light chain variable region have the following amino acid
sequences:
LCDR1: QSLLNSSNQKNY (SEQ ID NO: 8),
LCDR2: FAS (SEQ ID NO: 9), and
LCDR3: QQHYDTPYT (SEQ ID NO: 10).
(2) 19F3H2L2
The heavy chain variable region has an amino acid sequence set forth in SEQ
ID NO: 20, and the light chain variable region has an amino acid sequence set
forth in SEQ ID NO: 22.
The 3 CDRs of the heavy chain variable region have the same amino acid
sequences as 19F3.
The 3 CDRs of the light chain variable region have the same amino acid
sequences as 19F3.
(3) 19F3H2L3
The heavy chain variable region has an amino acid sequence set forth in SEQ
ID NO: 20, and the light chain variable region has an amino acid sequence set
forth in SEQ ID NO: 24.
The 3 CDRs of the heavy chain variable region have the same amino acid
sequences as 19F3.
The 3 CDRs of the light chain variable region have the same amino acid
sequences as 19F3.
(4) 14C12
The heavy chain variable region has an amino acid sequence set forth in SEQ
ID NO: 44, and the light chain variable region has an amino acid sequence set
forth in SEQ ID NO: 49.
The 3 CDRs of the heavy chain variable region have the following amino acid
sequences:
HCDR1: GFAFSSYD (SEQ ID NO: 45)
HCDR2: ISGGGRYT (SEQ ID NO: 46)
HCDR3: ANRYGEAWFAY (SEQ ID NO: 47)
26
CA 03176321 2022- 10- 20
IP190597
the 3 CDRs of the light chain variable region have the following amino acid
sequences:
LCDR1: QDINTY (SEQ ID NO: 50)
LCDR2: RAN (SEQ ID NO: 51)
LCDR3: LQYDEFPLT (SEQ ID NO: 52)
(5) 14C12H1L1
The heavy chain variable region has an amino acid sequence set forth in SEQ
ID NO: 62, and the light chain variable region has an amino acid sequence set
forth in SEQ ID NO: 64.
The 3 CDRs of the heavy chain variable region have the same amino acid
sequences as 14C12.
The 3 CDRs of the light chain variable region have the same amino acid
sequences as 14C12.
(6) The 9 CDRs of the heavy chain of NTPDV1, NTPDV2, NTPDV3 and
NTPDV4 has the same amino acid sequences as those of the CDRs of 13F9
heavy chain, 14C12 heavy chain and 14C12 light chain regions, respectively,
in the order from N terminus to C terminus. The sequences, in the order
described above, are as follows:
HCDR1: GYSFTGYT (SEQ ID NO: 3)
HCDR2: INPYNAGT (SEQ ID NO: 4)
HCDR3: ARSEYRYGGDYFDY (SEQ ID NO: 5)
HCDR4: GFAFSSYD (SEQ ID NO: 45)
HCDR5: ISGGGRYT (SEQ ID NO: 46)
HCDR6: ANRYGEAWFAY (SEQ ID NO: 47)
HCDR7: QDINTY (SEQ ID NO: 50)
HCDR8: RAN (SEQ ID NO: 51)
HCDR9: LQYDEFPLT (SEQ ID NO: 52)
The 3 CDRs of the light chain has the same amino acid sequences as those of
the three CDRs of 19F3 light chain, and the sequences are as follows:
LCDR1: QSLLNSSNQKNY (SEQ ID NO: 8)
27
CA 03176321 2022- 10- 20
IP190597
LCDR2: FAS (SEQ ID NO: 9)
LCDR3: QQHYDTPYT (SEQ ID NO: 10).
Yet another aspect of the present invention relates to hybridoma cell line
LT014 deposited at China Center for Type Culture Collection (CCTCC) with a
collection number of CCTCC NO: C2018137.
Yet another aspect of the present invention relates to hybridoma cell line
LT003 deposited at China Center for Type Culture Collection (CCTCC) with a
collection number of CCTCC NO: C2015105.
In the present invention, unless otherwise specified, the scientific and
technical
terms used herein have the meanings generally understood by those skilled in
the art. In addition, the laboratory operations of cell culture, molecular
genetics, nucleic acid chemistry and immunology used herein are the routine
procedures widely used in the corresponding fields. Meanwhile, in order to
better understand the present invention, the definitions and explanations of
the
relevant terms are provided below.
As used herein, the term EC50 refers to the concentration for 50% of maximal
effect, i.e., the concentration that can cause 50% of the maximal effect.
As used herein, the term "antibody" refers to an immunoglobulin molecule that
generally consists of two pairs of polypeptide chains (each pair with one
"light" (L) chain and one "heavy" (H) chain). Antibody light chains are
classified as lc and X, light chains. Heavy chains are classified as , 6, y,
a, or E.
Isotypes of antibodies are defined as IgM, IgD, IgG, IgA, and IgE. In light
chains and heavy chains, the variable region and constant region are linked by
a "J" region of about 12 or more amino acids, and the heavy chain further
comprises a "D" region of about 3 or more amino acids. Each heavy chain
consists of a heavy chain variable region (VH) and a heavy chain constant
region (CH). The heavy chain constant region consists of 3 domains (CH1,
CH2, and CH3). Each light chain consists of a light chain variable region (VL)
and a light chain constant region (CL). The light chain constant region
consists
28
CA 03176321 2022- 10- 20
IP190597
of one domain CL. The constant region of the antibody can mediate the
binding of immunoglobulins to host tissues or factors, including the binding
of
various cells of the immune system (e.g., effector cells) to the first
component
(Cl q) of classical complement system. The VH and VL regions can be further
subdivided into highly variable regions (called complementarity determining
regions (CDRs)), between which conservative regions called framework
regions (FRs) are distributed. Each VH and VL consists of 3 CDRs and 4 FRs
arranged from amino terminus to carboxyl terminus in the following order:
FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The variable regions (VH and
VL) of each heavy chain/light chain pair form an antibody-binding site. The
assignment of amino acids to the regions or domains is based on Bethesda
M.d., Kabat Sequences of Proteins of Immunological Interest (National
Institutes of Health, (1987 and 1991)), or Chothia & Lesk I Mol. Biol., 1987;
196:901-917; Chothia et al., Nature, 1989; 342:878-883, or the definition of
the IMGT numbering system, see the definition in Ehrenmann F, Kaas Q,
Lefranc M P., IMGT/3Dstructure-DB and IMGT/DomainGapAlign: a database
and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and
MhcSF[J]., Nucleic acids research, 2009; 38(suppl_1): D301¨D307.
In particular, the heavy chain may also comprise more than 3 CDRs, such as 6,
9 or 12. For example, in the bispecific antibody disclosed herein, the heavy
chain may be a heavy chain of IgG antibody with the C terminus linked to one
ScFv, and in this case, the heavy chain comprises 9 CDRs.
The term "antibody" is not limited by any specific method for producing
antibody. For example, the antibody includes a recombinant antibody, a
monoclonal antibody and a polyclonal antibody. The antibody may be
antibodies of different isotypes, such as IgG (e.g., subtype IgGl, IgG2, IgG3
or
IgG4), IgAl, IgA2, IgD, IgE or IgM.
As used herein, the terms "mAb" and "monoclonal antibody" refer to an
antibody or a fragment of an antibody that is derived from a group of highly
homologous antibodies, i.e., from a group of identical antibody molecules,
29
CA 03176321 2022- 10- 20
IP190597
except for natural mutations that may occur spontaneously. The monoclonal
antibody is highly specific for a single epitope on an antigen. The polyclonal
antibody, relative to the monoclonal antibody, generally comprises at least 2
or
more different antibodies which generally recognize different epitopes on an
antigen. Monoclonal antibodies can generally be obtained using hybridoma
technology first reported by Kohler et al (Kohler G, Milstein C. Continuous
cultures of fused cells secreting antibody of predefined specificity [J].
Nature,
1975; 256(5517): 495), but can also be obtained using recombinant DNA
technology (see, e.g., U.S. Patent 4,816,567).
As used herein, the term "humanized antibody" refers to an antibody or an
antibody fragment obtained when all or a part of CDR regions of a human
immunoglobulin (receptor antibody) are replaced by the CDR regions of a
non-human antibody (donor antibody), wherein the donor antibody may be a
non-human (e.g., mouse, rat or rabbit) antibody having expected specificity,
affinity or reactivity. In addition, some amino acid residues in the framework
regions (FRs) of the receptor antibody can also be replaced by the amino acid
residues of corresponding non-human antibodies or by the amino acid residues
of other antibodies to further improve or optimize the performance of the
antibody. For more details on humanized antibodies, see, e.g., Jones et al.,
Nature, 1986; 321:522 525; Reichmann et al., Nature, 1988; 332:323 329;
Presta, Curr. Op. Struct. Biol., 1992; 2:593-596; and Clark, Immunol. Today,
2000; 21: 397-402. In some cases, the antigen-binding fragments of the
antibodies are diabodies, in which the VH and VL domains are expressed on a
single polypeptide chain. However, the linker used is too short to allow the
pairing of the two domains on the same chain. Thereby the domains are forced
to pair with the complementary domains on the other chain and two
antigen-binding sites are generated (see, e.g., Holliger P. et al., Proc.
Natl.
Acad. Sci. USA, 1993; 90:6444-6448 and Poljak R. J. et al., Structure, 1994;
2:1121-1123).
As used herein, the term "single chain fragment variable (ScFv)" refers to a
CA 03176321 2022- 10- 20
IP190597
molecule in which the antibody heavy chain variable region (VH) and the
antibody light chain variable region (VL) are linked by a linker. The VL and
VH
domains are paired to form a monovalent molecule by a linker that enable them
to produce a single polypeptide chain (see, e.g., Bird et al, Science, 1988;
242:423-426 and Huston et al, Proc. Natl. Acad. ScL USA, 1988;
85:5879-5883). Such scFv molecules may have a general structure:
NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. An appropriate linker
in the prior art consists of a repeating GGGGS amino acid sequence or a
variant thereof. For example, a linker having the amino acid sequence
(GGGGS)4 may be used, but variants thereof may also be used (Holliger et al.,
Proc. Natl. Acad. Sci. USA, 1993; 90: 6444-6448). Other linkers that can be
used in the present invention are described by Alfthan et al., Protein Eng.,
1995; 8:725-731, Choi et al., Eur. I Immunol., 2001; 31: 94-106, Hu et al.,
Cancer Res., 1996; 56:3055-3061, Kipriyanov et al., I MoL Biol., 1999;
293:41-56 and Roovers et al., Cancer Immunology, Immunotherapy, 2001,
50(1): 51-59.
As used herein, the term "isolated" refers to obtaining by artificial means
from
natural state. If a certain "isolated" substance or component appears in
nature,
it may be the case that change occurs in its natural environment, or that it
is
isolated from the natural environment, or both. For example, a certain
non-isolated polynucleotide or polypeptide naturally occurs in a certain
living
animal, and the same polynucleotide or polypeptide with high purity isolated
in
such a natural state is referred to as an isolated polynucleotide or
polypeptide.
The term "isolated" does not exclude the existence of artificial or synthetic
substances or other impurities that do not affect the activity of the
substance.
As used herein, the term "vector" refers to a nucleic acid vehicle into which
a
polynucleotide can be inserted. When a vector allows the expression of the
protein encoded by the inserted polynucleotide, the vector is referred to as
an
expression vector. The vector can be introduced into a host cell by
transformation, transduction or transfection, such that the genetic substance
31
CA 03176321 2022- 10- 20
IP190597
elements carried by the vector can be expressed in the host cell. Vectors are
well known to those skilled in the art, including but not limited to:
plasmids,
phagemids, cosmids, artificial chromosomes, such as yeast artificial
chromosome (YAC), bacterial artificial chromosome (BAC), or P1-derived
artificial chromosome (PAC); phages such as lambda phages or M13 phages,
and animal viruses. Animal viruses that can be used as vectors include, but
are
not limited to retroviruses (including lentiviruses), adenoviruses,
adeno-associated viruses, herpes viruses (such as herpes simplex virus),
poxviruses, baculoviruses, papillomaviruses, and papovaviruses (such as
SV40). A vector may comprise a variety of elements that control expression,
including, but not limited to promoter sequences, transcription initiation
sequences, enhancer sequences, selection elements and reporter genes. In
addition, the vector may further comprise a replication initiation site.
As used herein, the term "host cell" refers to cells to which vectors can be
introduced, including, but not limited to, prokaryotic cells such as E. coil
or
bacillus subtilis, fungal cells such as yeast cells or aspergillus, insect
cells such
as S2 drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells,
GS cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells, or
human cells.
As used herein, the term "specifically bindi" refers to a non-random binding
reaction between two molecules, such as a reaction between an antibody and an
antigen it targets. In some embodiments, an antibody that specifically binds
to
an antigen (or an antibody that is specific for an antigen) means that the
antibody binds to the antigen with an affinity (KD) of less than about 10-5 M,
such as less than about 10-6M, 10-7M, 10-8 M, 10-9 M or 101 M or less.
As used herein, the term "KD" refers to a dissociation equilibrium constant
for
a specific antibody-antigen interaction, which is used to describe the binding
affinity between the antibody and the antigen. A smaller dissociation
equilibrium constant indicates a stronger antibody-antigen binding and a
higher
affinity between the antibody and the antigen. Typically, the antibody binds
to
32
CA 03176321 2022- 10- 20
IP190597
the antigen (e.g., PD-1 protein) with a dissociation equilibrium constant (KD)
of less than about 10-5 M, such as less than about 10-6 M, 10-7 M, 10-8 M, 10-
9
M or 101 M or less. KD can be determined using methods known to those
skilled in the art, for example, using a Fortebio system.
As used herein, the terms "monoclonal antibody" and "mAb" have the same
meaning and can be used interchangeably; the terms "polyclonal antibody" and
"pAb" have the same meaning and can be used interchangeably. Besides,
herein, amino acids are generally represented by single-letter and three-
letter
abbreviations known in the art. For example, alanine can be represented by A
or Ala.
As used herein, the term "pharmaceutically acceptable carrier and/or
excipient"
refers to a carrier and/or excipient that is pharmacologically and/or
physiologically compatible with the subject and the active ingredient. Such
carriers and/or excipients are well known in the art (see, e.g., Remington's
Pharmaceutical Sciences, edited by Gennaro AR, 19t1 Ed., Pennsylvania:
Mack Publishing Company, 1995), including, but not limited to: pH regulators,
surfactants, adjuvants, and ionic strength enhancers. For example, the pH
regulators include, but are not limited to, phosphate buffer; the surfactants
include, but are not limited to, cationic, anionic, or non-ionic surfactants,
such
as Tween-80, the ionic strength enhancers include, but are not limited to,
sodium chloride.
As used herein, the term "effective amount" refers to an amount sufficient to
obtain or at least partially obtain desired effects. For example, a
prophylactically effective amount against a disease (e.g., a tumor) refers to
an
amount sufficient to prevent, stop, or delay the onset of a disease (e.g., a
tumor); a therapeutically effective amount refers to an amount sufficient to
cure or at least partially stop a disease and complications thereof in
patients
suffering from the disease. It is undoubtedly within the ability of those
skilled
in the art to determine such an effective amount. For example, the amount
effective for therapeutic purpose will depend on the severity of the disease
to
33
CA 03176321 2022- 10- 20
IP190597
be treated, the overall state of the patient's own immune system, the general
condition of the patient such as age, body weight and gender, the route of
administration, and other treatments given concurrently, etc.
Beneficial Effects
The monoclonal antibody of the present invention (such as 13F9H2L3) can
well and specifically bind to CD73, and can effectively inhibit the enzyme
activity reaction of CD73 in a non-substrate competition mode, reduce the
production of adenosine, promote the activity of T cells and the tumor
inhibitory effect.
The bispecific antibody disclosed herein, such as NTPDV1, NTPDV2,
NTPDV3 and NTPDV4, can well and specifically bind to PD-1 and CD73, can
effectively block the binding of PD-1 to PDL1, specifically relieve the
immunosuppression of PD-1 in an organism, inhibit the catalytic activity of
CD73, relieve the inhibition on immune cells by adenosine, activate T
lymphocytes, and does not cause the release of cytokines IL-8 and IL-6,
showing effectively increased safety and efficacy.
The bifunctional antibody disclosed herein has the potential for use in
preparing an anti-tumor drug.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1. Binding of P1D7V01, P1D7V02R, P1D7V03, P1D7VO4R,
14C12H1L1 and nivolumab to PD-1-mFc determined by ELISA.
FIG. 2. Binding of P1D7V01, P1D7V02R, P1D7V03, P1D7VO4R, 19F3 H2L3
and MEDI9447 to human NT5E-Biotin determined by ELISA.
FIG. 3. Activity of P1D7V01, P1D7V02R, P1D7V03, P1D7VO4R,
14C12H1L1 and nivolumab competing with human PD-Li -mFc for binding to
human PD-1-mFc-Biotin.
FIG. 4. Affinity constant of P1D7V01 for PD-1-mFc.
FIG. 5. Affinity constant of 14C12H1L1 for PD-1-mFc.
34
CA 03176321 2022- 10- 20
IP190597
FIG. 6. Affinity constant of nivolumab for PD-1-mFc.
FIG. 7. Affinity constant of P1D7V01 for human NT5E(1-552)-his.
FIG. 8. Affinity constant of MEDI 9447 for human NT5E(1-552)-his.
FIG. 9. Binding activity of P1D7V01, P1D7V02R, P1D7V03, P1D7VO4R and
14C12H1L1 to PD-1 on 293T-PD1 cell surface determined by FACS.
FIG. 10. Binding activity of P1D7V01, P1D7V03, MEDI9447 and 19F3H2L3
to CD73 on MDA-MB-231 cell surface determined by FACS.
FIG. 11. Inhibition of anti-CD73/anti-PD-1 bispecific antibodies on the
enzyme activity of CD73 on MDA-MB-231 membrane surface.
FIG. 12. Inhibition of anti-CD73/anti-PD-1 bispecific antibodies on the
enzyme activity of CD73 on U87-MG membrane surface.
FIG. 13. Biological activity of anti-CD73/anti-PD-1 bispecific antibodies for
promoting IFN-y secretion in Raji-PDL1 mixed lymphocyte reaction system.
FIG. 14. Biological activity of anti-CD73/anti-PD-1 bispecific antibodies for
promoting IL-2 secretion in Raji-PDL1 mixed lymphocyte reaction system.
FIG. 15. Biological activity of anti-CD73/anti-PD-1 bispecific antibodies for
promoting IFN-y secretion in DC mixed lymphocyte reaction system.
FIG. 16. Biological activity of anti-CD73/anti-PD-1 bispecific antibodies for
promoting IL-2 secretion in DC mixed lymphocyte reaction system.
FIG. 17. Affinity constant of 14C12H1L1 (hG1 TM) for PD-1 -mFc.
FIG. 18. Affinity constant of nivolumab for PD-1-mFc.
FIG. 19. Affinity constant of NTPDV1 for PD-1-mFc.
FIG. 20. Affinity constant of NTPDV2 for PD-1-mFc.
FIG. 21. Affinity constant of NTPDV3 for PD-1-mFc.
FIG. 22. Affinity constant of NTPDV4 for PD-1-mFc.
FIG. 23. Affinity constant of 19F3H2L3(hG1M) for human NT5E(1-552)-his.
FIG. 24. Affinity constant of NTPDV1 for human NT5E(1-552)-his.
FIG. 25. Affinity constant of NTPDV2 for human NT5E(1-552)-his.
FIG. 26. Affinity constant of NTPDV3 for human NT5E(1-552)-his.
CA 03176321 2022- 10- 20
IP190597
FIG. 27. Affinity constant of NTPDV4 for human NT5E(1-552)-his.
FIG. 28. Inhibition of the enzyme activity of CD73 on U87-MG cell membrane
surface by anti-CD73/anti-PD-1 bispecific antibodies.
FIG. 29. Biological activity of anti-CD73/anti-PD-1 bispecific antibodies for
promoting IFN-y and IL-2 secretion determined by mixed lymphocyte reaction
(MLR).
FIG. 30. Effect of isotype control, 19F3H2L3(hG1M) and different doses of
NTPDV2 on tumor volume in mice.
FIG. 31. Effect of isotype control, 19F3H2L3(hG1M) and different doses of
NTPDV2 on body weight of mice.
FIG. 32. Effective elimination of PD-1/CD73 bispecific antibody-mediated
IL-8 secretion in human macrophages by the amino acid mutations of Fc
segments in a co-culture system of CHO-K1-PD1 cells and human
macrophages.
FIG. 33. Effective elimination of PD-1/CD73 bispecific antibody-mediated
IL-6 secretion in human macrophages by the amino acid mutations of Fc
segments in a co-culture system of CHO-K1-PD1 cells and human
macrophages.
FIG. 34. Effective elimination of PD-1/CD73 bispecific antibody-mediated
IL-8 secretion in human macrophages by the amino acid mutations of Fc
segments in a co-culture system of U87-MG cells and human macrophages.
FIG. 35. Effective elimination of PD-1/CD73 bispecific antibody-mediated
IL-6 secretion in human macrophages by the amino acid mutations of Fc
segments in a co-culture system of U87-MG cells and human macrophages.
Collection information of biological materials:
The hybridoma cell line LT003 (also called PD-1-14C12), which was
deposited at China Center for Type Culture Collection (CCTCC) on June 16,
2015 with a collection number of CCTCC NO: C2015105 and a collection
address of Wuhan University, Wuhan, China, postal code: 430072.
36
CA 03176321 2022- 10- 20
IP190597
The hybridoma cell line LT014 (also called CD73-19F3), which was deposited
at China Center for Type Culture Collection (CCTCC) on June 21, 2018 with a
collection number of CCTCC NO: C2018137 and a collection address of
Wuhan University, Wuhan, China, postal code: 430072.
DETAILED DESCRIPTION
The embodiments of the present invention will be described in detail below
with reference to the examples. Those skilled in the art will understand that
the
following examples are only for illustrating the present invention, and should
not be construed as limitations on the scope of the present invention. In the
cases where the techniques or conditions are not specified, the examples were
implemented according to the techniques or conditions described in the
literature in the art (e.g., see, Molecular Cloning: A Laboratory Manual,
authored by J. Sambrook et al., and translated by Peitang Huang et al., 3rd
Edition, Science Press) or according to the product manual. Reagents or
instruments used are commercially available conventional products if the
manufacturers thereof are not specified. For example, MDA-MB-231 cells and
U87-MG cells can be purchased from ATCC.
In the following examples of the present invention, BALB/c mice used were
purchased from Guangdong Medical Laboratory Animal Center.
In the following examples of the present invention, the positive control
antibody MEDI9447 (generic name: Oleclumab) used was produced by
Zhongshan Akesobio Co. Ltd., the sequence of which is identical to the
antibody SEQ ID NOs: 21-24 described in the Medmmune Limited's Patent
Publication No. U520160129108A1.
In the following examples of the present invention, the marketed antibody
nivolumab (trade name: Opdivo) for the same target was used, which was
purchased from Bristol-Myers Squibb.
In the following examples of the present invention, the cell line 293T-PD1
used was constructed by Zhongshan Akesobio Co. Ltd. The cell line 293T-PD1
37
CA 03176321 2022- 10- 20
IP190597
was prepared by viral infection of HEK293T cells using 3rd Generation
Lentiviral Systems (see, e.g., A Third Generation Lentivirus Vector with a
Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RI,
Nguyen M, Trono D, and Naldini L., J Virol., 1998. 72(11):8463-8471),
wherein the lentivirus expression vector used was pCDH-CMV-PD-1FL-Puro
(PD1, Genebank ID: NM_005018, vector pCDH-CMV-Puro, purchased from
Youbio, Cat. No. VT1480).
In the following examples of the present invention, the cell line Raji-PDL1
used was constructed by Zhongshan Akesobio Co. Ltd. The cell line
Raji-PDL1 was prepared by viral infection of Raji cells using 3rd Generation
Lentiviral Systems (see, e.g., A Third Generation Lentivirus Vector with a
Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RI,
Nguyen M, Trono D, and Naldini L., J Virol., 1998. 72(11):8463-8471),
wherein the lentivirus expression vector used was p1enti6.3-PDL1 (PDL1,
Genebank ID: NP 054862.1; vector p1enti6.3, purchased from Invitrogen, Cat.
No. K5315-20).
In the following examples of the present invention, the cell line CHO-Kl-PD1
used was constructed by Zhongshan Akesobio Co. Ltd. The cell line
CHO-K1-PD1 was prepared by viral infection of CHO-Kl cells using 3rd
Generation Lentiviral Systems (see, e.g., A Third Generation Lentivirus Vector
with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel
RI, Nguyen M, Trono D, and Naldini L., J Virol., 1998. 72(11):8463-8471),
wherein the lentivirus expression vector used was pCDH-CMV-PD-1FL-Puro
(PD1, Genebank ID: NM_005018, vector pCDH-CMV-Puro, purchased from
Youbio, Cat. No. VT1480).
Nivolumab (trade name: Opdivo), an IgG4 subtype anti-PD-1 antibody
carrying 5228P mutation, was used as a control antibody in the examples and
was purchased from Bristol-Myers Squibb.
In the following examples of the present invention, the isotype control
antibodiy used, i.e., hIgGl, was an antibody targeting human anti-hen egg
38
CA 03176321 2022- 10- 20
IP190597
lysozyme (HEL), and the variable region sequence of the antibody is from the
study reported by Aciemo et al., entitled "Affinity maturation increases the
stability and plasticity of the Fv domain of anti-protein antibodies" (Aciemo
et
al., J Mol biol., 2007; 374(1): 130-46). In the constant region fragment of
hIgGl, the heavy chain constant region is Ig gamma-1 chain C region,
ACCESSION: P01857, and the light chain constant region is Ig kappa chain C
region, ACCESSION: P01834; the hIgG1 was prepared in the laboratory of
Zhongshan Akesobio Co. Ltd.
Example 1: Preparation of anti-CD73 antibody 19F3
1. Preparation of hybridoma cell line LT014
The antigen used to prepare the anti-CD73 antibody was human NT5E-his (for
NT5E, Genbank ID: NP 002517.1, position: 1-552). Spleen cells of
immunized mice were fused with myeloma cells of the mice to prepare
hybridoma cells. With human NT5E-Biotin (for NT5E, Genbank ID:
NP 002517.1, position: 1-552) taken as an antigen, the hybridoma cells were
screened by indirect ELISA to obtain hybridoma cells capable of secreting
antibodies that can specifically bind to CD73. The hybridoma cells obtained by
ELISA screening were subjected to limiting dilution to obtain a stable
hybridoma cell line. The above hybridoma cell line was named as hybridoma
cell line LT014, and the monoclonal antibody secreted therefrom was named
19F3.
The hybridoma cell line LT014 (also called CD73-19F3) was deposited at
China Center for Type Culture Collection (CCTCC) on June 21, 2018 with a
collection number of CCTCC NO: C2018137 and a collection address of
Wuhan University, Wuhan, China, postal code: 430072.
2. Preparation of anti-CD73 antibody 19F3
The cell line LT014 prepared above was cultured with a chemical defined
medium (CD medium, containing 1% Penicillin-Streptomycin) in a 5% CO2,
39
CA 03176321 2022- 10- 20
IP190597
37 C incubator. After 7 days, the supernatants were collected and purified by
high-speed centrifugation, vacuum filtration through a microfiltration
membrane and a HiTrap protein A HP column to obtain an antibody 19F3.
Example 2: Sequence analysis of anti-CD73 antibody 19F3
mRNA was extracted from the cell line LT014 prepared in Example 1
according to the method described in the manual of RNAprep pure
Cell/Bacteria Kit (Tiangen, Cat. No. DP430).
cDNA was synthesized according to the manual of Invitrogen SuperScript III
First-Strand Synthesis System for RT-PCR and amplified by PCR.
The PCR-amplified products were directly subjected to TA cloning according
to the manual of the pEASY-T1 Cloning Kit (Transgen CT101).
The TA-cloned products were directly sequenced, and the sequencing results
are as follows:
The nucleotide sequence (363 bp) of 19F3 heavy chain variable region is set
forth in SEQ ID NO: 1, and the encoded amino acid sequence (121 aa) is set
forth in SEQ ID NO: 2.
According to the IMGT numbering system, the heavy chain CDR1 has a
sequence set forth in SEQ ID NO: 3, the heavy chain CDR2 has a sequence set
forth in SEQ ID NO: 4, and the heavy chain CDR3 has a sequence set forth in
SEQ ID NO: 5.
The nucleotide sequence (339 bp) of 19F3 light chain variable region is set
forth in SEQ ID NO: 6, and the encoded amino acid sequence (113 aa) is set
forth in SEQ ID NO: 7.
According to the IMGT numbering system, the light chain CDR1 has a
sequence set forth in SEQ ID NO: 8, the light chain CDR2 has a sequence set
forth in SEQ ID NO: 9, and the light chain CDR3 has a sequence set forth in
SEQ ID NO: 10.
The amino acid sequences of 4 framework regions (FR-H1 to FR-H4) of the
19F3 heavy chain are set forth in SEQ ID NO: 11 to SEQ ID NO: 14,
CA 03176321 2022- 10- 20
IP190597
respectively; the amino acid sequences of 4 framework regions (FR-H1 to
FR-H4) of the 19F3 light chain are set forth in SEQ ID NO: 15 to SEQ ID NO:
18, respectively.
Example 3: Design, preparation and detection of humanized anti-human
CD73 antibodies
1. Design of light and heavy chain sequences of humanized antibodies
19F3H2L3 and 19F3H2L2
Based on the three-dimensional crystal structure of human CD73 protein (Hage
T, Reinemer P, Sebald W., Crystals of a 1:1 complex between human
interleukin-4 and the extracellular domain of its receptor alpha chain., Eur J
Biochem., 1998; 258(2):831-6) and the sequence of murine antibody 19F3
obtained in Example 2, the variable region sequences of antibodies 19F3H1L1,
19F3H2L3 and 19F3H2L3 were obtained by computer modeling and mutation
design. The corresponding heavy chain variable region sequences were
19F3H1 and 19F3H2, respectively (with amino acid sequences set forth in
SEQ ID NO: 93 and SEQ ID NO: 97, respectively), and the light chain variable
region sequences were 19F3L1, 19F3L2 and 19F3L3, respectively (with amino
acid sequences set forth in SEQ ID NO: 95, SEQ ID NO: 98 and SEQ ID NO:
99, respectively). The antibody constant region sequences are from NCBI
database: the heavy chain constant region is Ig gamma-1 chain C region,
ACCESSION: P01857, the light chain constant region is Ig kappa chain C
region, ACCESSION: P01834. 19F3H2L3 is also known as
19F3H2L3(hG1WT) in the Chinese Patent Application No. 202110270671.X,
wherein the light and heavy chain variable regions of 19F3H1L1, 19F3H2L2
and 19F3H2L3 can further be noted as 19F3H1V (or 19F3H1v), 19F3H2V (or
19F3H2v), 19F3L1V (or 19F3L1v), 19F3L2V (or 19F3L2v) and 19F3L3V (or
19F3L3v).
(1) Heavy chain variable region and light chain variable region sequences of
41
CA 03176321 2022- 10- 20
IP190597
humanized monoclonal antibody 19F3H1L1 are as follows:
The nucleotide sequence (363 bp) of the heavy chain variable region is set
forth in SEQ ID NO: 92, and the encoded amino acid sequence (121 aa) is set
forth in SEQ ID NO: 93.
The nucleotide sequence (339 bp) of the light chain variable region is set
forth
in SEQ ID NO: 94, and the encoded amino acid sequence (113 aa) is set forth
in SEQ ID NO: 95.
(2) Heavy chain variable region and light chain variable region sequences of
humanized monoclonal antibody 19F3H2L2 are as follows:
The nucleotide sequence (363 bp) of the heavy chain variable region 19F3H2
is set forth in SEQ ID NO: 19, and the encoded amino acid sequence (121 aa)
is set forth in SEQ ID NO: 20.
The nucleotide sequence (339 bp) of the light chain variable region 19F3L3 is
set forth in SEQ ID NO: 21, and the encoded amino acid sequence (113 aa) is
set forth in SEQ ID NO: 22.
(3) Heavy chain variable region and light chain variable region sequences of
humanized monoclonal antibody 19F3H2L3 are as follows:
The nucleotide sequence (363 bp) of the heavy chain variable region 19F3H2
is set forth in SEQ ID NO: 19, and the encoded amino acid sequence (121 aa)
is set forth in SEQ ID NO: 20.
The nucleotide sequence (339 bp) of the light chain variable region 19F3L3 is
set forth in SEQ ID NO: 23, and the encoded amino acid sequence (113 aa) is
set forth in SEQ ID NO: 24.
2. Preparation of humanized antibodies 19F3H1L1, 19F3H2L2 and
19F3H2L3
Heavy chain constant regions used Ig gamma -1 chain C region, ACCESSION:
P01857; the light chain constant regions used Ig kappa chain C region,
ACCESSION: P01834.
The heavy chain cDNA and light chain cDNA of 19F3H1L1, 19F3H2L2 and
19F3H2L3 were separately cloned into pUC57simple (provided by GenScript)
42
CA 03176321 2022- 10- 20
IP190597
vectors to obtain pUC57simp1e-19F3H1, pUC57simp1e-19F3L1,
pUC57simple-19F3H2, pUC57simp1e-19F3L2 and pUC57simp1e-19F3L3.
Referring to the standard techniques described in Molecular Cloning: A
Laboratory Manual (Second Edition), the heavy and light chain full-length
genes synthesized by EcoRI&HindIII digestion were subcloned into an
expression vector pcDNA3.1 through digestion by an restriction enzyme
(EcoRI&HindIII) to obtain expression plasmids pcDNA3.1-19F3H1,
pcDNA3.1-19F3L1, pcDNA3 .1 -19F3H2, pcDNA3 .1-19F3L2,
and
pcDNA3.1-19F3L3, and the heavy/light chain genes of the recombinant
expression plasmids were further subjected to sequencing analysis. Then the
designed gene combinations comprising the corresponding light and heavy
chain recombinant plasmids (pcDNA3 .1 -19F3H1/pcDNA3 .1 -19F3L1 ,
pcDNA3.1-19F3H2/pcDNA3 .1 -19F3L2,
and
pcDNA3.1-19F3H2/pcDNA3.1-19F3L3) were separately co-transfected into
293F cells, and the culture solutions were collected and purified. After the
sequences were verified, endotoxin-free expression plasmids were prepared,
and were transiently transfected into HEK293 cells for antibody expression.
The culture solutions were collected after 7 days, and subjected to affinity
purification on a Protein A column to obtain humanized antibodies.
3. Design of light and heavy chain sequences of humanized antibodies
19F3H2L3(hG1M) and 19F3H2L3(hG1TM)
On the basis of 19F3H2L3 obtained in of Example 3 1, 19F3H2L3(hG1M) was
obtained by introducing a leucine-to-alanine point mutation at position 234
(L234A) and a leucine-to-alanine point mutation at position 235 (L235A) of
the heavy chain. The nucleotide and amino acid sequences of the heavy chain
of 19F3H2L3(hG1M) are set forth in SEQ ID NO: 25 and SEQ ID NO: 26,
respectively; the light chain constant region of 19F3H2L3(hG1M) is an Ig
kappa chain C region, ACCESSION: P01834, and the nucleotide and amino
acid sequences of the light chain of 19F3H2L3(hG1M) are set forth in SEQ ID
43
CA 03176321 2022- 10- 20
IP190597
NO: 27 and SEQ ID NO: 28, respectively.
On the basis of 19F3H2L3 obtained in step 1 of Example 3,
19F3H2L3(hG1TM) was obtained by introducing a leucine-to-alanine point
mutation at position 234 (L234A), a leucine-to-alanine point mutation at
position 235 (L235A), and a glycine-to-alanine point mutation at position 237
(G23 7A) in the heavy chain. The nucleotide and amino acid sequences of the
heavy chain are set forth in SEQ ID NO: 29 and SEQ ID NO: 30, respectively;
and the light chain is identical to 19F3H2L3(hG1M).
The amino acid sequences of 4 framework regions (FR-H1 to FR-H4) of
19F3H2 are set forth in SEQ ID NO: 31 to SEQ ID NO: 34, respectively;
the amino acid sequences of 4 framework regions (FR-H1 to FR-H4) of the
19F3L2 light chain are set forth in SEQ ID NO: 35 to SEQ ID NO: 38,
respectively; and
the amino acid sequences of 4 framework regions (FR-H1 to FR-H4) of the
19F3L3 light chain are set forth in SEQ ID NO: 39 to SEQ ID NO: 42,
respectively.
4. Preparation of humanized antibody 19F3H2L3(hG1M)
The heavy chain cDNA and light chain cDNA of 19F3H2L3(hG1M) were
separately cloned into vector pUC57simple (provided by Genscript) to obtain
pUC57simple-19F3H2(hG1M) and pUC57simp1e-19F3L3, respectively.
Referring to the standard techniques described in Molecular Cloning: A
Laboratory Manual (Second Edition), the heavy and light chain full-length
genes synthesized by EcoRl&HindIII digestion were subcloned into an
expression vector pcDNA3.1 through digestion by an restriction enzyme
(EcoRl&HindIII) to obtain expression plasmids pcDNA3.1-19F3H2(hG1M)
and pcDNA3.1-19F3L3, and the heavy/light chain genes of the recombinant
expression plasmids were further subjected to sequencing analysis. Then the
designed gene combination comprising the corresponding light and heavy
chain recombinant plasmids pcDNA3 .1-19F3H2(hG1M)/pcDNA3 .1 -19F3L3
was co-transfected into 293F cells, and the culture solutions were collected
and
44
CA 03176321 2022- 10- 20
IP190597
purified. After the sequences were verified, endotoxin-free expression
plasmids
were prepared, and were transiently transfected into HEK293 cells for antibody
expression. The culture solutions were collected after 7 days, and subjected
to
affinity purification on a Protein A column to obtain a humanized antibody
19F3H2L3(hG1M).
Example 4: Preparation of anti-PD-1 antibody 14C12
1. Preparation of the hybridoma cell line LT003
Using PD-1-mFc fusion protein (PD-1 GenBank: NM-005018, mFc SEQ ID
NO: 89) as an antigen, spleen cells of an immunized BALB/c mice (purchased
from Guangdong Medical Laboratory Animal Center) and mouse myeloma
cells were fused into hybridoma cells, and the established methods (e.g.,
Stewart, S.J., "Monoclonal Antibody Production", in Basic Methods in
Antibody Production and Characterization, Eds. G.C. Howard and D.R.
Bethell, Boca Raton: CRC Press, 2000) were referred to.
The plate was coated with PD-1-hFc (PD-1, Genbank ID: NM 0050i8, hFc is
a human IgG Fc purification tag, specifically Ig gamma-1 chain C region,
Genbank ID: P01857, positions 114-330) for indirect ELISA. By screening,
hybridoma cells secreting new antibodies specifically binding to PD-1 were
obtained.
Hybridoma cell lines capable of secreting a monoclonal antibody that competes
with the ligand PD-Li -hFc (PD-Li Genbank ID: NP 054862.1) for binding to
PD-1 were screened by competitive ELISA, and a stable hybridoma cell line
was obtained by limiting dilution. The LT003 stable cell line (PD-1-14C12)
was obtained by limiting dilution, and the secreted monoclonal antibody was
named as 14C12.
The hybridoma cell line LT003 (also called PD-1-14C12) was deposited at
China Center for Type Culture Collection (CCTCC) on June 16, 2015 with a
collection number of CCTCC NO: C2015105 and a collection address of
Wuhan University, Wuhan, China, postal code: 430072.
CA 03176321 2022- 10- 20
IP190597
2. Preparation of anti-PD-1 antibody 14C12
The LT003 cells prepared above were cultured in an IMDM medium
containing 10% low IgG fetal bovine serum (IMDM medium containing 1%
Penicillin-Streptomycin, cultured in a 5% CO2, 37 C cell incubator). After 7
days, the cell culture supernatant was collected and purified to obtain
antibody
14C12.
Example 5: Sequence analysis of anti-PD-1 antibody 14C12
mRNA was extracted from the hybridoma cell line LT003 prepared in
Example 1 according to the method described in the manual of RNAprep pure
Cell/Bacteria Kit (Tiangen, Cat. No. DP430).
cDNA was synthesized according to the manual of Invitrogen SuperScript III
First-Strand Synthesis System for RT-PCR and amplified by PCR.
The PCR-amplified products were directly subjected to TA cloning according
to the manual of the pEASY-T1 Cloning Kit (Transgen CT101).
The TA-cloned products were directly sequenced, and the sequencing results
are as follows:
The nucleotide sequence (354 bp) of the heavy chain variable region is set
forth in SEQ ID NO: 43, and the encoded amino acid sequence (118 aa) is set
forth in SEQ ID NO: 44.
According to the IMGT numbering system, the heavy chain CDR1 has a
sequence set forth in SEQ ID NO: 45, the heavy chain CDR2 has a sequence
set forth in SEQ ID NO: 46, and the heavy chain CDR3 has a sequence set
forth in SEQ ID NO: 47.
The nucleotide sequence (321 bp) of the light chain variable region is set
forth
in SEQ ID NO: 48, and the encoded amino acid sequence (107 aa) is set forth
in SEQ ID NO: 49.
According to the IMGT numbering system, the light chain CDR1 has a
sequence set forth in SEQ ID NO: 50, the light chain CDR2 has a sequence set
46
CA 03176321 2022- 10- 20
IP190597
forth in SEQ ID NO: 51, and the light chain CDR3 has a sequence set forth in
SEQ ID NO: 52.
The amino acid sequences of 4 framework regions (FR-H1 to FR-H4) of the
14C12 heavy chain are set forth in SEQ ID NO: 53 to SEQ ID NO: 56,
respectively; the amino acid sequences of 4 framework regions (FR-H1 to
FR-H4) of the 14C12 light chain are set forth in SEQ ID NO: 57 to SEQ ID
NO: 60, respectively.
Example 6: Design and preparation of humanized anti-PD-1 antibodies
14C12H1L1 and 14C12H1L1(hG1TM)
1. Design of humanized anti-PD-1 antibody 14C12H1L1
The light and heavy chain sequences of the humanized antibody 14C12H1L1
were designed according to the three-dimensional crystal structure of PD-1
protein (Shinohara T, et al., Structure and chromosomal localization of the
human PD-1 gene (PDCD1). Genomics 1995, 23 (3): 704-6) and the sequence
of antibody 14C12 obtained in Example 5 by computer simulation of antibody
model and designing mutations according to the model to obtain the variable
region sequences of antibody 14C12H1L1.
The designed variable region sequences are as follows.
The nucleotide sequence (354 bp) of the heavy chain variable region 14C 12H1
of the humanized monoclonal antibody 14C12H1L1 is set forth in SEQ ID NO:
61, and the encoded amino acid sequence (118 aa) is set forth in SEQ ID NO:
62.
The nucleotide sequence (321 bp) of the light chain variable region 14C12L1
of the humanized monoclonal antibody 14C12H1L1 is set forth in SEQ ID NO:
63, and the encoded amino acid sequence (107 aa) is set forth in SEQ ID NO:
64.
The constant region of the antibody 14C12H1L1 is from NCBI database (the
heavy chain constant region is Ig gamma-1 chain C region, ACCESSION:
P01857; the light chain constant region is Ig kappa chain C region,
47
CA 03176321 2022- 10- 20
IP190597
ACCESSION: P01834). The nucleotide sequence and amino acid sequence of
the 14C12H1L1 heavy chain are set forth in SEQ ID NOs: 65 and 66,
respectively, and the nucleotide sequence and amino acid sequence of the
14C12H1L1 light chain are set forth in SEQ ID NOs: 67 and 68, respectively.
14C12H1L1 is also known as 14C12H1L1(hG1WT) herein and in Chinese
Patent Application No. 202110270671.X, wherein the heavy chain variable
region and the light chain variable region of 14C12H1L1 are also known as
14C12H1V (or 14C12H1v) and 14C12L1v (or 14C12L1v) herein and in
Chinese Patent Application No. 202110270671.X.
2. Design of light and heavy chain sequences of humanized antibody
14C12H1L1(hG1TM)
On the basis of 14C12H1L1 obtained in step 1 of Example 6,
14C12H1L1(hG1TM) was obtained by introducing a leucine-to-alanine point
mutation at position 234 (L234A), a leucine-to-alanine point mutation at
position 235 (L235A), and a glycine-to-alanine point mutation at position 237
(G237A) in the heavy chain. The nucleotide and amino acid sequences of the
heavy chain of 14C12H1L1(hG1TM) are set forth in SEQ ID NO: 69 and SEQ
ID NO: 70, respectively; and the light chain is identical to 14C12H1L1.
The amino acid sequences of 4 framework regions (FR-H1 to FR-H4) of
14C12H1 are set forth in SEQ ID NO: 71 to SEQ ID NO: 74, respectively;
the amino acid sequences of 4 framework regions (FR-H1 to FR-H4) of the
14C12L1 light chain are set forth in SEQ ID NO: 75 to SEQ ID NO: 78,
respectively.
3. Preparation of humanized antibodies 14C12H1L1
and
14C12H1L1(hG1TM)
The heavy chain cDNA and light chain cDNA of 14C12H1L1(hG1TM) and
14C12H1L1 were separately cloned into pUC57simple (provided by
GenScript) vectors to obtain pUC57simp1e-14C12H1, pUC57simple-14C12L1
and pUC57simp1e-14C12H1(hG1TM). Referring to the standard techniques
described in Molecular Cloning: A Laboratory Manual (Second Edition), the
48
CA 03176321 2022- 10- 20
IP190597
heavy and light chain full-length genes synthesized by EcoRI&HindIII
digestion were subcloned into an expression vector pcDNA3.1 through
digestion by an restriction enzyme (EcoRI&HindIII) to obtain expression
plasmids pcDNA3.1-14C12H1, pcDNA3.1-14C12L1
and
pcDNA3.1-14C12H1(hG1TM), and the heavy/light chain genes of the
recombinant expression plasmids were further subjected to sequencing
analysis. Then the designed gene combinations comprising the corresponding
light and heavy chain recombinant
plasmids
(pcDNA3.1-14C12H1(hG1TM)/pcDNA3.1-14C12L1, and pcDNA3.1-
14C12H1/pcDNA3.1-14C12L1) were separately co-transfected into 293F cells,
and the culture solutions were collected and purified. After the sequences
were
verified, endotoxin-free expression plasmids were prepared, and were
transiently transfected into HEK293 cells for antibody expression. The culture
solutions were collected after 7 days, and subjected to affinity purification
on a
Protein A column to obtain humanized antibodies.
Example 7: Sequence design and expression of anti-PD-1/CD73
bifunctional antibodies
1. Sequence design
The structure of the bifunctional antibody described herein is in the Morrison
form (IgG-scFv), i.e., C-termini of two heavy chains of an IgG antibody are
each linked to a scFv fragment of another antibody, and the main composition
design of the heavy and light chains is as shown in Table 1 below. Table 1
Table 1. Composition design of heavy and light chains of P1D7V01,
P1D7V02R, P1D7V03, P1D7VO4R, P1D7V07 and P1D7V08.
Bispecific Heavy chain
antibody
Light chain
IgG moiety Linker scFv moiety
No.
P1D7V01 14C12H1 Linkerl 19F3H2v-Linkerl-19F3L3v
14C12L1
P1D7V02R 14C12H1 Linkerl 19F3L3v-Linkerl-19F3H2v 14C12L1
49
CA 03176321 2022- 10- 20
IP190597
P1D7V03 14C12H1 Linker2
19F3H2v-Linker1-19F3L3v 14C12L1
P1D7VO4R 14C12H1 Linker2 19F3L3v-Linker1-19F3H2v 14C12L1
P1D7V07 19F3H2 Linkerl
14C12H1 v-Linker1-14C12L1v 19F3L3
P1D7V08 19F3H2 Linker2
14C12H1 v-Linker1-14C12L1v 19F3L3
In the Table 1 above:
(1) Those with "V" label at lower right corner refer to the variable region of
corresponding heavy chain or the variable region of corresponding light chain.
For those without "V" label, the corresponding heavy or light chain is the
full
length comprising the constant region. The corresponding sequences described
in the above examples are referred to for the amino acid sequences of these
variable regions or the full length and the nucleotide sequences encoding
them.
(2) The amino acid sequence of linker 1 is (GGGGS)4 (the nucleotide sequence
is SEQ ID NO: 80, and the amino acid sequence is SEQ ID NO: 79), and the
amino acid sequence of linker 2 is (GGGGS)3 (the nucleotide sequence is SEQ
ID NO: 82, and the amino acid sequence is SEQ ID NO: 81).
2. Expression and purification of antibodies
The heavy chain cDNA sequence and the light chain cDNA sequence of
P1D7V01 were each cloned into vector pUC57simple (provided by Genscript)
to obtain plasmids pUC57simple-VP101H and pUC57simple-VP101L,
respectively.
Plasmids pUC57simple-VP101H and pUC57simp1e-VP101L were
enzyme-digested (HindIII&EcoRI), and heavy and light chains isolated by
electrophoresis were subcloned into vector pcDNA3.1, and recombinant
plasmids were extracted to co-transfect 293F cells. After 7 days of cell
culture,
the culture medium was separated by centrifugation at high speed, and the
supernatant was concentrated and loaded onto a HiTrap MabSelect SuRe
column. The protein was eluted in one step with an elution buffer. The target
sample was isolated and the buffer was exchanged into PBS.
The purified antibodies P1D7V02R, P1D7V03, P1D7VO4R, P1D7V07 and
CA 03176321 2022- 10- 20
IP190597
P1D7V08 were obtained according to the above expression and purification
methods for P1D7V01.
Example 8: Assay for binding activity of anti-CD73/anti-PD-1 bispecific
antibodies to antigens by ELISA
1. Binding activity of P1D7V01, P1D7V02R, P1D7V03 and P1D7VO4R to
antigen PD-1-mFc determined by ELISA The method is specifically as
follows.
A microplate was coated with PD-1-mFc at 0.5 g/mL and incubated at 4 C
overnight. Then the microplate coated with antigens was washed once with
PBST, and then blocked with a PBS solution containing 1% BSA as blocking
solution at 37 C for 2 h. After blocking, the microplate was washed 3 times
with PBST. The antibodies serially diluted with PBST solution (the dilution
gradients for the antibody are shown in Table 2) were added. The microplate
containing the test antibodies was incubated at 37 C for 30 min, and then
washed 3 times with PBST. After washing, HRP-labeled goat anti-human IgG
(H+L) (Jackson, Cat. No. 109-035-088) secondary antibody working solution
diluted in a ratio of 1:5000 was added, and then the microplate was incubated
at 37 C for 30 min. After incubation, the plate was washed 4 times with
PBST, TMB (Neogen, 308177) was added in the dark for chromogenesis for 5
min, and then a stop solution was added to terminate chromogenic reaction.
The microplate was put into a microplate reader immediately, and the OD
value of each well in the microplate was read at 450 nm. The data were
analyzed and processed by SoftMax Pro 6.2.1.
The results are shown in Table 2 and FIG. 1. It can be seen from the figure
that
P1D7V01, P1D7V02R, P1D7V03 and P1D7VO4R can effectively bind to the
antigen PD-1-mFc in a dose-dependent manner. The absorbance intensity of
each dose is shown in Table 2. By quantitative analysis of the absorbance of
the bound antibodies, the binding efficiency EC50 values of the antibodies
P1D7V01, P1D7V02R, P1D7V03, P1D7VO4R, 14C12H1L1 and nivolumab
51
CA 03176321 2022- 10- 20
IP 190597
(as a control) obtained by curve fitting were 0.078 nIVI, 0.078 nIVI, 0.075
nM,
0.089 nIVI, 0.033 nIVI and 0.051 nIVI, respectively.
The above experimental results showed that in the same experimental
condition, the binding activities of P1D7V01, P1D7V02R, P1D7V03 and
P1D7VO4R to PD-1-mFc are comparable to that of the reference drugs
14C12H1L1 and nivolumab for the same target, suggesting that P1D7V01,
P1D7V02R, P1D7V03, P1D7VO4R have the activity of effectively binding to
PD-1 -mF c.
Table 2. Binding of P1D7V01, P1D7V02R, P1D7V03, P1D7VO4R,
14C12H1L1 and nivolumab to PD-1-mFc determined by ELISA
Antigen coating PD-1-mFc 0.5 1.(g/mL
Antibody dilution
concentration
( g/mL) P1D7V01 P1D7V02R P1D7V03 P1D7VO4R
14C12 H1L1 Nivolumab
1
2.345 2.300 2.169 2.323 2.406 2.292 2.225 2.393 2.441 2.609 2.386 2.473
1:3
2.461 2.295 2.114 2.361 2.288 2.303 2.199 2.302 2.414 2.548 2.441 2.600
1:9
2.279 2.085 2.063 2.094 2.135 2.178 2.075 2.043 2.461 2.525 2.519 2.572
1:27
1.838 1.765 1.701 1.696 1.777 1.764 1.659 1.659 2.236 2.295 2.196 2.219
1:81
1.153 1.097 1.089 1.120 1.149 1.154 1.062 1.131 1.858 1.954 1.711 1.712
1:243
0.629 0.684 0.570 0.582 0.675 0.686 0.584 0.592 1.251 1.318 0.980 0.965
1:729
0.361 0.364 0.334 0.349 0.360 0.370 0.340 0.341 0.683 0.709 0.521 0.498
0
0.201 0.198 0.187 0.210 0.197 0.197 0.213 0.257 0.208 0.199 0.196 0.190
Secondary antibody Goat anti-human IgG (H+L), HRP
(1:5000)
EC50(nM) 0.078 0.078 0.075 0.089 0.033
0.051
2. Binding activity of P1D7V01, P1D7V02R, P1D7V03 and P1D7VO4R to
antigen human NT5E-biotin determined by ELISA
A microplate was coated with streptavidin at 2 ixg/mL and then incubated at
4 C overnight. After incubation, the microplate coated with streptavidin was
washed once with PBST, and blocked with a PBS solution containing 1% BSA
as a microplate blocking solution at 37 C for 2 h. After blocking, the
microplate was washed 3 times with PBST. Then, 0.5 ixg/mL antigen human
NT5E-Biotin was added and incubated at 37 C for 30 min. Then, the plate was
52
CA 03176321 2022- 10- 20
IP190597
washed 3 times with PBST. The antibodies serially diluted with PBST solution
(the dilution gradients for the antibody are shown in Table 3) were added to
wells of the microplate. The microplate containing the test antibodies was
incubated at 37 C for 30 min, and then washed 3 times with PBST. After
washing, HRP-labeled goat anti-human IgG (H+L) (Jackson, Cat. No.
109-035-088) secondary antibody working solution diluted in a ratio of 1:5000
was added, and the microplate was incubated at 37 C for 30 min. After
incubation, the plate was washed 4 times with PBST, TMB (Neogen, 308177)
was added in the dark for chromogenesis for 5 min, and then a stop solution
was added to terminate chromogenic reaction. The microplate was put into a
microplate reader immediately, and the OD value of each well in the
microplate was read at 450 nm. The data were analyzed and processed by
SoftMax Pro 6.2.1.
The results are shown in Table 3 and FIG. 2. It can be seen from the figure
that
P1D7V01, P1D7V02R, P1D7V03 and P1D7VO4R can effectively bind to the
antigen human NT5E-biotin in a dose-dependent manner. The absorbance
intensity of each dose is shown in Table 3. By quantitative analysis of the
absorbance of the bound antibodies, the binding efficiency EC50 values of the
antibodies P1D7V01, P1D7V02R, P1D7V03, P1D7VO4R, 19F3H2L3 and
MEDI9447 (as a control antibody) obtained by curve fitting were 0.063 nM,
0.230 nM, 0.068 nM, 0.439 nM, 0.045 nM and 0.042 nM, respectively.
The above experimental results showed that in the same experimental
condition, the binding activities of bispecific antibodies P1D7V01,
P1D7V02R, P1D7V03 and P1D7VO4R to human NT5E-biotin are comparable
to that of the reference drugs 19F3H2L3 and MEDI9447 for the same target,
suggesting that P1D7V01, P1D7V02R, P1D7V03 and P1D7VO4R have the
activity of effectively binding to human NT5E-biotin.
Table 3. Binding of P1D7V01, P1D7V02R, P1D7V03, P1D7VO4R, 19F3H2L3
and MEDI9447 to human NT5E-biotin determined by ELISA
53
CA 03176321 2022- 10- 20
IP 190597
Antigen coating: SA (2 g/mL)
Antibody dilution
concentration Human NT5E-biotin (0.5 g/mL)
(j.tg/mL)
P1D7V01 P1D7V02R P1D7V03 P1D7VO4R 19F3
H2L3 MEDI9447
0.333
2.465 2.254 2.125 2.024 2.245 2.311 1.992 1.864 2.345 2.413 2.460 2.570
1:3
2.310 2.207 1.718 1.680 2.202 2.194 1.385 1.397 2.366 2.376 2.434 2.528
1:9
1.899 1.856 1.090 1.086 1.834 1.782 0.886 0.898 2.164 2.120 2.219 2.345
1:27
1.276 1.239 0.556 0.554 1.199 1.132 0.464 0.465 1.681 1.631 1.729 1.810
1:81
0.704 0.654 0.289 0.279 0.610 0.601 0.235 0.230 1.048 0.978 1.091 1.166
1:243
0.363 0.333 0.183 0.178 0.308 0.302 0.155 0.156 0.548 0.504 0.547 0.587
1:729
0.199 0.197 0.138 0.141 0.183 0.184 0.130 0.122 0.283 0.278 0.288 0.305
0
0.135 0.119 0.115 0.117 0.116 0.119 0.115 0.111 0.120 0.126 0.121 0.121
Secondary antibody Goat anti-human IgG (H+L), HRP
(1:5000)
EC50(nM) 0.063 0.230 0.068 0.439 0.045
0.042
Example 9: Activity of anti-CD73/anti-PD-1 bispecific antibodies
completing with human PD-L1-mFc for binding to human
PD-1-mFc-biotin determined by competitive ELISA
A microplate was coated with human PD-L1-mFc (PD-Li Genbank ID:
NP 054862.1, mFc SEQ ID NO: 143) at 2 g/mL and incubated at 4 C
overnight. After incubation, the microplate was blocked with a PBS solution
containing 1% BSA at 37 C for 2 h. After blocking, the plate was washed
three times and dried. The antibody was serially diluted to 7 concentrations
in a
gradient ratio of 1:3 on a dilution plate with 10 g/mL as the starting
concentration, and a blank control was set. Then an equal volume of 0.3 g/mL
human PD-1-mFc-biotin solution was added, and the system was mixed well
and incubated at room temperature for 20 min. Then the mixture after reaction
was added to the coated microplate, and the microplate was incubated for at
37 C for 30 min. After incubation, the plate was washed three times with
PBST and dried. SA-HRP (KPL, 14-30-00) working solution was added, and
the plate was incubated at 37 C for 30 min. After incubation, the plate was
washed four times and patted dry. Then TMB (Neogen, 308177) was added in
the dark for chromogenesis for 5 min, and a stop solution was added to
54
CA 03176321 2022- 10- 20
IP 190597
terminate chromogenic reaction. Then the microplate was put into a microplate
reader immediately, and the OD value of each well in the microplate was read
at 450 nrn. The data were analyzed and processed by SoftMax Pro 6.2.1.
The results are shown in FIG. 3. The OD values for all the dosages are shown
in Table 4. By quantitative analysis of the absorbance intensity of the bound
antibody, the curve simulation was performed to give the binding efficiency
EC50 of the antibody (Table 4).
The results showed that P1D7V01, P1D7V02R, P1D7V03, P1D7VO4R,
14C12H1L1 and nivolumab (as a control) can effectively block the binding of
the antigen human PD-1-mFc-biotin to its receptor human PD-Li-mFc in a
dose-dependent manner. The EC50 values of P1D7V01, P1D7V02R, P1D7V03,
P1D7VO4R, 14C12H1L1 and nivolumab for blocking the binding of human
PD-1-mFc-biotin to its ligand human PD-Li-mFc were 1.115 nIVI, 1.329 nIVI,
1.154 nIVI, 1.339 nIVI, 1.459 nM and 1.698 nIVI, respectively.
Table 4. Activity of P1D7V01, P1D7V02R, P1D7V03, P1D7VO4R,
14C12H1L1 and nivolumab competing with human PD-Li-mFc for binding to
human PD-1-mFc-biotin
Antibody dilution Antigen coating: human PD-Ll-mFc 2
g/mL
( g/mL) P1D7V01 P1D7V02R P1D7V03 P1D7VO4R
14C12 H1L 1 Nivolumab
0.049 0.047 0.047 0.048 0.048 0.048 0.048 0.051 0.046 0.047 0.057 0.057
1:3
0.050 0.050 0.051 0.051 0.052 0.050 0.052 0.054 0.048 0.050 0.075 0.076
1:9
0.070 0.065 0.097 0.104 0.067 0.068 0.105 0.107 0.053 0.055 0.107 0.100
1:27
1.056 1.109 1.253 1.216 1.109 1.121 1.187 1.158 0.817 0.849 1.014 0.875
1:81
1.460 1.505 1.414 1.372 1.453 1.491 1.424 1.337 1.263 1.299 1.235 1.152
1:243
1.474 1.551 1.503 1.505 1.449 1.447 1.442 1.382 1.316 1.383 1.387 1.207
1:729
1.499 1.604 1.501 1.493 1.569 1.452 1.436 1.424 1.336 1.403 1.347 1.284
0
1.399 1.283 1.467 1.456 1.288 1.252 1.343 1.342 1.302 1.391 1.265 1.156
Human PD-1-mFc-biotin: 0.3 g/mL
Secondary antibody SA-HRP(1 :4000)
EC50(nM) 1.115 1.329 1.154 1.339 1.459
1.698
Example 10: Kinetic parameters for binding of anti-CD73/anti-PD-1
CA 03176321 2022- 10- 20
IP190597
bispecific antibodies to antigen human PD-1-mFc determined by Fortebio
system
The sample dilution buffer was PBST, 0.1% BSA, pH 7.4. The antibody was
immobilized on an AHC sensor at a concentration of 5 ixg/mL with an
immobilization height of about 0.4 nm. The sensor was equilibrated in a buffer
for 60 s, and the binding of the immobilized antibody on the sensor to the
antigen PD-1-mFc at concentrations of 0.6-50 nM (three-fold dilution) was
determined in 120 s. The protein was dissociated in the buffer for 180 s. The
detection temperature was 37 C, the detection frequency was 0.3 Hz, and the
sample plate shaking rate was 1000 rpm. The data were analyzed by 1:1 model
fitting to obtain affinity constants.
The determination results of the affinity constants of the humanized
antibodies
P1D7V01, 14C12H1L1 and nivolumab (as a control antibody) for human
PD-1-mFc are shown in Table 5, and the detection results are shown in FIG. 4,
FIG. 5 and FIG. 6. The affinity constants of the humanized antibodies
P1D7V01, 14C12H1L1 and nivolumab for human PD-1 -mF c were 1.76E-10
M, 1.64E-10 M and 2.32E-10 M, respectively. The above experimental results
show that the binding ability of P1D7V01 is comparable to that of 14C12H1L1
and nivolumab, suggesting that the humanized antibody P1D7V01 has stronger
binding ability to human PD-1-mFc.
Table 5. Determination of affinity constants of P1D7V01, 14C12H1L1 and
nivolumab for PD-1-mFc
Test antibodies KD (M) Kon (1/Ms) SE (kon) Kdis (Vs) S E
(kdis) Rmax (nm)
P1D7V01 1.76E-10 4.19E+05 1.52E+04 7.37E-05 3.12E-05
0.13-0.17
14C12H1L1 1.64E-10 4.55E+05 1.61E+04 7.47E-05 2.98E-05 0.24-0.28
Nivolumab 2.32E-10 5.85E+05 2.03E+04 1.36E-04 3.47E-05 0.02-0.14
KD is the affinity constant; KD = kdis/kon
56
CA 03176321 2022- 10- 20
IP190597
Example 11: Kinetic parameters for binding of anti-CD73/anti-PD-1
bispecific antibodies to antigen human NT5E(1-552)-his determined by
Fortebio system
The sample dilution buffer was PBST, pH 7.4. The antibody was immobilized
on a Protein A sensor at a concentration of 5 ixg/mL with the immobilization
time of about 15 s. The sensor was equilibrated in a buffer for 120 s, and the
binding of the immobilized antibody on the sensor to the antigen human
NT5E(1-552)-his at concentrations of 3.125-200 nM (two-fold dilution) was
determined for 120 s. The protein was dissociated in the buffer for 600 s. The
sensor was refreshed with 10 mM Gly solution, pH 1.5. The detection
temperature was 37 C, the detection frequency was 0.6 Hz, and the sample
plate shaking rate was 1000 rpm. The data were analyzed by 1:1 model fitting
to obtain affinity constants.
The determination results of the affinity constants of the humanized
antibodies
P1D7V01 and MEDI9447 (as a control antibody) for human NT5E(1-552)-his
are shown in Table 6, and the detection results are shown in FIG. 7 and FIG.
8.
The affinity constants of the humanized antibodies P1D7V01 and MEDI9447
for human NT5E(1-552)-his are 2.29E-10 M and 1.04E-10 M respectively.
The above experimental results showed that the binding ability of P1D7V01 is
comparable to that of MEDI9447, suggesting that the humanized antibody
P1D7V01 has stronger binding ability to human NT5E(1-552)-his.
Table 6. Affinity constants of P1D7V01 and MEDI9447 for NT5E(1-552)-his
Test antibodies KD (M) Kon (1/Ms) S E (kon) Kdis (Vs) S E
(kdis) Rmax (nm)
P1D7V01 2.29E-10 1.81E+05 2.30E+03 4.13E-05 4.54E-06 0.47-0.57
MEDI 9447 1.04E-10 2.34E+05 3.20E+03 2.44E-05
5.02E-06 0.59-0.82
KD is the affinity constant; KD = kdis/kon
Example 12: Binding activity of anti-CD73/anti-PD-1 bispecific antibodies
57
CA 03176321 2022- 10- 20
IP190597
determined by FACS
1. Binding activity of anti-CD73/anti-PD-1 bispecific antibody to PD-1 on
293T-PD1 membrane surface determined by FACS
293T-PD1 cells in logarithmic growth phase were collected and transferred to
a 1.5 mL centrifuge tube at 3 x 105 cells/tube. 500 4, of PBSA was added, and
the mixture was centrifuged at 5600 rpm for 5 min to remove the supernatant.
100 4, of antibodies diluted by PBSA (at the final concentrations of 100 nM,
33.33 nM, 11.11 nM, 3.7 nM, 1.23 nM, 0.41 nM, 0.14 nM and 0.05 nM,
respectively) were added, respectively. The system was mixed gently and
uniformly, and then was incubated on ice for 1 h. Then 500 4, of PBSA was
added, and the mixture was centrifuged at 5600 rpm for 5 min to remove the
supernatant. The 500-fold diluted FITC labeled goat anti-human IgG secondary
antibody (Jackson, Cat. No. 109-095-098) was added to resuspend and mix
well, and the mixture was incubated on ice in the dark for 0.5 h. 500 4, of
PBSA was added, and the mixture was centrifuged at 5600 rpm for 5 min to
remove the supernatant. At last, 200 4, of PBSA was added to resuspend cell
precipitates, and the mixture was transferred to a flow tube for FACSCalibur
detection.
The experimental results are shown in Table 7 and FIG. 9, and P1D7V01,
P1D7V02R, P1D7V03, and P1D7VO4R can specifically bind to PD-1 on the
293T-PD1 membrane surface in a dose-dependent manner, and compared with
PD1 single-target control antibody 14C12H1L1, it is stronger than that of
14C12H1L1.
Under the same experimental conditions, EC50 values of P1D7V01,
P1D7V02R, P1D7V03 and P1D7VO4R binding to 293T-PD1 were 1.000 nM,
1.075 nM, 1.377 nM and 1.57 nM, respectively, and the EC50 value of
14C12H1L1 binding to 293T-PD1 was 2.111 nM.
The above experimental results showed that in the same experimental
condition, P1D7V01, P1D7V02R, P1D7V03, P1D7VO4R and 293 T-PD1 all
have binding activity superior to that of the PD1 single-target control
antibody
58
CA 03176321 2022- 10- 20
IP190597
14C12H1L1, suggesting that P1D7V01, P1D7V02R, P1D7V03 and
P1D7VO4R have the activity of effectively binding to PD-1 on the 293T-PD1
membrane surface.
Table 7. Binding activity of P1D7V01, P1D7V02R, P1D7V03, P1D7VO4R
and 14C12H1L1 to PD-1 on 293T-PD1 cell surface determined by FACS.
Concentration (nM) 0.05 0.14 0.41 1.23 3.70 11.11
33.33 100.00 EC50
14C12H1L1
35.69 57.70 129.42 437.62 974.97 1384.91 1174.75 1500.20 2.111
P1D7V01
26.65 58.65 150.57 307.19 530.77 577.76 479.34 531.15 1.000
P1D7V02R
23.44 42.98 108.44 217.56 404.33 426.06 405.29 301.40 1.075
P1D7V03
24.05 49.21 118.03 289.08 384.62 459.40 808.38 343.48 1.377
P1D7VO4R
24.79 52.43 112.56 288.79 466.72 1284.73 400.33 360.79 1.57.0
2. Binding activity of anti-CD73/anti-PD-1 bispecific antibody to CD73
on MDA-MB-231 membrane surface determined by FACS
MDA-MB-231 cells in logarithmic phase were digested with conventional
trypsin and transferred to a 1.5 mL centrifuge tube at 3 x 105 cells/tube. 500
L
of PBSA was added, and the mixture was centrifuged at 5600 rpm for 5 min to
remove the supernatant. 100 L of antibodies diluted by PBSA (at the final
concentrations of 100 nM, 33.33 nM, 11.11 nM, 3.7 nM, 1.23 nM, 0.41 nM,
0.14 nM and 0.05 nM, respectively) were added, respectively. The system was
mixed gently and uniformly, and then was incubated on ice for 1 h. Then 500
L of PBSA was added, and the mixture was centrifuged at 5600 rpm for 5
min to remove the supernatant. The 500-fold diluted FITC labeled goat
anti-human IgG secondary antibody (Jackson, Cat. No. 109-095-098) was
added to resuspend and mix well, and the mixture was incubated on ice in the
dark for 0.5 h. 500 L of PBSA was added, and the mixture was centrifuged at
5600 rpm for 5 min to remove the supernatant. At last, 200 L of PBSA was
added to resuspend cell precipitates, and the mixture was transferred to a
flow
tube for FACSCalibur detection.
59
CA 03176321 2022- 10- 20
IP190597
The experimental results are as shown in Table 8 and FIG. 10. The binding
activities of P1D7V01 and P1D7V03 to CD73 on the MDA-MB-231
membrane surface were superior to that of 19F3H2L3, wherein P1D7V01 was
superior to the reference drug MEDI9447 for the same target. In the same
experimental condition, the EC50 values of P1D7V01 and P1D7V03 binding to
CD73 on the MDA-MB-231 membrane surface were 1.384 nM and 2.009 nM,
respectively, and the EC50 values of MEDI9447 and 19F3H2L3 binding to
CD73 on MDA-MB-231 membrane surface were 1.589 nM and 2.773 nM,
respectively.
The above experimental results showed that P1D7V01, P1D7V03, 19F3H2L3
and the reference drug MEDI9447 for the same target can specifically bind to
CD73 on the MDA-MB-231 membrane surface in a dose-dependent manner.
The binding activities of P1D7V01 and P1D7V03 were superior to that of
19F3H2L3, wherein P1D7V01 was superior to the reference drug MEDI9447
for the same target. It was suggested that P1D7V01 and P1D7V03 have the
activity of effectively binding to CD73 on the MDA-MB-231 membrane
surface.
Table. 8. Binding activity of P1D7V01, P1D7V03, MEDI9447 and 19F3H2L3
to CD73 on the MDA-MB-231 cell surface determined by FACS
Concentration
0.05 0.14 0.41 1.23 3.70 11.11 33.33 100.00 EC50
(nM)
MED19447
32.59 64.38 157.75 388.51 697.80 829.29 930.26 878.04 1.589
19F3H2L3
25.95 45.13 102.56 189.07 466.87 658.72 843.09 639.57 2.773
P1D7V01
23.37 38.02 76.84 271.72 571.56 560.81 525.91 705.50 1.384
P1D7V03
16.96 44.05 106.39 233.32 457.61 525.37 576.19 677.66 2.009
Example 13: Detection of inhibition of anti-CD73/anti-PD-1 bispecific
antibody on enzyme activity of CD73 on cell membrane surface
1. Detection of inhibition of anti-CD73/anti-PD-1 bispecific antibody on
enzyme activity of CD73 on MDA-MB-231 membrane surface
The experimental procedures were as follows. MDA-MB-231 cells in
CA 03176321 2022- 10- 20
IP190597
logarithmic phase in good condition were taken, resuspended in a serum-free
RPMI-1640 culture solution, and then counted. The MDA-MB-231 cells were
seeded into a 96-well plate at 2 x 104 cells/100 L/well. The antibody was
diluted with the serum-free RPMI-1640 culture solution (serial 2.5-fold
dilution). The antibody was added to the 96-well plate at 50 L/well, and the
plate was incubated at 37 C for 1 h. After 1 h, 50 L of 1200 M
RPMI-1640-diluted AMP (TCL, Cat. No. A0157) was added to each well.
After 3 h, 25 L of cell culture supernatant was taken and transferred to a
new
96-well plate, and 25 L of 100 M ATP (TCL, Cat. No. A0158) was added to
each well. 50 L of CTG (CellTiterGlo, promega, Cat. No. G8641)
chromogenic solution was added to each well for chromogenesis, and relative
fluorescence intensity RLU was read by a multi-label microplate tester
(PerkinElmer 2140-0020).
The experimental results are as shown in FIG. 11. The AMP amounts of
P1D7V01, P1D7V02R, P1D7V03 and P1D7VO4R are comparable to that of
the positive control MEDI9447 in concentration-dependent manners.
The above experimental results showed that the added AMP can be converted
into adenosine A without antibodies by the enzyme activity of CD73 on the
MDA-MB-231 cell surface, and that after the addition of the antibody, the
enzyme-catalyzed activity was decreased due to the binding of
antibodiesP1D7V01, P1D7V02R, P1D7V03 and P1D7VO4R to CD73, so that
the AMP was not converted into adenosine A. It was suggested that the
antibodies effectively inhibit the enzyme activity reaction thereof in a
non-substrate competition mode and reduce the production of adenosine.
2. Detection of inhibition of anti-CD73/anti-PD-1 bispecific antibody on
enzyme activity of CD73 on U87-MG membrane surface
U87-MG cells in logarithmic phase in good condition were taken, resuspended
in a serum-free RPMI-1640 culture solution, and then counted. The U87-MG
cells were seeded into a 96-well plate at 2 x 104 cells/100 L/well. The
61
CA 03176321 2022- 10- 20
IP190597
antibody was diluted with the serum-free RPMI-1640 culture solution (serial
2.5-fold dilution). The antibody was added to the 96-well plate at 50 L/well,
and the plate was incubated at 37 C for 1 h. After 1 h, 50 L of 1200 M
RPMI-1640-diluted AMP was added to each well. After 3 h, 25 L of cell
culture supernatant was taken and transferred to a new 96-well plate, and 25
L of 100 M ATP was added to each well. 50 L of CTG (CellTiterGlo)
chromogenic solution was added to each well for chromogenesis, and relative
fluorescence intensity RLU were read by a multi-label microplate tester
(PerkinElmer 2140-0020).
The experimental results are as shown in FIG. 12. The AMP amounts of
P1D7V01, P1D7V02R, P1D7V03 and P1D7VO4R are comparable to that of
the positive control MEDI9447 in concentration-dependent manners.
The above experimental results showed that the added AMP can be converted
into adenosine A without antibodies by the enzyme activity of CD73 on the
U87-MG cell surface, and that after the addition of the antibody, the
enzyme-catalyzed function was decreased due to the binding of
antibodiesP1D7V01, P1D7V02R, P1D7V03 and P1D7VO4R to CD73, so that
the AMP was not converted into adenosine A. It was suggested that the
antibodies effectively inhibit the enzyme activity reaction thereof in a
non-substrate competition mode and reduce the production of adenosine.
Example 14: Biological activity of anti-CD73/anti-PD-1 bispecific
antibodies for promoting IFN-y and IL-2 secretion determined by mixed
lymphocyte reaction (MLR)
1. Biological activity of anti-CD73/anti-PD-1 bispecific antibodies for
promoting IFN-y secretion in Raj i-PDL1 mixed lymphocyte reaction system
Raji-PDL1 cells were normally subcultured. PBMCs were thawed, incubated
with 10 mL of a 1640 complete medium, and stimulated with 0.5 g,/mL SEB
(Dianotech, Cat. No. S010201) for two days. Raji-PDL1 cells were treated
with 25 g/mL MMC (Sigma, Cat. No. M4287) and placed in a 37 C
62
CA 03176321 2022- 10- 20
IP190597
incubator for 1 h. PBMCs (peripheral blood mononuclear cells) stimulated
with SEB for 2 days and Raji-PDL1 cells treated with MMC for 1 h were
collected, washed twice with PBS, resuspended in the complete medium, and
counted. The cells were separately added to a U-shaped 96-well plate at
100,000 cells/well. The antibodies were added according to the study design
and cultured in an incubator for 3 days. After 3 days, the cell culture
supernatant was collected and determined for IFN-y by ELISA.
As shown in FIG. 13, the mixed culture of human PBMCs and Raji-PDL1 cells
significantly promoted the secretion of IFN-y from PBMCs, and the addition of
antibodies to the mixed culture system significantly induced secretion of IFN-
y
in PBMCs. In terms of the level of promoting IFN-y secretion activity, the
antibodies P1D7V01, P1D7V02R, P1D7V03 and P1D7VO4R have the activity
comparable to that of the parent PD-1 single-target antibody 14C12H1L1.
2. Biological activity of anti-CD73/anti-PD-1 bispecific antibodies for
promoting IL-2 secretion in Raji-PDL1 mixed lymphocyte reaction system
Raji-PDL1 cells were normally subcultured. PBMCs were thawed, incubated
with 10 mL of a 1640 complete medium, and stimulated with SEB (0.5 g/mL)
for two days. Raji-PDL1 cells were treated with 25 g/mL MMC and placed in
a 37 C incubator for 1 h. PBMCs (peripheral blood mononuclear cells)
stimulated with SEB for 2 days and Raji-PDL1 cells treated with MMC for 1 h
were collected, washed twice with PBS, resuspended in the complete medium,
and counted. The cells were separately added to a U-shaped 96-well plate at
100,000 cells/well. The antibodies were added according to the study design
and cultured for 3 days. The cell culture supernatant was collected and
determined for IL-2 by ELISA.
As shown in FIG. 14, the mixed culture of human PBMCs and Raji-PDL1 cells
had certain promoting effect on the secretion of IL-2 in PBMCs, and the
simultaneous addition of antibodies to the mixed culture system significantly
induced IL-2 secretion in PBMCs in a significant dose-dependent manner. In
63
CA 03176321 2022- 10- 20
IP190597
terms of the level of promoting IL-2 secretion activity, the bifunctional
antibodies P1D7V01, P1D7V02R, P1D7V03 and P1D7VO4R have the activity
at low concentrations slightly lower than that of the parent PD-1 single-
target
antibody 14C12H1L1, and the activity at medium-high concentrations
comparable to that of the parent PD-1 single-target antibody 14C12H1L1.
Compared with the PD1 target positive control drug nivolumab, P1D7V01,
P1D7V02R, P1D7V03 and P1D7VO4R have better IL-2 secretion promotion
potential at three different antibody concentration levels.
3. Bioactivity detection of anti-CD73/anti-PD-1 bispecific antibody
promoting DC mixed lymph reaction system to secrete IFN-y
PBMCs in normal human peripheral blood were isolated, resuspended in a
complete medium, and seed into a culture dish. The culture dish was placed in
an incubator overnight for culture. The suspended PBMCs were collected and
removed. The adherent cells at the bottom of the dish were washed with PBS
buffer and then subjected to DC maturation induction. 10 mL of RPMI1640
complete medium containing GM-CSF and IL-4 was added to each dish with
GM-CSF and IL-4 each at a concentration of 1000 U/mL. The dishes were
cultured in a 37 C, 5% carbon dioxide incubator for three days. Then half of
the medium was exchanged, 1000 U/mL GM-CSF and IL-4 each was added,
and the dishes were put into a 37 C, 5% carbon dioxide incubator for
continuous culture for three days. After three days, half amount of the medium
was changed again, 1000 U/mL GM-CSF and IL-4 each, and 100 U/mL TNF-a
were added, and the dishes were cultured for another two days. PBMCs from
other donors were freshly isolated and seeded into a 96-well plate at 100,000
cells/well after cell counting. DCs induced to mature were collected and
washed once with the complete medium. The cells were counted and seed into
the 96-well plate containing PBMC at 10,000 cells/well. The antibodies were
added according to the study design. The system was mixed well and cultured
in a 37 C, 5% carbon dioxide incubator for 5 days for co-culture. After 5
days,
64
CA 03176321 2022- 10- 20
IP190597
the cell culture supernatant was collected and quantitatively determined for
IFN-y by ELISA.
The results are as shown in FIG. 15. Compared with the culture of DCs or
PBMCs alone, the mixed culture of DCs and PBMCs significantly promoted
the secretion of IFN-y, and compared with an isotype control, IFN-y secretion
level was further significantly improved by the addition of the
anti-CD73/anti-PD-1 bispecific antibody based on the mixed culture of DCs
and PBMCs.
Biological activity of anti-CD73/anti-PD-1 bispecific antibodies for promoting
IL-2 secretion in DC mixed lymphocyte reaction system
PBMCs in normal human peripheral blood were isolated, resuspended in a
complete medium, and seed into a culture dish. The culture dish was placed in
an incubator overnight for culture. The suspended PBMCs were collected and
removed. The adherent cells at the bottom of the dish were washed with PBS
buffer and then subjected to DC maturation induction. 10 mL of RPMI1640
complete medium containing GM-CSF and IL-4 was added to each dish with
GM-CSF and IL-4 each at a concentration of 2000 U/mL. The dishes were
cultured in a 37 C, 5% carbon dioxide incubator for three days. Then half
amount of the medium was changed, 50 ng/mL IFN-y and 100 ng/mL LPS
were added, and the dishes were cultured for another two days. PBMCs from
other donors were thawed and seeded into a 96-well plate at 100,000 cells/well
after cell counting. DCs induced to mature were collected and washed once
with the complete medium. The cells were counted and seed into the 96-well
plate containing PBMCs at 10,000 cells/well. The antibodies were added
according to the study design. The system was mixed well and cultured in a
37 C, 5% carbon dioxide incubator for 5 days for co-culture. After 5 days,
the
cell culture supernatant was collected and quantitatively determined for IL-2
by ELISA. The results are as shown in FIG. 16. Compared with the culture of
DCs or PBMCs alone, the mixed culture of DCs and PBMCs significantly
promoted the secretion of IL-2, and compared with an isotype control, IL-2
CA 03176321 2022- 10- 20
IP190597
secretion level was further significantly improved by the addition of the
anti-CD73/anti-PD-1 bispecific antibody based on the mixed culture of DCs
and PBMCs.
Example 15: Preparation of anti-PD-1/CD73 bispecific antibodies
NTPDV1, NTPDV2, NTPDV3 and NTPDV4
The structural patterns of the bispecific antibodies NTPDV1, NTPDV2,
NTPDV3 and NTPDV4 are in the Morrison format (IgG-scFv), i.e., C termini
of two heavy chains of one IgG antibody are separately linked to the scFv
fragment of another antibody via linkers. The components for the heavy and
light chain design are shown in Table 9 below.
NTPDV1, NTPDV2, NTPDV3 and NTPDV4 are known as
NTPDV1 (hG1 TM), NTPDV2(hG1 TM), NTPDV3 (hG1 TM)
and
NTPDV4(hG1TM) herein and in Chinese Patent Application No.
202110270671.X, because the constant regions of the immunoglobulin
moieties thereof have introduced amino acid mutations to eliminate their
binding activity to FcyR.
Table 9. Sequence design of NTPDV1, NTPDV2, NTPDV3 and NTPDV4
Heavy chain
Light
Immuno globulin .
Linker scFv moiety
chain
moiety
NTPDV1 14C12H1v-Linker 2-14C12L1v
19F3L3
NTPDV2 19F3H2 14C12H1v-Linker 1-14C12L1v
Linkerl
NTPDV3 (hG1TM) 14C12H1v-Linker 2-14C12L1v
19F3L2
NTPDV4 14C12H1v-Linker1-14C12L1v
In the Table 9 above:
Those with "V" label at lower right corner refer to the variable region of
corresponding heavy chain or the variable region of corresponding light chain.
For those without "V" label, the corresponding heavy or light chain is the
full
length comprising the constant region. The corresponding sequences described
66
CA 03176321 2022- 10- 20
IP190597
in the above examples are referred to for the amino acid sequences of these
variable regions or the full length and the nucleotide sequences encoding
them.
The amino acid sequence of linked consists of 4 repeats of (GGGGS), i.e.,
(GGGGS)4 or (G4S)4 (nucleotide sequence SEQ ID NO: 80, and amino acid
sequence SEQ ID NO: 79).
The amino acid sequence of 1inker2 consists of 3 repeats of (GGGGS), i.e.,
(GGGGS)4 or (G45)3 (nucleotide sequence SEQ ID NO: 82, and amino acid
sequence SEQ ID NO: 81).
The 3 CDR sequences of the light chains 19F3L2 and 19F3L3 of the
immunoglobulin moiety in NTPDV1, NTPDV2, NTPDV3 and NTPDV4 are
identical to the light chain CDR sequences of 19F3.
The 3 CDR sequences of 19F3H2(hG1TM) of the immunoglobulin moiety in
NTPDV1, NTPDV2, NTPDV3 and NTPDV4 are identical to the heavy chain
CDR sequences of 19F3.
The CDR sequences of 14C12H1V-Linker2-14C12L1V and
14C12H1V-Linkerl -14C12L1V of the scFv moiety in NTPDV1, NTPDV2,
NTPDV3 and NTPDV4 are identical to the heavy chain CDRs and light chain
CDRs of 14C12.
The amino acid sequences of the heavy chains of NTPDV2 and NTPDV4 are
identical and are marked as NTPDH2/4 (SEQ ID NO: 83), and the nucleotide
sequence of the heavy chains of NTPDV2 or NTPDV4 is SEQ ID NO: 84.
The amino acid sequences of the heavy chains of NTPDV1 and NTPDV3 are
identical and are marked as NTPDH1/3 (SEQ ID NO: 85), and the nucleotide
sequence of the heavy chains of NTPDV1 or NTPDV3 is SEQ ID NO: 86.
The 3 CDR sequences of 19F3L3 and 19F3L2 of the immunoglobulin moiety
in NTPDV1, NTPDV2, NTPDV3 and NTPDV4 are identical to the three
CDRs of the light chain of antibody 19F3.
The amino acid sequence of the light chain 19F3L3 of the immunoglobulin
moiety in NTPDV1 or NTPDV2 is identical to the light chain sequence (SEQ
ID NO: 28) of antibody 19F3H2L3(G1M), and the nucleotide sequence of the
67
CA 03176321 2022- 10- 20
IP190597
light chain 19F3L3 of the immunoglobulin moiety in NTPDV1 or NTPDV2 is
SEQ ID NO: 27. The amino acid sequence of the light chain 19F3L2 of the
immunoglobulin moiety in NTPDV3 or NTPDV4 is SEQ ID NO: 96, and the
nucleotide sequence of the light chain 19F3L2 of the immunoglobulin moiety
in NTPDV3 or NTPDV4 is SEQ ID NO: 100.
(1) NTPDV1, of which the heavy chain has an amino acid sequence set forth in
SEQ ID NO: 85, the light chain has an amino acid sequence set forth in SEQ
ID NO: 28, the linker 1 has an amino acid sequence set forth in SEQ ID NO:
79, 14C12H1V has an amino acid sequence set forth in SEQ ID NO: 66, the
linker 2 has an amino acid sequence set forth in SEQ ID NO: 81, and
14C12L1V has an amino acid sequence set forth in SEQ ID NO: 68;
(2) NTPDV2, of which the heavy chain has an amino acid sequence set forth in
SEQ ID NO: 85, the light chain has an amino acid sequence set forth in SEQ
ID NO: 28, the linker 1 has an amino acid sequence set forth in SEQ ID NO:
79, 14C12H1V has an amino acid sequence set forth in SEQ ID NO: 66, the
linker 1 has an amino acid sequence set forth in SEQ ID NO: 79, and
14C12L1V has an amino acid sequence set forth in SEQ ID NO: 68;
(3) NTPDV3, of which the heavy chain has an amino acid sequence set forth in
SEQ ID NO: 85, the light chain has an amino acid sequence set forth in SEQ
ID NO: 96, the linker 1 has an amino acid sequence set forth in SEQ ID NO:
79, 14C12H1V has an amino acid sequence set forth in SEQ ID NO: 66, the
linker 2 has an amino acid sequence set forth in SEQ ID NO: 81, and
14C12L1V has an amino acid sequence set forth in SEQ ID NO: 68; and
(4) NTPDV4, of which the heavy chain has an amino acid sequence set forth in
SEQ ID NO: 85, the light chain has an amino acid sequence set forth in SEQ
ID NO: 96, the linker 1 has an amino acid sequence set forth in SEQ ID NO:
79, 14C12H1V has an amino acid sequence set forth in SEQ ID NO: 66, the
linker 1 has an amino acid sequence set forth in SEQ ID NO: 79, and
14C12L1V has an amino acid sequence set forth in SEQ ID NO: 68.
68
CA 03176321 2022- 10- 20
IP190597
Expression and purification of antibodies
The heavy chain cDNA sequences of NTPDV1 and NTPDV3, the heavy chain
cDNA sequences of NTPDV2 and NTPDV4, and the light chain cDNA
sequences thereof were separately cloned into vector pUC57simple (provided
by Genscript) to obtain plasmids pUC57simple-NTPDH2/4,
pUC57simple-NTPDH1/3, pUC57simple-19F3L3 and pUC57simp1e-19F3L2,
respectively.
Plasmid pUC57simple-NTPDH2/4 and plasmid pUC57simple-19F3L3,
plasmid pUC57simple-NTPDH2/4 and plasmid pUC57simp1e-19F3L2,
plasmid pUC57simp1e-NTPDH1/3 and plasmid pUC57simp1e-19F3L3, and
plasmid pUC57simple-NTPDH1/3 and plasmid pUC57simple-19F3L2 were
digested (HindIII&EcoRI). The recovered heavy and light chains were
separately subcloned into vector pcDNA3.1 to obtain plasmids
pcDNA3.1-NTPDH2/4 and pcDNA3.1-19F3L3,
plasmids
pcDNA3.1-NTPDH2/4 and pcDNA3.1-19F3L2,
plasmids
pcDNA3.1-NTPDH1/3 and pcDNA3 .1 -19F3L3, and
plasmids
pcDNA3.1-NTPDH1/3 and pcDNA3.1-19F3L2. The recombinant plasmids
were extracted and co-transfected into 293F cells. After 7 days of cell
culture,
the culture medium was separated by centrifugation at high speed, and the
supernatant was concentrated and loaded onto a HiTrap MabSelect SuRe
column. The protein was eluted in one step with an elution buffer. The target
sample was isolated and the buffer was exchanged into PBS.
The purified antibodies NTPDV1, NTPDV2, NTPDV3 and NTPDV4 were
obtained according to the expression and purification methods mentioned in
the above preparation examples.
Example 16: Assay for binding activity of anti-CD73/anti-PD-1 bispecific
antibodies to antigens by ELISA
1. Binding activity of NTPDV1, NTPDV2, NTPDV3 and NTPDV4 to
69
CA 03176321 2022- 10- 20
IP190597
antigen PD-1-mFc determined by ELISA
A microplate was coated with PD-1-mFc (0.5 g/mL) and incubated at 4 C
overnight. Then the microplate coated with antigens was washed once with
PBST, and then blocked with a PBS solution containing 1% BSA as blocking
solution at 37 C for 2 h. After blocking, the microplate was washed 3 times
with PBST. The antibodies serially diluted with PBST solution (the dilution
gradients for the antibody are shown in Table 2) were added. The microplate
containing the test antibodies was incubated at 37 C for 30 min, and then
washed 3 times with PBST. After washing, HRP-labeled goat anti-human IgG
Fc (Jackson, Cat. No. 109-035-098) secondary antibody working solution
diluted in a ratio of 1:5000 was added, and then the microplate was incubated
at 37 C for 30 min. After incubation, the plate was washed 4 times with
PBST, TMB (Neogen, 308177) was added in the dark for chromogenesis for 8
min, and then a stop solution was added to terminate chromogenic reaction.
The microplate was put into a microplate reader immediately, and the OD
value of each well in the microplate was read at 450 nm. The data were
analyzed and processed by SoftMax Pro 6.2.1.
The results are shown in Table 10. It can be seen that NTPDV1, NTPDV2,
NTPDV3 and NTPDV4 can effectively bind to the antigen PD-1-mFc in a
dose-dependent manner. The absorbance intensity of each dose is shown in
Table 10. By quantitative analysis of the absorbance of the bound antibodies,
the binding efficiency EC50 values of the antibodies NTPDV1, NTPDV2,
NTPDV3, NTPDV4 and 14C12H1L1(hG1TM) (as a control) obtained by
curve fitting were 0.101 nM, 0.119 nM, 0.110 nM, 0.123 nM and 0.031 nM,
respectively.
The above experimental results showed that in the same experimental
condition, the binding activities of NTPDV1, NTPDV2, NTPDV3 and
NTPDV4 to PD-1-mFc are comparable to that of the reference drugs
14C12H1L1(hG1TM) for the same target, suggesting that NTPDV1, NTPDV2,
NTPDV3 and NTPDV4 have the activity of effectively binding to PD-1-mFc.
CA 03176321 2022- 10- 20
IP190597
Table 10. Binding of NTPDV1, NTPDV2, NTPDV3, NTPDV4 and
14C12H1L1(hG1TM) to PD-1-mFc determined by ELISA
Antigen coating PD-1-mFc 0.5 ug/mL
Antibody dilution
concentration (nM) NTPDV1 NTPDV2 NTPDV3
NTPDV4 14C12H1L1
(hG1TM)
2.222 2.231 2.249 2.249 2.204 2.171 2.244 2.289 2.399 2.524
1:3
2.206 2.195 2.160 2.223 2.211 2.167 2.222 2.209 2.361 2.441
1:9
2.039 2.027 1.922 2.013 2.010 1.971 1.920 1.944 2.273 2.401
1:27
1.514 1.530 1.425 1.446 1.489 1.414 1.417 1.464 2.071 2.091
1:81
0.880 0.844 0.804 0.802 0.829 0.807 0.794 0.804 1.644 1.691
1:243
0.400 0.396 0.363 0.369 0.386 0.381 0.373 0.379 1.006 1.059
1:729
0.183 0.184 0.176 0.174 0.175 0.174 0.170 0.178 0.503 0.531
0
0.053 0.056 0.055 0.056 0.056 0.056 0.054 0.059 0.057 0.059
Secondary antibody HRP-labeled goat anti-human IgG Fc
(1:5000)
EC50
0.101 0.119 0.110 0.123
0.031
(nM)
2. Binding activity of NTPDV1, NTPDV2, NTPDV3 and NTPDV4 to
antigen human NT5E-biotin determined ELISA
A microplate was coated with streptavidin SA (2 g/mL) and then incubated at
4 C overnight. After incubation, the microplate coated with streptavidin was
washed once with PBST, and blocked with a PBS solution containing 1% BSA
as a microplate blocking solution at 37 C for 2 h. After blocking, the
microplate was washed 3 times with PBST. Then, 0.5 g/mL antigen human
NT5E-Biotin was added and incubated at 37 C for 30 min. Then, the plate was
washed 3 times with PBST. The antibodies serially diluted with PBST solution
(the dilution gradients for the antibody are shown in Table 11) were added to
wells of the microplate. The microplate containing the test antibodies was
incubated at 37 C for 30 min, and then washed 3 times with PBST. After
washing, HRP-labeled goat anti-human IgG Fc (Jackson, Cat. No.
71
CA 03176321 2022- 10- 20
IP190597
109-035-098) secondary antibody working solution diluted in a ratio of 1:5000
was added, and the microplate was incubated at 37 C for 30 min. After
incubation, the plate was washed 4 times with PBST, TMB (Neogen, 308177)
was added in the dark for chromogenesis for 7 min, and then a stop solution
was added to terminate chromogenic reaction. The microplate was put into a
microplate reader immediately, and the OD value of each well in the
microplate was read at 450 nm. The data were analyzed and processed by
SoftMax Pro 6.2.1.
The results are shown in Table 11. It can be seen that NTPDV1, NTPDV2,
NTPDV3, NTPDV4 and 19F3H2L3(hG1M) can effectively bind to the antigen
human NT5E-biotin in a dose-dependent manner (the absorbance intensity of
each dose is shown in Table 11). By quantitative analysis of the absorbance of
the bound antibodies, the binding efficiency EC50 values of the antibodies
NTPDV1, NTPDV2, NTPDV3, NTPDV4 and 19F3H2L3(hG1M) (as a control
antibody) obtained by curve fitting were 0.079 nM, 0.082 nM, 0.084 nM, 0.077
nM and 0.029 nM, respectively.
The above experimental results showed that in the same experimental
condition, the binding activities of bispecific antibodies NTPDV1, NTPDV2,
NTPDV3 and NTPDV4 to human NT5E-biotin are comparable to that of the
reference drug 19F3H2L3(hG1M) for the same target, suggesting that
NTPDV1, NTPDV2, NTPDV3 and NTPDV4 have the activity of effectively
binding to human NT5E-biotin.
Table 11. Binding of NTPDV1, NTPDV2, NTPDV3, NTPDV4 and
19F3H2L3(hG1M) to human NT5E-biotin determined by ELISA
Antigen coating SA: 2 lig/mL
Antibody dilution Human NT5E-biotin (0.5 lig/mL)
concentration (nM)
NTPDV1 NTPDV2 NTPDV3 NTPDV4 19F3H2L3
(hG1M)
2.286 2.300 2.322 2.333 2.364 2.286 2.298 2.291 2.371 2.383
1:3
2.412 2.347 2.450 2.409 2.381 2.412 2.427 2.421 2.420 2.506
1:9
2.227 2.177 2.226 2.238 2.230 2.081 2.186 2.222 2.322 2.345
72
CA 03176321 2022- 10- 20
IP190597
1:27
1.795 1.729 1.744 1.746 1.768 1.698 1.734 1.759 2.125 2.162
1:81
1.071 1.070 1.103 1.058 1.068 1.025 1.095 1.125 1.649 1.752
1:243
0.528 0.527 0.540 0.551 0.552 0.534 0.552 0.611 1.067 1.143
1:729
0.273 0.274 0.271 0.275 0.279 0.267 0.275 0.309 0.542 0.601
0
0.092 0.092 0.090 0.087 0.092 0.090 0.092 0.095 0.112 0.206
Secondary antibody HRP-labeled goat anti-human IgG Fe
(1:5000)
EC50
0.079 0.082 0.084 0.077
0.029
(nM)
Example 17: Activity of anti-CD73/anti-PD-1 bispecific antibodies
completing with human PD-L1-mFc for binding to human
PD-1-mFc-biotin determined by competitive ELISA
A microplate was coated with human PD-L1-mFc (PD-Li Genbank ID:
NP 054862.1, mFc SEQ ID NO: 89) at 2 g/mL and incubated at 4 C
overnight. After incubation, the microplate was blocked with a PBS solution
containing 1% BSA at 37 C for 2 h. After blocking, the plate was washed
once and dried. The antibody was serially diluted to 7 concentrations in a
gradient ratio of 1:3 on a dilution plate with 10 g/mL as the starting
concentration, and a blank control was set. Then an equal volume of 0.3 g/mL
human PD-1-mFc-biotin solution was added, and the system was mixed well
and incubated at room temperature for 10 min. Then the mixture after reaction
was added to the coated microplate, and the microplate was incubated for at
37 C for 30 min. After incubation, the plate was washed three times with
PBST and dried. SA-HRP (KPL, 14-30-00) working solution was added, and
the plate was incubated at 37 C for 30 min. After incubation, the plate was
washed four times and patted dry. Then TMB (Neogen, 308177) was added in
the dark for chromogenesis for 5 min, and a stop solution was added to
terminate chromogenic reaction. Then the microplate was put into a microplate
reader immediately, and the OD value of each well in the microplate was read
at 450 nm. The data were analyzed and processed by SoftMax Pro 6.2.1.
The OD values for all the dosages are shown in Table 12. By quantitative
analysis of the absorbance intensity of the bound antibody, the curve
73
CA 03176321 2022- 10- 20
IP190597
simulation was performed to give the binding efficiency EC50 of the antibody
(Table 12).
The results showed that NTPDV1, NTPDV2, NTPDV3, NTPDV4 and
14C12H1L1(hG1TM) (as a control) can effectively block the binding of the
antigen human PD-1-mFc-biotin to its receptor human PD-L1-mFc in a
dose-dependent manner. The EC50 values of NTPDV1, NTPDV2, NTPDV3,
NTPDV4 and 14C12H1L1(hG1TM) for blocking the binding of human
PD-1-mFc-biotin to its ligand human PD-L1-mFc were 2.249 nM, 2.253 nM,
2.332 nM, 2.398 nM, 2.216 nM and 2.231 nM, respectively.
Table 12. Activity of NTPDV1, NTPDV2, NTPDV3, NTPDV4 and
14C12H1L1(hG1TM) competing with human PD-L1-mFc for binding to
human PD-1-mFc-biotin
Antibody Antigen coating: human PD-L1-mFc 2 lig/mL
dilution
14C12H1L1
(nM) NTPDV1 NTPDV2 NTPDV3 NTPDV4
(hG1TM)
50 0.086 0.082
0.084 0.081 0.077 0.087 0.076 0.076 0.081 0.077
1:3 0.083 0.083
0.083 0.084 0.083 0.085 0.084 0.090 0.087 0.082
1:9 0.202 0.195
0.204 0.204 0.195 0.183 0.189 0.214 0.120 0.119
1:27 0.604 0.616
0.564 0.593 0.628 0.598 0.521 0.584 0.576 0.634
1:81 0.837 0.821
0.790 0.809 0.816 0.884 0.782 0.768 0.797 0.871
1:243 0.946 0.938
0.822 0.929 0.895 0.851 0.926 0.891 0.880 0.934
1:729 0.956 0.938
0.884 0.878 0.928 0.923 0.854 0.902 0.901 0.964
0 1.012 0.952
0.891 0.966 0.918 0.983 0.919 0.966 0.904 0.954
Human PD-1-mFc-biotin: 0.3 lig/mL
Secondary antibody SA-HRP (1:4000)
EC50
(nM) 2.253 2.332 2.398 2.216
2.231
Example 18: Kinetic parameters for binding of anti-CD73/anti-PD-1
bispecific antibodies to antigen human PD-1-mFc determined by Fortebio
system
The sample dilution buffer was PBS (0.02% Tween-20, 0.1% BSA, pH 7.4).
PD1-mFc was immobilized on the AMC sensor at a concentration of 5 g/mL
with an immobilization height of about 0.1 nM (time 60 s). The sensor was
74
CA 03176321 2022- 10- 20
IP190597
equilibrated in a buffer for 60 s, and the binding of the immobilized PD1-mFc
on the sensor to the antibodies at concentrations of 0.62-50 nM (three-fold
dilution) was determined for 120 s. The protein was dissociated in the buffer
for 300 s. The detection temperature was 30 C, the detection frequency was
0.3 Hz, and the sample plate shaking rate was 1000 rpm. The data were
analyzed by 1:1 model fitting to obtain affinity constants.
The determination results of the affinity constants of humanized antibodies
NTPDV1, NTPDV2, NTPDV3, NTPDV4 and nivolumab (as control antibody)
for human PD-1-mFc are shown in Table 13, and the detection results are
shown in FIGs. 19, 20, 21, 22 and 18. The affinity constants of the humanized
antibodies NTPDV1, NTPDV2, NTPDV3, NTPDV4 and nivolumab for human
PD-1-mFc were 1.40E-10 M, 7.39E-11 M, 1.25E-10 M, 1.13E-11 M and
2.26E-10 M, respectively. The above experimental results showed that the
binding ability of NTPDV1, NTPDV3 and nivolumab is comparable, and the
binding ability of NTPDV2 and NTPDV4 is superior to that of nivolumab,
suggesting that the humanized antibodies NTPDV1, NTPDV2, NTPDV3 and
NTPDV4 have stronger binding ability to human PD-1-mFc.
Table 13. Affinity constants of 14C12H1L1(hG1TM), NTPDV1, NTPDV2,
NTPDV3, NTPDV4 and nivolumab for PD-1-mFc
Test antibodies KD (M) Kon (1/Ms) S E (kon) Kdis (Vs) S E
(kdis) Rmax (nm)
14C12H1L1(hG1TM) 4.45E-11 1.18E+06 5.74E+04 5.23E-05 4.47E-05 0.38-0.57
Nivolumab 2.26E-10 1.52E+06 7.79E+04 3.43E-04 4.66E-05
0.25-0.37
NTPDV1 1.40E-10 6.09E+05 2.01E+04 8.55E-05 3.18E-05
0.38-0.52
NTPDV2 7.39E-11 6.83E+05 2.47E+04 5.05E-05 3.50E-05
0.40-0.55
NTPDV3 1.25E-10 6.68E+05 2.52E+04 8.35E-05 3.44E-05
0.38-0.50
NTPDV4 1.13E-11 5.35E+05 1.59E+04 6.03E-06 2.77E-05
0.35-0.47
KD is the affinity constant; KD = kdis/kon
Example 19: Kinetic parameters for binding of anti-CD73/anti-PD-1
bispecific antibodies to antigen human NT5E (1-552)-his determined by
Fortebio system
CA 03176321 2022- 10- 20
IP190597
The sample dilution buffer was PBS (0.02% Tween-20, 0.1% BSA, pH 7.4).
HNT5E(1-552)-his was immobilized on the HIS1K sensor at a concentration of
g/mL with an immobilization height of about 0.4 nM (time 50 s). The
sensor was equilibrated in a buffer for 60 s, and the binding of the
immobilized
HNT5E(1-552)-his on the sensor to the antibodies at concentrations of 0.31-25
nM (three-fold dilution) was determined for 100 s. The protein was dissociated
in the buffer for 180 s. The detection temperature was 30 C, the detection
frequency was 0.3 Hz, and the sample plate shaking rate was 1000 rpm. The
data were analyzed by 1:1 model fitting to obtain affinity constants.
The determination results of the affinity constants of the humanized
antibodies
19F3H2L3(hG1M) (as a control antibody), NTPDV1, NTPDV2, NTPDV3 and
NTPDV4 for human NT5E(1-552)-his are shown in Table 14, and the
detection results are shown in FIGs. 24-27. The affinity constants of the
humanized antibodies NTPDV1, NTPDV2, NTPDV3 and NTPDV4 for human
NT5E(1-552)-his were 3.29E-11 M, 2.88E-11 M, 7.92E-11 M and 5.77E-11
M, respectively.
The above experimental results showed that the binding ability of
19F3H2L3(hG1M), NTPDV1, NTPDV2, NTPDV3 and NTPDV4 is
comparable, suggesting that the humanized antibodies NTPDV1, NTPDV2,
NTPDV3 and NTPDV4 has stronger binding ability to human
NT5E(1-552)-his.
Table 14. Affinity constants of 19F3H2L3(hG1M), NTPDV1, NTPDV2,
NTPDV3 and NTPDV4 for human NT5E(1-552)-his
Test antibodies KID (M) kon (1/Ms) S E (kon) kdis (Vs) S E (kdis) Rmax (nm)
19F3H2L3
(hG1M) 4'05E-11 1.16E+06 6.50E+04 4.68E-05 8.96E-05 0.36-0.77
NTPDV1 3.29E-11 1.16E+06 3.27E+04 3.80E-05 4.63E-05 0.49-0.61
NTPDV2 2.88E-11 1.27E+06 3.84E+04 3.66E-05 4.88E-05 0.63-0.71
NTPDV3 7.92E-11 1.28E+06 4.08E+04 1.02E-04 5.29E-05 0.55-0.65
76
CA 03176321 2022- 10- 20
IP190597
NTPDV4 5.77E-11 1.23E+06 3.82E+04 7.09E-05 4.95E-05 0.52-0.63
KD is the affinity constant; KD = kdis/kon
Example 20: Detection of inhibition of anti-CD73/anti-PD-1 bispecific
antibody on enzyme activity of CD73 on U87-MG cell membrane surface
U87-MG cells in logarithmic phase in good condition were taken, resuspended
in a serum-free RPMI-1640 culture solution, and then counted. The U87-MG
cells were seeded into a 96-well plate at 2.5 x 104 cells/60 L/well. The
antibody was diluted according to the study design with the serum-free
RPMI-1640 culture solution. The antibody was added to the 96-well plate at 60
L/well, and the plate was incubated at 37 C for 1 h. After 1 h, 60 L of 600
M RPMI-1640-diluted AMP was added to each well. After 3 h, 100 L of cell
culture supernatant was taken and transferred to a new 96-well plate, 40 L of
CTG (CellTiterGlo) chromogenic solution was added to each well, and the
plate was placed in the dark at room temperature for 5 min. After 5 min, 10 L
of 300 M ATP was added to each well for chromogenesis. Relative
fluorescence intensity RLU were read by a multi-label microplate tester
(PerkinElmer 2140-0020).
The experimental results are as shown in Table 15 and FIG. 28, the AMP
amount of NTPDV2 is comparable to that of the positive control MEDI9447.
The above experimental results showed that the added AMP can be converted
into adenosine A without antibodies by the enzyme activity of CD73 on the
U87-MG cell surface, and that after the addition of the antibody, the
enzyme-catalyzed function was decreased due to the binding of antibody
NTPDV2 to CD73, so that the AMP was not converted into adenosine A. It
was suggested that the antibodies effectively inhibit the enzyme activity
reaction thereof in a non-substrate competition mode and reduce the production
of adenosine.
Table 15. Detection of inhibition of anti-CD73/anti-PD-1 bispecific antibody
on enzyme activity of CD73 on U87-MG cell membrane surface
77
CA 03176321 2022- 10- 20
IP190597
Name of antibody MEDI9447 19F3H2L3(hG1M) NTPDV2
IC50 (nM) 0.1189 0.3647 0.5551
Example 21: Biological activity of anti-CD73/anti-PD-1 bispecific
antibodies for promoting IFN-y and IL-2 secretion determined by mixed
lymphocyte reaction (MLR)
1. Biological activity of anti-CD73/anti-PD-1 bispecific antibodies for
promoting IFN-y secretion in Raj i-PDL1 mixed lymphocyte reaction system
Raji-PDL1 cells were normally subcultured. PBMCs were thawed, incubated
with 10 mL of a 1640 complete medium, and stimulated with 0.5 ixg/mL SEB
(Dianotech, Cat. No. S010201) for two days. Raji-PDL1 cells were treated
with 25 ixg/mL MMC (mitomycin C, Stressmarq, catalog: SIH-246, Cat. No.
SM286474) and placed in a 37 C incubator for 1 h. PBMCs (peripheral blood
mononuclear cells) stimulated with SEB for 2 days and Raji-PDL1 cells treated
with MMC for 1 h were collected, washed twice with PBS, resuspended in the
complete medium, and counted. The cells were separately added to a U-shaped
96-well plate at 1 x 105 cells/well. The antibodies were added according to
the
study design and cultured in an incubator for 3 days. After 3 days, the cell
culture supernatant was collected and determined for IFN-y by ELISA.
As shown in FIG. 29, the mixed culture of human PBMCs and Raji-PDL1 cells
significantly promoted the secretion of IFN-y from PBMCs, and the addition of
antibodies to the mixed culture system significantly induced secretion of IFN-
y
in PBMCs. In terms of the level of promoting IFN-y secretion activity, the
antibody NTPDV2 has the activity comparable to that of the parent PD-1
single-target antibody 14C12H1L1.
2. Biological activity of anti-CD73/anti-PD-1 bispecific antibodies for
promoting IL-2 secretion in Raj i-PDL1 mixed lymphocyte reaction system
Raji-PDL1 cells were normally subcultured. PBMCs were thawed, incubated
78
CA 03176321 2022- 10- 20
IP190597
with 10 mL of a 1640 complete medium, and stimulated with SEB (0.5 iig/mL)
for two days. Raji-PDL1 cells were treated with 25 iig/mL MMC and placed in
a 37 C incubator for 1 h. PBMCs (peripheral blood mononuclear cells)
stimulated with SEB for 2 days and Raji-PDL1 cells treated with MMC for 1 h
were collected, washed twice with PBS, resuspended in the complete medium,
and counted. The cells were separately added to a U-shaped 96-well plate at 1
x 105 cells/well. The antibodies were added according to the study design and
cultured for 3 days. The cell culture supernatant was collected and determined
for IL-2 by ELISA.
As shown in FIG. 29, the mixed culture of human PBMCs and Raji-PDL1 cells
had certain promoting effect on the secretion of IL-2 from PBMCs, and the
simultaneous addition of antibodies to the mixed culture system significantly
induced IL-2 secretion in PBMCs in a significant dose-dependent manner. In
terms of the level of promoting IL-2 secretion activity, the bifunctional
antibody NTPDV2 has the activity at low a concentration comparable to that of
the parent PD-1 single-target antibody 14C12H1L1, and the activity at a
medium-high concentration slightly lower than that of the parent PD-1
single-target antibody 14C12H1L1.
Example 22: Experiment of inhibition of tumor growth in vivo by
anti-CD73/anti-PD-1 bispeeifie antibody
In order to determine the anti-tumor activity in vivo of the
anti-CD73/anti-PD-1 bispecific antibody, firstly, MC38-hPDLl/hCD73 cells
(from GemPharmatech Co., Ltd.) were subcutaneously inoculated into female
C57BL6-hPD1hPDL1hCD73 triple-transgenic mice aged 5-7 weeks (from
GemPharmatech Co., Ltd.). The modeling and specific administration methods
are shown in Table 16. After the administration, the length and width of each
group of tumors were measured, and the tumor volume was calculated.
Table 16. Study design
Grouping n Tumor xenograft Condition of
administration
79
CA 03176321 2022- 10- 20
IP190597
Isotype control antibody hIgG, 10
Isotype control 8 mg/kg
Twice weekly, for three weeks
19F3H2L3 1 9F3H2L3 (hG1M)m
10 mg/kg
8 MC3 8-hPDL 1 /hCD73,
(hG 1 M) Twice weekly, for
three weeks
1 million cells/mouse, s.c.
NTPDV2 8 NTPDV2, 13.3
mg/kg
Twice weekly, for three weeks
NTPDV2 8 NTPDV2, 1.33
mg/kg
Twice weekly, for three weeks
The experimental results are as shown in FIG. 30 and FIG. 31. The results
showed that compared with an isotype control antibodies hIgG and
19F3H2L3(hG1M), NTPDV2 at different doses can effectively inhibit the
growth of mouse tumors, and NTPDV2 at high dose is superior to NTPDV2 at
low-dose in inhibiting tumors. In addition, NTPDV2 had no effect on the body
weight of the tumor-bearing mouse.
Experimental Example 23: Effective elimination of bispecific immune
checkpoint inhibitor PD-1/CD73 bispecific antibody-mediated IL-8 and
IL-6 secretions in human macrophages by the amino acid mutations of Fc
segments
HPMMs were prepared by induction of PBMCs. PBMCs used in this study
were isolated and prepared in Zhongshan Akesobio Co. Ltd., with informed
consent of the donor.
Ficoll-Paque PLUS lymphocyte isolation solution (GE, Cat. No. 17-1440-03);
RPMI 1640 (Gibco, Cat. No. 22400-105); CHO-K1-PD1 cells (constructed by
Zhongshan Akesobio Co. Ltd.); U87-MG cells (cells from ATCC, purchased
from Beijing Zhongyuan Ltd.); FBS (Fetal Bovine Serum, Excell bio, Cat. No.
FSP 500); human IFN-y protein (Sinobio, Cat. No. 11725-HNAS-100), LPS
(lipopolysaccharide) (Sigma, Cat. No. L4391), a 96-well cell culture plate
(Coming).
Healthy human PBMCs were isolated according to the instructions of
insolation solution Ficoll-PaqueTM Plus reagent and resuspended in a 1640
medium containing 2% FBS. The plate was incubated in a 5% CO2 cell
CA 03176321 2022- 10- 20
IP190597
incubator at 37 C. After 2 h, the supernatant was removed, and the adherent
cells were washed twice with PBS and 1640 complete medium (containing
10% FBS) and 100 ng/mL human M-CSF were added for 7 days of induction.
On day 3 and day 5, the medium was exchanged, and M-CSF was added to
induce HPMM. On day 7, after induction of HPMM, the cells were collected,
adjusted to the concentration of 0.1 million cells/mL with the complete
medium, and filled into a 96-well plate. The recombinant human IFN-y (50
ng/mL) was added, and incubated in an incubator for 24 h. After 24 h,
CHO-K1-PD1 cells expressing human PD-1 or U87-MG cells constitutively
expressing human CD73 in logarithmic phase were collected. The cells were
resuspended and then adjusted to the concentration of 0.3 million cells/mL
with the complete medium. The antibody was diluted with the complete
medium to working concentrations of 25 nM, 2.5 nM and 0.25 nM. An isotype
control antibody and a blank control were designed simultaneously. The
supernatant in the 96-well plate was removed, the CHO-Kl-PD1 or U87-MG
cell suspension and antibodies were added (with a final volume of 200 lL).
The system was mixed well and incubated in an incubator for 24 h. The
mixture was centrifuged at 500x g for 5 min, the supernatant was collected,
and the secretion amounts of IL-8 and IL-6 were determined with a Dakewe
kit. LPS was used as a positive control and was adjusted to a concentration of
100 ng/mL with the complete medium in the experiment.
In this example, the co-culture of CHO-Kl-PD1 and U87-MG cells as target
cells with HPMM induced the activation of HPMM, and after the activated
HPMM was linked to the target cells by antibody Fab, the Fc fragment of the
antibody interacted with FcyR on HPMM, causing the secretion of cytokine by
HPMM.
3. Experimental results
The results are shown in FIGs. 32-35.
The results showed that compared with the wild-type IgG1 subtype PD-1
antibody or CD73 antibody, the anti-PD-1/CD73 bispecific antibody carrying
81
CA 03176321 2022- 10- 20
IP190597
the Fc fragment mutation is able to effectively eliminate the secretion of IL-
6
and/or IL-8 in immune cells.
The preferred embodiments of the present invention have been described above
in detail, but the present invention is not limited to the embodiments. Those
skilled in the art can make various equivalent modifications or replacements
without violating the spirit of the present invention. These equivalent
modifications or replacements are included in the scope defined by the claims
of the present application.
82
CA 03176321 2022- 10- 20
IP190597
SEQUENCE LISTING
Nucleotide sequence of 19F3 heavy chain variable region:
GAGGTGCAGCTGCAGCAGTCCGGACCAGAGCTGGTGAAGCCTGGCGCCTCCATGCGGATGT
CTTGTAAGGCCTCTGGCTACAGCTTCACCGGCTATACAATGAACTGGGTGAAGCAGTCTC
ACGGCAAGAATCTGGAGTGGATCGGCCTGATCAACCCTTACAATGCCGGCACCAGCTATA
ACCAGAAGTTTAAGGGCAAGGCCACCCTGACAGTGGACAAGAGCTCCTCTACCGCCTACAT
GGAGCTGCTGTCCCTGACATCTGAGGATAGCGCCGTGTACTATTGCGCCCGGTCCGAGTAC
AGATATGGCGGCGACTACTTTGATTATTGGGGCCAGGGCACCACACTGACAGTGAGCTCC
(SEQ ID NO: 1, with CDR sequences underlined)
Amino acid sequence of 19F3 heavy chain variable region:
EVQLQQSGPELVKPGASMRMSCKA SGYSFTGYTMNWVKQSHGKNLEWIGLINPYNAGTSYNQ
KFKGKATLTVDKSSSTAYMELLSLTSEDSAVYYCARSEYRYGGDYFDYWGQGTTLTVSS
(SEQ ID NO: 2, with CDR sequences underlined)
HCDR1 of 19F3: GYSFTGYT
(SEQ ID NO: 3)
HCDR2 of 19F3: INPYNAGT
(SEQ ID NO: 4)
HCDR3 of 19F3: ARSEYRYGGDYFDY
(SEQ ID NO: 5)
Nucleotide sequence of 19F3 light chain variable region:
GACATCGTGATGACCCAGTCTCCAAGCTCCCTGGCAATGAGCGTGGGACAGAAGGTGACAA
TGTCTTGTAAGTCTAGCCAGAGCCTGCTGAACTCCTCTAATCAGAAGAACTACCTGGCCT
GGTATCAGCAGAAGCCAGGCCAGTCTCCCAAGCTGCTGGTGTACTTTGCCAGCACCAGGGA
GTCCGGAGTGCCTGACAGATTCATCGGCTCCGGCTCTGGCACAGACTTCACCCTGACAATCA
GCTCCGTGCAGGCAGAGGACCTGGCAGATTATTTCTGCCAGCAGCACTACGACACCCCTT
ATACATTTGGCGGCGGCACCAAGCTGGAGATCAAG
(SEQ ID NO: 6, with CDR sequences underlined)
Amino acid sequence of 19F3 light chain variable region:
DIVMTQSPSSLAMSVGQKVTMSCKSSCISLLNSSNQKNYLAWYQQKPGQSPKLLVYFASTRESG
VPDRFIGSGSGTDFTLTISSVQAEDLADYFCQQHYDTPYTFGGGTKLEIK
(SEQ ID NO: 7, with CDR sequences underlined)
LCDR1 amino acid sequence of 19F3: QSLLNSSNQKNY
(SEQ ID NO: 8)
LCDR2 amino acid sequence of 19F3: FAS
(SEQ ID NO: 9)
LCDR3 amino acid sequence of 19F3: QQHYDTPYT
(SEQ ID NO: 10)
Amino acid sequences of 19F3 heavy chain framework regions:
FR-HI: EVQLQQSGPELVKPGASMRMSCKAS (SEQ ID NO: 11)
FR-H2: MNWVKQSHGKNLEWIGL (SEQ ID NO: 12)
FR-H3: SYNQKFKGKATLTVDKSSSTAYMELLSLTSEDSAVYYC (SEQ ID NO: 13)
FR-H4: WGQGTTLTVSS (SEQ ID NO: 14)
Amino acid sequences of 19F3 light chain framework regions:
FR-Ll: DIVMTQSPSSLAMSVGQKVTMSCKSS (SEQ ID NO: 15)
FR-L2: LAWYQQKPGQSPKLLVY (SEQ ID NO: 16)
FR-L3: TRESGVPDRFIGSGSGTDFTLTISSVQAEDLADYFC (SEQ ID NO: 17)
83
CA 03176321 2022- 10- 20
IP190597
FR-L4: FGGGTKLEIK (SEQ ID NO: 18)
Nucleotide sequence of 19F3H2: (SEQ ID NO: 19, with CDR sequences underlined)
CA GGTGCA GCTGGTGCA GTCTGGA GCA GA GGTGGTGAA GCCAGGAGCCTCTGTGAAGGTGA
GCTGTAAGGCCAGCGGCTACTCCTTCACCGGCTATACAATGAACTGGGTGAGGCAGGCAC
CA GGA CA GAA TCTGGA GTGGA TCGGCCTGATCAACCCTTACAATGCCGGCACC TCTTA TA
ACCA GAA GTTTCAGGGCAA GGTGACCCTGACA GTGGA CAA GTCCACCTCTACA GCCTACA T
GGAGCTGAGCTCCCTGCGGAGCGAGGA TACA GCCGTGTACTATTGCGCCCGGTCCGAGTA
CAGATATGGCGGCGACTACTTTGATTATTGGGGCCAGGGCACCACACTGACCGTGTCTAG
C
Amino acid sequence of 19F3H2: (SEQ ID NO: 20, with CDR sequences underlined)
QVQLVQSGAEVVKPGASVKVSCKASGYSFTGYTMNWVRQAPGQNLEWIGLINPYNAGTSYNQ
KFQGKVTLTVDKSTSTAYMELSSLRSEDTAVYYCARSEYRYGGDYFDYWGQGTTLTVSS
Nucleotide sequence of 19F3L2: (SEQ ID NO: 21, with CDR sequences underlined)
GACATCGTGATGACCCAGTCCCCAAGCTCCCTGGCCGTGTCTGTGGGAGAGCGGGTGACAAT
CTCCTGTAAGTCTAGCCAGTCTCTGCTGAACTCCTCTAATCAGAAGAACTACCTGGCCTG
GTATCAGCAGAAGCCCGGCCAGGCCCCTAAGCTGCTGATCTACTTCGCCTCTACCAGGGAG
AGCGGA GTGCCAGA CA GA TTCTCTGGCA GCGGCTCCGGCA CA GACTTCACCCTGA CAA TCA
GCTCCGTGCAGGCAGAGGACGTGGCAGATTACTATTGCCAGCAGCACTACGATACCCCCT
ATACATTTGGCGGCGGCACCAAGCTGGAGATCAAG
Amino acid sequence of 19F3L2: (SEQ ID NO: 22, with CDR sequences underlined)
DIVMTQSPS SLA VSVGERVTIS CKS S QSLLNSSNQKNYLA WYQQKPGQAPKLLIYFASTRESGVP
DRFSGSGSGTDFTLTISSVQAEDVADYYCQQHYDTPYTFGGGTKLEIK
Nucleotide sequence of 19F3L3: (SEQ ID NO: 23, with CDR sequences underlined)
GACATCGTGATGACCCAGTCCCCAAGCTCCCTGGCCGTGTCTGTGGGAGAGCGGGTGACAAT
CTCCTGTAAGTCTAGCCAGTCTCTGCTGAACTCCTCTAATCAGAAGAACTACCTGGCCTG
GTATCAGCAGAAGCCCGGCCAGGCCCCTAAGCTGCTGATCTACTTCGCCTCTACCAGGGAG
AGCGGA GTGCCAGA CA GA TTCTCTGGCA GCGGCTCCGGCA CA GACTTCACCCTGA CAA TCA
GCTCCCTGCAGGCAGAGGACGTGGCCGTGTACTATTGCCAGCAGCACTACGATACCCCCT
ATACATTTGGCGGCGGCACCAAGCTGGAGATCAAG
Amino acid sequence of 19F3L3: (SEQ ID NO: 24, with CDR sequences underlined)
DIVMTQSPSSLAVSVGERVTISCKSSQSLENSSNQKNYLAWYQQKPGQAPKWYFASTRESGVP
DRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYDTPYTFGGGTKLEIK
Nucleotide sequence of 19F3H2L3(G1M) heavy chain (SEQ ID NO: 25, with non-
variable region
sequences underlined)
CA GGTGCA GCTGGTGCA GTCTGGA GCA GA GGTGGTGAA GCCAGGAGCCTCTGTGAAGGTGA
GCTGTAAGGCCAGCGGCTACTCCTTCACCGGCTATACAATGAACTGGGTGAGGCA GGCA CC
A GGACA GAA TCTGGA GTGGA TCGGCCTGA TCAACCCTTACAA TGCCGGCACCTCTTA TAA CC
A GAA GTTTCA GGGCAA GGTGA CCCTGA CA GTGGA CAA GTCCACCTCTA CA GCCTA CA TGGA
GCTGA GCTCCCTGCGGA GCGA GGA TA CA GCCGTGTACTA TTGCGCCCGGTCCGA GTA CA GAT
A TGGCGGCGACTACTTTGA TTA TTGGGGCCA GGGCACCA CA CTGA CCGTGTCTA GCGCCTCC
ACAAAGggG ccC ago gtg ttt cot ctc gcc ccc too too aaa a
gcaccagcggaggaaccgctgctctcggatgtctggtgaaggactacttccctgaacccgtcaccgtgag
ctggaatagcggcgctctgacaagcggagtccatacattccctgctgtgctgcaaagcagcggactctat
tccctgtccagcgtcgtcacagtgcccagcagcagcctgggcacccagacctacatctgtaacgtcaacc
acaagccctccaacaccaaggtggacaagaaagtggagcccaaatcctgcgacaagacacacacctgtcc
cccctgtcctgctcccgaaGCTGCTggaggccctagcgtcttcctctttcctcccaaacccaaggacac
84
CA 03176321 2022- 10- 20
IP190597
cctcatgatcagcagaacccctgaagtcacctgtgtcgtcgtggatgtcagccatgaggaccccgaggtg
aaattcaactggtatgtcgatggcgtcgaggtgcacaacgccaaaaccaagcccagggaggaacagtaca
actccacctacagggtggtgtccgtgctgacagtcctccaccaggactggctgaacggcaaggagtacaa
gtgcaaggtgtccaacaaggctctccctgcccccattgagaagaccatcagcaaggccaaaggccaaccc
agggagccccaggtctatacactgcctccctccagggacgaactcaccaagaaccaggtgtccctgacct
gcctggtcaagggcttttatcccagcgacatcgccgtcgagtgggagtccaacggacagcccgagaataa
ctacaagaccacccctcctgtcctcgactccgacggctccttcttcctgtacagcaagctgaccgtggac
aaaagcaggtggcagcagggaaacgtgttctcctgcagcgtgatgcacgaagccctccacaaccactaca
cccagaaaagcctgtccctgagccccggcaaatga
Amino acid sequence of 19F3H2L3(G1M) heavy chain (SEQ ID NO: 26, with non-
variable region
sequences underlined)
QVQLVQSGAEVVKPGASVKVSCKASGYSFTGYTMNWVRQAPGQNLEWIGLINPYNAGTSYNQKFQGKVTL
TVDKSTSTAYMELSSLRSEDTAVYYCARSEYRYGGDYFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTS
GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP
SNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLEPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFELYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Nucleotide sequence of 19F3H2L3(G1M) light chain (SEQ ID NO: 27, with non-
variable region
sequences underlined)
GACATCGTGATGACCCAGTCCCCAAGCTCCCTGGCCGTGTCTGTGGGAGAGCGGGTGACAAT
CTCCTGTAAGTCTAGCCAGTCTCTGCTGAACTCCTCTAATCAGAAGAACTACCTGGCCTGGT
ATCAGCAGAAGCCCGGCCAGGCCCCTAAGCTGCTGATCTACTTCGCCTCTACCAGGGAGAGC
GGAGTGCCA GA CA GA TTCTCTGGCAGCGGCTCCGGCA CA GACTTCACCCTGA CAA TCAGCTC
CCTGCAGGCAGAGGACGTGGCCGTGTA CTA TTGCCA GCA GCACTA CGA TACCCCCTA TA CAT
TTGGCGGCGGCACCAAGCTGGAGATCAAGCGTACGGTGGCAGCCCCATCTGTCTTCATTTTTCCCC
CTAGTGACGAGCAGCTGAAATCCGGAACAGCCTCTGTGGTCTGTCTGCTGAACAATTTCTACCCTCGCGA
AGCCAAGGTGCAGTGGAAAGTCGATAACGCTCTGCAGAGTGGCAATTCACAGGAGAGCGTGACTGAACAG
GACTCCAAGGATTCTACCTATAGTCTGAGCTCCACTCTGACCCTGTCCAAAGCAGATTACGAAAAGCACA
AAGTGTATGCCTGTGAGGTCACCCACCAGGGGCTGAGTTCTCCAGTCACCAAATCCTTCAACAGAGGCGA
ATGT
Amino acid sequence of 19F3H2L3(G1M) light chain (SEQ ID NO: 28, with non-
variable region
sequences underlined)
DIVMTQSPSSLAVSVGERVTISCKSSQSLLNSSNQKNYLAWYQQKPGQAPKLLIYFASTRESGVPDRFSG
SGSGTDFTLTISSLQAEDVAVYYCQQHYDTPYTEGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVC
LLNNEYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP
VTKSFNRGEC
Nucleotide sequence of 19F3H2L3(hG1TM) heavy chain (SEQ ID NO: 29, with non-
variable region
sequences underlined)
CAGGTGCAGCTGGTGCAGTCTGGAGCAGA GGTGGTGAA GCCAGGAGCCTCTGTGAAGGTGA
GCTGTAAGGCCAGCGGCTACTCCTTCACCGGCTATACAATGAACTGGGTGAGGCA GGCA CC
AGGACAGAA TCTGGAGTGGA TCGGCCTGA TCAACCCTTACAA TGCCGGCACCTCTTA TAA CC
AGAAGTTTCAGGGCAAGGTGACCCTGACAGTGGACAAGTCCACCTCTACAGCCTACA TGGA
GCTGA GCTCCCTGCGGAGCGAGGA TA CA GCCGTGTACTA TTGCGCCCGGTCCGAGTA CA GAT
A TGGCGGCGACTACTTTGA TTA TTGGGGCCA GGGCACCA CA CTGA CCGTGTCTA GCGCCTCC
ACAAAG ggG ccC ago gtg ttt cot ctc gcc ccc too too aaa a
gcaccagcggaggaaccgctgctctcggatgtctggtgaaggactacttccctgaacccgtcaccgtgag
ctggaatagcggcgctctgacaagcggagtccatacattccctgctgtgctgcaaagcagcggactctat
tccctgtccagcgtcgtcacagtgcccagcagcagcctgggcacccagacctacatctgtaacgtcaacc
acaagccctccaacaccaaggtggacaagaaagtggagcccaaatcctgcgacaagacacacacctgtcc
cccctgtcctgctcccgaaGCTGCTggaGCCcctagcgtcttcctctttcctcccaaacccaaggacac
CA 03176321 2022- 10- 20
IP190597
cctcatgatcagcagaacccctgaagtcacctgtgtcgtcgtggatgtcagccatgaggaccccgaggtg
aaattcaactggtatgtcgatggcgtcgaggtgcacaacgccaaaaccaagcccagggaggaacagtaca
actccacctacagggtggtgtccgtgctgacagtcctccaccaggactggctgaacggcaaggagtacaa
gtgcaaggtgtccaacaaggctctccctgcccccattgagaagaccatcagcaaggccaaaggccaaccc
agggagccccaggtctatacactgcctccctccagggacgaactcaccaagaaccaggtgtccctgacct
gcctggtcaagggcttttatcccagcgacatcgccgtcgagtgggagtccaacggacagcccgagaataa
ctacaagaccacccctcctgtcctcgactccgacggctccttcttcctgtacagcaagctgaccgtggac
aaaagcaggtggcagcagggaaacgtgttctcctgcagcgtgatgcacgaagccctccacaaccactaca
cccagaaaagcctgtccctgagccccggcaaatga
Amino acid sequence of 19F3H2L3(hG1TM) heavy chain variable region: (SEQ ID
NO: 30)
QVQLVQ S GA EVVKPGA SVKVSCKA SGYSFTGYTMNWVRQAPGQNLEWIGLINPYNA GT SYNQ
KF QGKVTLTVDKS T S TA YMEL S SLRSED TA VYYCA RSEYRYGGDYFDYWGQGT TLTVS SA STK
GPSVFPLAPS SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLS SVV
TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTL
MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIA
VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL
SLSPGK
Amino acid sequences of 19F3H2 framework regions:
FR-HI: QVQLVQSGAEVVKPGASVKVSCKAS (SEQ ID NO: 31)
FR-H2: MNWVRQAPGQNLEWIGL (SEQ ID NO: 32)
FR-H3: SYNQKFQGKVTLTVDKSTSTAYMELSSLRSEDTAVYYC (SEQ ID NO: 33)
FR-H4: QVQLVQSGAEVVKPGASVKVSCKAS (SEQ ID NO: 34)
Amino acid sequences of 19F3L2 framework regions:
FR-Ll: DIVMTQSPSSLAVSVGERVTISCKSS (SEQ ID NO: 35)
FR-L2: LAWYQQKPGQAPKLLIY (SEQ ID NO: 36)
FR-L3: TRESGVPDRFSGSGSGTDFTLTISSVQAEDVADYYC (SEQ ID NO: 37)
FR-L4: FGGGTKLEIK (SEQ ID NO: 38)
Amino acid sequences of 19F3L3 framework regions:
FR-Ll: DIVMTQSPSSLAVSVGERVTISCKSS (SEQ ID NO: 39)
FR-L2: LAWYQQKPGQAPKLLIY (SEQ ID NO: 40)
FR-L3: TRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC (SEQ ID NO: 41)
FR-L4: FGGGTKLEIK (SEQ ID NO: 42)
Nucleotide sequence of 14C12 heavy chain variable region: (SEQ ID NO: 43)
GAGGTCAAACTGGTGGAGAGCGGCGGCGGGCTGGTGAAGCCCGGCGGGTCACTGAAACTGA
GCTGCGCCGCTTCCGGCTTCGCCTTTA GCTCCTA CGA CA TGTCA TGGGTGA GGCA GA CCCCT
GA GA A GCGCCTGGA A TGGGTCGCTA CTA TCA GCGGAGGCGGGCGA TA CA CCTA CTA TCCTG
A CTCTGTCA AA GGGA GA TTCA CA A TTA GTCGGGA TAA CGCCA GAA A TA CTCTGTA TCTGCAG
A TGTCTA GTCTGCGGTCCGA GGA TA CA GCTCTGTA CTA TTGTGCA AA CCGGTA CGGCGA A GC
A TGGTTTGCCTA TTGGGGA CA GGGCA CCCTGGTGA CA GTCTCTGCC
Amino acid sequence of 14C12 heavy chain variable region: (SEQ ID NO: 44)
EVKLVE S GGGLVKPGG SLKL S CA A SGFA FS SYDMSWVRQTPEKRLEWVATISGGGRYTYYPDS
VKGRF TISRDNA RNTLYLQMS S LRSEDTA LYYCANRYGEA WFA YWGQGTLVTVSA
HCDR1 amino acid sequence of 14C12: GFAFSSYD
(SEQ ID NO: 45)
HCDR2 amino acid sequence of 14C12: ISGGGRYT
(SEQ ID NO: 46)
HCDR3 amino acid sequence of 14C12: ANRYGEAWFAY
86
CA 03176321 2022- 10- 20
IP190597
(SEQ ID NO: 47)
Nucleotide sequence of 14C12 light chain variable region: (SEQ ID NO: 48)
GACATTAAGATGACACAGTCCCCTTCCTCAATGTACGCTAGCCTGGGCGAGCGAGTGACCTT
CA CA TGCAAAGCA TCCCA GGA CA TCAA CA CA TA CCTGTCTTGGTTTCA GCA GAA GCCA GGC
AAAA GCCCCAA GA CCCTGA TCTA CCGGGCCAA TA GA CTGGTGGA CGGGGTCCCCA GCA GA T
TCTCCGGA TCTGGCA GTGGGCA GGA TTA CTCCCTGA CCA TCA GCTCCCTGGA GTA TGAA GA C
A TGGGCATCTACTATTGCCTGCAGTATGATGA GTTCCCTCTGA CCTTTGGAGCAGGCACAAA
A CTGGAACTGAAG
Amino acid sequence of 14C12 light chain variable region: (SEQ ID NO: 49)
DIKMTQSPSSMYA SLGERVTFTCKA SQDINTYLSWFQQKPGKSPKTLIYRANRLVDGVPSRFSGS
GS GQDYSLTIS SLEYEDMGIYYCLQYDEFPLTF GA GTKLELK
LCDR1 amino acid sequence of 14C12: QDINTY (SEQ ID NO: 50)
LCDR2 amino acid sequence of 14C12: RAN (SEQ ID NO: 51)
LCDR3 amino acid sequence of 14C12: LQYDEFPLT (SEQ ID NO: 52)
Amino acid sequences of 14C12 heavy chain framework regions:
FR-HI: EVKLVESGGGLVKPGGSLKLSCAAS (SEQ ID NO: 53)
FR-H2: MSWVRQTPEKRLEWVAT (SEQ ID NO: 54)
FR-H3: YYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTALYYC (SEQ ID NO: 55)
FR-H4: WGQGTLVTVSA (SEQ ID NO: 56)
Amino acid sequences of 14C12 light chain framework regions:
HR-Ll: DIKMTQSPSSMYASLGERVTFTCKAS (SEQ ID NO: 57)
HR-L2: LSWFQQKPGKSPKTLIY (SEQ ID NO: 58)
HR-L3: RLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYC (SEQ ID NO: 59)
HR-L4: FGAGTKLELK (SEQ ID NO: 60)
Nucleotide sequence of 14C12H1: (SEQ ID NO: 61)
GAAGTGCAGCTGGTCGAGTCTGGGGGAGGGCTGGTGCAGCCCGGCGGGTCACTGCGACTGA
GCTGCGCA GCTTCCGGA TTCGCCTTTA GCTCCTA CGA CA TGTCCTGGGTGCGA CA GGCA CCA
GGAAAGGGACTGGA TTGGGTCGCTA CTA TCTCA GGA GGCGGGA GA TA CA CCTA CTATCCTG
A CA GCGTCAA GGGCCGGTTCA CAA TCTCTA GA GA TAA CA GTAA GAA CAA TCTGTA TCTGCA
GA TGAA CA GCCTGA GGGCTGA GGA CA CCGCA CTGTA CTATTGTGCCAACCGCTACGGGGAA
GCATGGTTTGCCTATTGGGGGCA GGGAA CCCTGGTGA CA GTCTCTA GT
Amino acid sequence of 14C12H1: (SEQ ID NO: 62)
EVQLVE S GGGLVQPGGSLRL S CAA SGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDS
VKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSS
Nucleotide sequence of 14C12L1: (SEQ ID NO: 63)
GA CA TTCA GA TGA CTCA GA GCCCCTCCTCCA TGTCCGCCTCTGTGGGCGA CA GGGTCA CCTT
CA CA TGCCGCGCTAGTCA GGA TA TCAA CA CCTA CCTGA GCTGGTTTCA GCA GAA GCCA GGG
AAAA GCCCCAA GA CA CTGA TCTA CCGGGCTAA TA GACTGGTGTCTGGAGTCCCAA GTCGGTT
CA GTGGCTCA GGGA GCGGA CA GGA CTA CA CTCTGACCATCA GCTCCCTGCAGCCTGAGGAC
A TGGCAACCTA CTA TTGCCTGCAGTATGATGAGTTCCCACTGACCTTTGGCGCCGGGACAAA
A CTGGAGCTGAAG
Amino acid sequence of 14C12L1: (SEQ ID NO: 64)
DIQMTQSPSSMSA SVGDRVTFTCRA SQDINTYLSWFQQKPGKSPKTLIYRANRLV SGVPSRFSGS
GSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK
Nucleotide sequence of 14C12H1L1 heavy chain (SEQ ID NO: 65)
GAAGTGCAGCTGGTCGAGTCTGGGGGAGGGCTGGTGCAGCCCGGCGGGTCACTGCGACTGA
87
CA 03176321 2022- 10- 20
IP190597
GCTGCGCA GCTTCCGGA TTCGCCTTTA GCTCCTA CGA CA TGTCCTGGGTGCGA CA GGCA CCA
GGAAAGGGACTGGA TTGGGTCGCTA CTA TCTCA GGA GGCGGGA GA TA CA CCTA CTATCCTG
ACAGCGTCAAGGGCCGGTTCACAATCTCTAGAGATAACAGTAAGAACAATCTGTATCTGCA
GA TGAA CA GCCTGA GGGCTGA GGA CA CCGCA CTGTA CTA TTGTGCCAA CCGCTA CGGGGAA
GCATGGTTTGCCTATTGGGGGCAGGGAACCCTGGTGACAGTCTCTAGTGCCAGCACCAAAG
GACCTAGCGTGTTTCCTCTCGCCCCCTCCTCCAAAAGCACCAGCGGAGGAACCGCTGCTCTC
GGATGTCTGGTGAAGGACTACTTCCCTGAACCCGTCACCGTGAGCTGGAATAGCGGCGCTCT
GACAAGCGGAGTCCATACATTCCCTGCTGTGCTGCAAAGCAGCGGACTCTATTCCCTGTCCA
GCGTCGTCACAGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTCAACCAC
AA GCCCTCCAA CA CCAA GGTGGA CAA GAAA GTGGAGCCCAAA TCCTGCGA CAA GA CA CACA
CCTGTCCCCCCTGTCCTGCTCCCGAACTCCTCGGAGGCCCTAGCGTCTTCCTCTTTCCTCCCA
AA CCCAA GGA CA CCCTCA TGA TCA GCAGAACCCCTGAAGTCACCTGTGTCGTCGTGGATGTC
AGCCATGAGGACCCCGAGGTGAAATTCAACTGGTATGTCGATGGCGTCGAGGTGCACAACG
CCAAAACCAAGCCCAGGGAGGAACAGTACAACTCCACCTACAGGGTGGTGTCCGTGCTGAC
AGTCCTCCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTGTCCAACAAGGCT
CTCCCTGCCCCCATTGAGAAGACCATCAGCAAGGCCAAAGGCCAACCCAGGGAGCCCCAGG
TCTATACACTGCCTCCCTCCAGGGACGAACTCACCAAGAACCAGGTGTCCCTGACCTGCCTG
GTCAA GGGCTTTTA TCCCA GCGA CA TCGCCGTCGAGTGGGAGTCCAA CGGA CA GCCCGA GA
ATAACTACAAGACCACCCCTCCTGTCCTCGACTCCGACGGCTCCTTCTTCCTGTACAGCAAG
CTGACCGTGGACAAAAGCAGGTGGCAGCAGGGAAACGTGTTCTCCTGCAGCGTGATGCACG
AAGCCCTCCACAACCACTACACCCAGAAAAGCCTGTCCCTGAGCCCCGGCAAA
Amino acid sequence of 14C12H1L1 heavy chain variable region: (SEQ ID NO: 66)
EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDS
VKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSSASTKGPSV
FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP
EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
K
Nucleotide sequence of 14C12H1L1 light chain (SEQ ID NO: 67)
GACATTCAGATGACTCAGAGCCCCTCCTCCATGTCCGCCTCTGTGGGCGACAGGGTCACCTT
CA CA TGCCGCGCTAGTCA GGA TA TCAA CA CCTA CCTGA GCTGGTTTCA GCA GAA GCCA GGG
AAAA GCCCCAA GA CA CTGA TCTA CCGGGCTAA TA GA CTGGTGTCTGGA GTCCCAA GTCGGTT
CA GTGGCTCA GGGA GCGGA CA GGA CTA CA CTCTGA CCATCA GCTCCCTGCAGCCTGAGGAC
A TGGCAACCTA CTA TTGCCTGCAGTATGATGAGTTCCCACTGACCTTTGGCGCCGGGACAAA
A CTGGAGCTGAAGCGAA CTGTGGCCGCTCCCTCCGTCTTCATTTTTCCCCCTTCTGA CGAA CA
GCTGAAA TCA GGCA CA GCCA GCGTGGTCTGTCTGCTGAA CAA TTTCTACCCTAGA GA GGCAA
AA GTGCA GTGGAA GGTCGA TAA CGCCCTGCA GTCCGGCAA CA GCCA GGA GA GTGTGACTGA
ACAGGACTCAAAAGATAGCACCTATTCCCTGTCTAGTACACTGACTCTGTCCAAGGCTGATT
A CGAGAAGCACAAAGTGTATGCA TGCGAA GTGA CA CA TCA GGGACTGTCAAGCCCCGTGAC
TAAGTCTTTTAACCGGGGCGAATGT
Amino acid sequence of 14C12H1L1 light chain: (SEQ ID NO: 68)
DIQMTQSPSSMSA SVGDRVTFTCRA SQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGS
GSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC
EVTHQGLSSPVTKSFNRGEC
Nucleotide sequence of 14C12H1L1(G1TM) heavy chain (SEQ ID NO: 69)
GAAGTGCAGCTGGTCGAGTCTGGGGGAGGGCTGGTGCAGCCCGGCGGGTCACTGCGACTGA
GCTGCGCA GCTTCCGGA TTCGCCTTTA GCTCCTA CGA CA TGTCCTGGGTGCGA CA GGCA CCA
GGAAAGGGACTGGA TTGGGTCGCTA CTA TCTCA GGA GGCGGGA GA TA CA CCTA CTATCCTG
A CA GCGTCAA GGGCCGGTTCA CAA TCTCTA GA GA TAACA GTAA GAA CAA TCTGTA TCTGCA
GA TGAA CA GCCTGA GGGCTGA GGA CA CCGCA CTGTA CTA TTGTGCCAA CCGCTA CGGGGAA
GCATGGTTTGCCTATTGGGGGCAGGGAACCCTGGTGACAGTCTCTAGTGCCAGCACCAAAG
88
CA 03176321 2022- 10- 20
IP190597
GGCCCA GCGTGTTTCCTCTCGCCCCCTCCTCCAA AA GCACCAGCGGAGGAA CCGCTGCTCTC
GGA TGTCTGGTGA A GGA CTA CTTCCCTGA A CCCGTCA CCGTGA GCTGGAA TA GCGGCGCTCT
GACAAGCGGAGTCCATACATTCCCTGCTGTGCTGCAAAGCAGCGGACTCTATTCCCTGTCCA
GCGTCGTCA CA GTGCCCA GCA GCA GCCTGGGCA CCCA GA CCTA CA TCTGTAA CGTCA A CCA C
AA GCCCTCCAA CA CCAA GGTGGA CAA GA AA GTGGAGCCCAA A TCCTGCGA CA A GA CA CACA
CCTGTCCCCCCTGTCCTGCTCCCGAAGCTGCTGGAGCCCCTAGCGTCTTCCTCTTTCCTCCCA
AA CCCA A GGA CA CCCTCA TGA TCA GCAGAACCCCTGAAGTCACCTGTGTCGTCGTGGATGTC
AGCCA TGA GGACCCCGA GGTGA AA TTCAA CTGGTA TGTCGA TGGCGTCGA GGTGCA CA ACG
CCAA A A CCA A GCCCA GGGA GGA A CA GTA CA A CTCCA CCTA CA GGGTGGTGTCCGTGCTGAC
AGTCCTCCA CCA GGA CTGGCTGA A CGGCA A GGA GTACA A GTGCA A GGTGTCCA A CAA GGCT
CTCCCTGCCCCCATTGAGAAGACCATCAGCAAGGCCAAAGGCCAACCCAGGGAGCCCCAGG
TCTA TA CA CTGCCTCCCTCCA GGGACGAACTCACCAAGAACCAGGTGTCCCTGACCTGCCTG
GTCAA GGGCTTTTA TCCCA GCGA CA TCGCCGTCGAGTGGGAGTCCAA CGGA CA GCCCGA GA
A TAA CTA CAA GA CCA CCCCTCCTGTCCTCGA CTCCGA CGGCTCCTTCTTCCTGTA CA GCAA G
CTGACCGTGGA CAA AA GCA GGTGGCA GCA GGGAA A CGTGTTCTCCTGCA GCGTGA TGCA CG
AA GCCCTCCA CAA CCA CTA CA CCCA GA AAA GCCTGTCCCTGAGCCCCGGCA A A
Amino acid sequence of 14C12H1L1 (G1TM) heavy chain variable region: (SEQ ID
NO: 70)
EVQLVE S GGGLVQPGG SLRL S CAA SGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDS
VKGRF TISRDNSKNNLYL QMNS LRAEDTA LYYCANRYGEA WFA YWGQGTLVTVS SA S TKGPS V
FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTP
EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
Amino acid sequences of 14C12H1 heavy chain framework regions:
FR-HI: EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO: 71)
FR-H2: MSWVRQAPGKGLDWVAT (SEQ ID NO: 72)
FR-H3: YYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYC (SEQ ID NO: 73)
FR-H4: WGQGTLVTVSS (SEQ ID NO: 74)
Amino acid sequences of 14C12L1 light chain framework regions:
FR-Ll: DIQMTQSPSSMSASVGDRVTFTCRAS (SEQ ID NO: 75)
FR-L2: LSWFQQKPGKSPKTLIY (SEQ ID NO: 76)
FR-L3: RLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYC (SEQ ID NO: 77)
FR-L4: FGAGTKLELK (SEQ ID NO: 78)
Amino acid sequence of Linkerl: GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 79)
Nucleotide sequence of Linkerl: (SEQ ID NO: 80)
GGCGGCGGCGGCAGCGGCGGCGGCGGCTCCGGAGGAGGCGGCTCTGGCGGCGGCGGCAGC
Amino acid sequence of Linker2: GGGGSGGGGSGGGGS (SEQ ID NO: 81)
Nucleotide sequence of Linker2: (SEQ ID
NO: 82)
GGCGGCGGCGGCTCCGGA GGA GGCGGCTCTGGCGGCGGCGGCA GC
The amino acid sequence of the heavy chain of NTPDV2 and NTPDV4 (SEQ ID NO:
83): wherein the
CDR regions of 19F3H2(hG1TM) in the immunoglobulin moiety are marked in bold
underlines, the
CDR regions of 14C12H1V-Linkerl-14C12L1V in the scFv part are marked in
hplajjliskrjims, the
mutated amino acids in the heavy chain region are marked in bold italics, and
the linker regions are
marked in bold:
QVQLVQ S GA EVVKPGA SVKVSCKA S GYSFTGYTMNWVRQAPGQNLEWIGLINPYNAGTSYNQ
KFQGKVTLTVDKSTSTAYMELS SLRSEDTA VYYCARSEYRYGGDYFDYWGQGTTLTVS SA STK
GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV
89
CA 03176321 2022- 10- 20
IP190597
TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTL
MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIA
VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL
SLSPGKGGGGSGGGGSGGGGSGGGGSEVQL VESGGGLVQPGGSLRLSCAASGFAFSSYDMSWV
R APGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYL MNSLRAEDTALYYCANRYGEA
WFAY WGQGTL VTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSSMSAS VGDR VTFTCRASQDI
NTYLSWFQQKPGKSPKTLIYRANRL VSGVPSRFSGSGSGQDYTLTISSLQPEDMA TYYCLQYDEFPLT
FGAGTKLELKR
Nucleotide sequence of the heavy chain of NTPDV2 and NTPDV4: (SEQ ID NO: 84)
CA GGTGCA GCTGGTGCA GTCTGGA GCA GA GGTGGTGAA GCCA GGAGCCTCTGTGA A GGTGA
GCTGTA A GGCCA GCGGCTA CTCCTTCA CCGGCTA TA CA A TGA A CTGGGTGA GGCA GGCA CC
AGGA CA GA A TCTGGAGTGGA TCGGCCTGA TCA A CCCTTA CAA TGCCGGCACCTCTTA TAA CC
AGAAGTTTCAGGGCAAGGTGA CCCTGA CA GTGGA CAA GTCCA CCTCTA CA GCCTA CA TGGA
GCTGA GCTCCCTGCGGAGCGAGGA TA CA GCCGTGTA CTA TTGCGCCCGGTCCGA GTA CA GAT
A TGGCGGCGACTACTTTGA TTA TTGGGGCCA GGGCA CCA CA CTGA CCGTGTCTA GCgc ctccaca
aaggggcccagcgtgtttcctctcgccccctcctccaaaagcaccagcggaggaaccgctgctctcggatgtctggtga
aggactacttccctgaaccc
gtcaccgtgagctggaatagcggcgctctgacaagcggagtccatacattccctgctgtgctgcaaagcagcggactct
attccctgtccagcgtcgtca
cagtgcccagcagcagcctgggcacccagacctacatctgtaacgtcaaccacaagccctccaacaccaaggtggacaa
gaaagtggagcccaaatc
ctgcgacaagacacacacctgtccoccctgtcctgctcccgaaGCTGCTggagCcoctagcgtatcctattcctcccaa
acccaaggacaccct
catgatcagcagaacccctgaagtcacctgtgtcgtcgtggatgtcagccatgaggaccccgaggtgaaattcaactgg
tatgtcgatggcgtcgaggt
gcacaacgccaaaaccaagcccagggaggaacagtacaactccacctacagggtggtgtccgtgctgacagtcctccac
caggactggctgaacgg
caaggagtacaagtgcaaggtgtccaacaaggctctccctgcccccattgagaagaccatcagcaaggccaaaggccaa
cccagggagccccaggt
ctatacactgcctccctccagggacgaactcaccaagaaccaggtgtccctgacctgcctggtcaagggcttttatccc
agcgacatcgccgtcgagtgg
gagtccaacggacagcccgagaataactacaagaccacccctcctgtcctcgactccgacggctccttcttcctgtaca
gcaaactgaccgtcgataaat
ctaggtggcagcagggcaacgtgttctcttgttccgtgatgcatgaagcactgcacaaccattatacccagaagtctct
gagcctgtcccccggcaagG
GCGGCGGCGGCTCTGGAGGAGGAGGCA GCGGCGGAGGAGGCTCCGGAGGCGGCGGCTCTG
AGGTGCAGCTGGTGGAGTCTGGAGGAGGA CTGGTGCAGCCTGGA GGCTCCCTGAGGCTGTC
TTGCGCAGCAAGCGGA TTCGCCTTTA GCTCCTA CGA CA TGAGCTGGGTGCGGCAGGCACCTG
GCA A GggtCTGGA TTGGGTGGCA A CCA TCA GCGGA GGCGGCA GA TACA CA TA CTA TCCCGAC
TCCGTGA A GGGCA GGTTCA CCA TCTCCCGCGA TA A CTCTAA GAA CA A TCTGTA TCTGCA GA T
GA A CA GCCTGA GGGCCGA GGA CACA GCCCTGTA CTA TTGCGCCA A CCGCTA CGGCGA GGCC
TGGTTTGCCTATTGGGGCCAGGGCACCCTGGTGACAGTGTCTAGCGGCGGCGGCGGCAGCG
GCGGCGGCGGCTCCGGAGGAGGCGGCTCTGGCGGCGGCGGCAGCGA TA TCCA GA TGACCCA
GTCCCCCTCCTCTA TGTCTGCCA GCGTGGGCGA CCGGGTGA CCTTCA CA TGTA GA GCCTCCC
AGGA TA TCA A CA CCTA CCTGTCTTGGTTTCA GCA GA A GCCCGGCA A GA GCCCTA A GA CA
CTG
ATCTATCGGGCCAATAGACTGGTGAGCGGAGTGCCTTCCCGGTTCTCCGGCTCTGGCAGCGG
A CA GGA CTA TA CCCTGA CAA TCA GC TCCCTGCA GCCA GA GGA TA TGGCCA CA TA CTA
TTGCC
TGCAGTA TGACGAGTTCCCCCTGA CCTTCGGGgctGGCA CTA A GCTGGA GCTGA AA A GA
The amino acid sequence of the heavy chain of NTPDV1 and NTPDV3 (SEQ ID NO:
85): wherein the
CDR regions of 19F3H2(hG1TM) in the immunoglobulin moiety are marked in bold
underlines, the
CDR regions of 14C12H1V-Linker2-14C12L1V in the scFv part are marked in
111:41Limaprittio, the
mutated amino acids in the heavy chain region are marked in bold italics, and
the linker regions are
marked in bold:
QVQLVQ S GA EVVKPGA SVKVSCKA S GYSFT GYTMNWVRQA PGQNLEWIGL INPYNA GT SYNQ
KFQGKVTLTVDKSTSTAYMELSSLRSEDTAVYYCARSEYRYGGDYFDYWGQGTTLTVSSA STK
GPSVFPLAPS SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLS SVV
TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTL
MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIA
VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL
SLSPGKGGGGSGGGGSGGGGSGGGGSE V_L VESGGGLVQPGGSLRLSCAASGFAFSSYDMSWV
R APGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYL MNSLRAEDTALYYCANRYGEA
WFAY WGQGTL VTVSSGGGGSGGGGSGGGGSDIQMTQSPSSMSASVGDR VTFTCRASQDINTYLS
WFQQKPGKSPKTLIYRANRLVSGVP5RFSG5GSGQDYTLTI55LQPE12M4TYYCLQYDEFPLTFGA GT
KLELKR
CA 03176321 2022- 10- 20
IP190597
Nucleotide sequence of the heavy chain of NTPDV1 and NTPDV3: (SEQ ID NO: 86)
CA GGTGCA GCTGGTGCA GTCTGGA GCA GA GGTGGTGAA GCCA GGAGCCTCTGTGA A GGTGA
GCTGTA A GGCCA GCGGCTA CTCCTTCA CCGGCTA TA CA A TGA A CTGGGTGA GGCA GGCA CC
A GGA CA GA A TCTGGA GTGGA TCGGCCTGA TCA A CCCTTA CAA TGCCGGCACCTCTTA TAA CC
A GAA GTTTCA GGGCAA GGTGA CCCTGA CA GTGGA CAA GTCCA CCTCTA CA GCCTA CA TGGA
GCTGA GCTCCCTGCGGA GCGA GGA TA CA GCCGTGTA CTA TTGCGCCCGGTCCGA GTA CA GAT
A TGGCGGCGACTACTTTGA TTA TTGGGGCCA GGGCA CCA CA CTGA CCGTGTCTA GCGCCTCC
A CA A aggggcc cagcgtgtttcctctcgcc cc ctc ctc caaaagc acc ageggaggaac
cgctgctctoggatgtctggtgaaggactacttcc ctg
aacccgtcaccgtgagctggaatageggcgctctgacaageggagtccatacattccctgctgtgctgcaaagcagegg
actctattccctgtccagcgt
cgtcacagtgcccagcagcagcctgggcacccagacctacatctgtaacgtcaaccacaagccctccaacaccaaggtg
gacaagaaagtggagccc
aaatcctgcgacaagacacacacctgtoccocctgtoctgctcccgaaGCTGCTggagCcoctagcgtatcctattcct
cccaaacccaaggac
accctcatgatcagcagaaccCCTGAAGTCACCTGTGTCGTCGTGGATGTCAGCCATGAGGACCCCGAG
GTGA AA TTCAA CTGGTA TGTCGA TGGCGTCGA GGTGCA CAA CGCCA AAA CCA A GCCCA GGG
A GGA A CA GTA CAA CTCCA CCTA CA GGGTGGTGTCCGTGCTGA CA GTCCTCCACCA GGACTG
GCTGA A CGGCA AGGA GTA CAA GTGCAA GGTGTCCA A CA A GGCTCTCCCTGCCCCCA TTGA G
A A GA CCA TCA GCAA GGCCA AA GGCCA A CCCA GGGA GCCCCA GGTCTA TA CA CTGCCTCCCT
CCA GGGA CGA A CTCA CCA A GAA CCAGGTGTCCCTGA CCTGCCTGGTCA A GGGCTTTTA TCCC
A GCGA CA TCGCCGTCGA GTGGGA GTCCAA CGGA CA GCCCGA GA A TA ACTA CA A GA CCA CCC
CTCCTGTCCTCGACTCCGA CGGCTCCTTCTTCCTGTA CA GCAA A CTGA CCGTCGA TAAA TCTA
GGTGGCAGCAGGGCAACGTGTTCTCTTGTTCCGTGATGCATGAAGCACTGCACAACCATTAT
A CCCA GAAGTCTCTGAGCCTGTCCCCCGGCAAGGGCGGCGGCGGCTCTGGAGGAGGAGGCA
GCGGCGGAGGAGGCTCCGGAGGCGGCGGCTCTGA GGTGCAGCTGGTGGAGTCTGGAGGAG
GA CTGGTGCA GCCTGGA GGCTCCCTGA GGCTGTCTTGCGCA GCA A GCGGA TTCGCCTTTA GC
TCCTA CGA CA TGA GCTGGGTGCGGCA GGCA CCTGGCAA GGGTCTGGA TTGGGTGGCA A CCA
TCA GCGGA GGCGGCA GA TA CA CATA CTA TCCCGA CTCCGTGAAGGGCAGGTTCACCATCTCC
CGCGA TA A CTCTAA GAA CA A TCTGTA TCTGCA GA TGAA CA GCCTGA GGGCCGA GGA CA CAG
CCCTGTACTA TTGCGCCAA CCGCTACGGCGAGGCCTGGTTTGCCTATTGGGGCCAGGGCA CC
CTGGTGACAGTGTCTAGCGGCGGCGGCGGCTCCGGAGGAGGCGGCTCTGGCGGCGGCGGCA
GCGA TA TCCA GA TGA CCCAGTCCCCCTCCTCTATGTCTGCCAGCGTGGGCGACCGGGTGA CC
TTCA CA TGTA GA GCCTCCCA GGA TA TCAA CA CCTA CCTGTCTTGGTTTCA GCA GAA GCCCGG
CAAGAGCCCTAAGACACTGATCTATCGGGCCAATAGACTGGTGAGCGGAGTGCCTTCCCGG
TTCTCCGGCTCTGGCA GCGGA CA GGA CTA TA CCCTGA CAA TCA GCTCCCTGCA GCCA GA GGA
TATGGCCACATACTATTGCCTGCAGTATGACGAGTTCCCCCTGACCTTCGGGGCTGGCACTA
AGCTGGAGCTGAAAAGATGATAAGAATTC
Amino acid sequence of NT5E(1-552)-his (SEQ ID NO: 87)
MCPRA A RA PA TLLLA LGA VLWPAA GA WELTILHTNDVH SRLEQT SEDS SKCVNASRCMGGVAR
LFTKVQQIRRAEPNVLLLDA GDQYQGTIWF TVYKGA EVA HFMNA LRYDA MA LGNHEFDNGVE
GLIEPLLKEA KFPIL SA NIKA KGPLA SQISGLYLPYKVLPVGDEVVGIVGYTSKETPFLSNPGTNLV
FEDEITALQPEVDKLKTLNVNKIIALGHSGFEMDKLIAQKVRGVDVVVGGHSNTFLYTGNPPSKE
VPAGKYPFIVTSDDGRKVPVVQAYAFGKYLGYLKIEFDERGNVISSHGNPILLNSSIPEDPSIKADI
NKWRIKLDNYSTQELGKTIVYLDGSSQSCRFRECNMGNLICDAMINNNLRHTDEMFWNHVSMC
ILNGGGIRSPIDERNNGTITWENLAAVLPFGGTFDLVQLKGSTLKKAFEHSVHRYGQSTGEFLQV
GGIHVVYDLSRKPGDRVVKLDVLCTKCRVPSYDPLKMDEVYKVILPNFLANGGDGFQMIKDEL
LRHDSGDQDINVVSTYISKMKVIYPAVEGRIKFSTGSHHHHHH
Nucleotide sequence of NT5E(1-552)-his (SEQ ID NO: 88)
A TGTGTCCTA GA GCCGCCA GA GCTCCA GCTA CA CTGCTGCTGGCTCTGGGA GCA GTCCTCTG
GCCAGCAGCAGGAGCTTGGGAA CTGA CCA TCCTGCA CA CCA A CGA CGTGCA CA GCA GGCTG
GA A CA GA CCA GCGA GGA CA GCA GCAA GTGCGTGAACGCCAGTCGCTGTATGGGAGGAGTG
GCAAGGCTGTTCACCAAGGTGCAGCAGATCCGGAGAGCCGAACCTAACGTGCTGCTGCTGG
A CGCCGGA GA TCAGTATCAGGGAACCATCTGGTTCACCGTGTA CA A GGGCGCCGA A GTGGC
CCACTTCATGAACGCTCTGCGCTACGACGCTATGGCCCTGGGCAATCACGAGTTCGATAACG
GCGTGGA GGGA CTGA TCGA GCCTCTGCTGA A GGA GGCCAA GTTCCCCA TCCTGA GCGCCA A
CATCAAGGCCAAGGGACCTCTGGCTAGCCAGATTAGCGGCCTGTACCTGCCTTACAAGGTGC
TGCCCGTGGGA GA CGA A GTGGTGGGA A TCGTGGGCTA CA CCA GCAA GGA GA CCCCTTTCCT
GA GCA A CCCA GGCA CCA A CCTGGTGTTCGA GGA CGA GA TCA CCGCTCTGCAGCCA GA GGTG
91
CA 03176321 2022- 10- 20
IP190597
GA CAA GCTGAAGA CCCTGAA CGTGAA CAA GA TCA TCGCCCTGGGA CA CA GCGGCTTCGA GA
TGGA CAA GCTGA TCGCCCA GAAA GTGCGA GGA GTGGA CGTGGTCGTGGGCGGA CA CA GCAA
CA CCTTCCTGTA CA CCGGCAA CCCTCCTTCTAA GGAAGTGCCAGCCGGCAAGTACCCCTTCA
TCGTGACCAGCGACGACGGAAGAAAGGTGCCAGTGGTGCAGGCTTACGCCTTCGGCAAGTA
CCTGGGCTA CCTGAA GA TCGA GTTCGA CGA GCGGGGCAA CGTGATCTCTAGCCACGGCAAC
CCCA TCCTGCTGAA CA GCA GCA TCCCA GA GGACCCCAGCATCAAGGCCGA CA TCAA CAA GT
GGCGGA TCAA GCTGGA CAA CTA CA GCA CCCA GGA GCTGGGAAA GA CCA TCGTGTA CCTGGA
CGGCAGCTCTCAGTCTTGCCGGTTCCGCGAGTGCAA CA TGGGCAA CCTGA TTTGCGA CGCCA
TGA TCAA CAA CAA CCTGCGGCA CA CCGA CGA GA TGTTTTGGAA CCA CGTCAGCATGTGCATC
CTGAA CGGCGGAGGCATCAGAAGCCCTATTGACGA GCGGAA CAA CGGCACCATCACTTGGG
AGAACCTGGCAGCAGTGCTGCCTTTTGGCGGAACATTCGACCTGGTGCAGCTGAAGGGCAG
CACACTGAAGAAGGCCTTCGAGCACAGCGTGCACAGATACGGCCAGAGCACAGGCGAGTTC
CTGCAGGTCGGAGGAATCCA CGTGGTGTA CGA CCTGAGCA GGAA GCCAGGA GA CA GA GTGG
TGAAGCTGGACGTGCTCTGCA CCAAGTGTCGGGTGCCAA GCTA CGA CCCCCTGAA GA TGGA
CGA GGTGTA CAA GGTCA TCCTGCCCAA CTTCCTGGCTAA CGGA GGA GA CGGCTTCCA GA TG
A TCAA GGA CGAGCTGCTGA GGCA CGA CA GCGGA GA CCA GGA CA TCAA CGTCGTGTCCA CCT
A CA TCA GCAA GA TGAA GGTCA TCTACCCCGCCGTGGAAGGCAGGATCAAGTTCAGCA CCGG
CTCTCA CCACCACCATCA CCAC
Amino acid sequence of mFc: (SEQ ID
NO: 89)
PRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNV
EVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAP
QVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSK
LRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK
Amino acid sequence of 19F3H1V-Linker-19F3L2V: (SEQ ID NO: 90)
QVQLQQSGAEVVKPGA SMKMSCKA SGYSFTGYTMNWVKQA HGQNLEWIGLINPYNA GT SYN
QKFQGKA TLTVDKS T STA YMEL S SLRSEDTA VYYCA RSEYRYGGDYFDYWGQGT TLTV S SGGG
GSGGGGS GGGGSDIVMTQ SP S SLA VS VGERVTISCKS S Q SLLNS SNQKNYLA WYQQKPGQA PKL
LIYFASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVADYYCQQHYDTPYTFGGGTKLEIK
Nucleotide sequence of 19F3H1V-Linker2-19F3L2V: (SEQ ID NO: 91)
CA GGTGCA GCTGCA GCA GTCTGGA GCA GA GGTGGTGAA GCCAGGAGCCTCTA TGAA GA TGA
GCTGTAA GGCCA GCGGCTA CTCCTTCA CCGGCTA TA CAA TGAA CTGGGTGAA GCA GGCCCA
CGGCCA GAA TCTGGA GTGGA TCGGCCTGA TCAA CCCTTA CAA TGCCGGCA CCTCTTA TAA CC
AGAAGTTTCAGGGCAAGGCCA CCCTGA CA GTGGA CAA GTCCA CCTCTA CAGCCTA CA TGGA
GCTGA GCTCCCTGCGGA GCGA GGA TA CA GCCGTGTA CTA TTGCGCCCGGTCCGA GTA CA GAT
A TGGCGGCGA CTA CTTTGA TTA TTGGGGCCA GGGCA CCA CA CTGA CCGTGTCTA GC
GGCCTGTACGGCCTGTACGGCCTGTACGGCCTGTACAGCGAGAGGGGCCTGTACGGCCTGTA
CGGCCTGTA CGGCCTGTA CA GCGA GAGGGGCCTGTA CGGCCTGTA CGGCCTGTA CGGCCTGT
A CA GCGA GA GGGA CA TCGTGA TGA CCCA GTCCCCAA GCTCCCTGGCCGTGTCTGTGGGA GA
GCGGGTGACAATCTCCTGTAAGTCTAGCCAGTCTCTGCTGAACTCCTCTAATCAGAAGAACT
ACCTGGCCTGGTATCAGCAGAAGCCCGGCCAGGCCCCTAAGCTGCTGATCTACTTCGCCTCT
ACCAGGGAGAGCGGAGTGCCAGACAGATTCTCTGGCAGCGGCTCCGGCACAGACTTCACCC
TGA CAA TCA GCTCCGTGCA GGCA GAGGA CGTGGCA GA TTA CTA TTGCCAGCA GCA CTA CGA
TA CCCCCTA TA CA TTTGGCGGCGGCA CCAA GCTGGA GA TCAA G
Nucleotide sequence of 19F3H1: (SEQ ID NO: 92)
CA GGTGCA GCTGCA GCA GTCTGGA GCA GA GGTGGTGAA GCCAGGAGCCTCTA TGAA GA TGA
GCTGTAA GGCCA GCGGCTA CTCCTTCA CCGGCTA TA CAA TGAA CTGGGTGAA GCA GGCCCA
CGGCCA GAA TCTGGA GTGGA TCGGCCTGA TCAA CCCTTA CAA TGCCGGCA CCTCTTA TAA CC
A GAA GTTTCA GGGCAA GGCCA CCCTGA CA GTGGA CAA GTCCA CCTCTA CAGCCTA CA TGGA
GCTGA GCTCCCTGCGGA GCGA GGA TA CA GCCGTGTA CTA TTGCGCCCGGTCCGA GTA CA GAT
A TGGCGGCGACTACTTTGA TTA TTGGGGCCA GGGCA CCA CA CTGA CCGTGTCTA GC
Amino acid sequence of 19F3H1: (SEQ ID
NO: 93)
QVQLQQSGAEVVKPGA SMKMSCKA SGYSFTGYTMNWVKQA HGQNLEWIGLINPYNA GT SYN
QKFQGKA TLTVDKS T S TA YMEL S SLRSEDTA VYYCA RSEYRYGGDYFDYWGQGT TLTV S S
92
CA 03176321 2022- 10- 20
IP190597
Nucleotide sequence of 19F3L1: (SEQ ID NO: 94)
GA CA TCGTGA TGA CCCA GTCCCCA A GCTCCCTGGCA A TGTCTGTGGGA GA GA GGGTGA CA A
TGTCCTGTAA GTCTAGCCAGTCTCTGCTGAA CTCCTCTA A TCA GA A GAA CTACCTGGCCTGG
TA TCA GCA GA A GCCCGGCCA GGCCCCTA A GCTGCTGGTGTA CTTTGCCTCTA CCAGGGA GAG
CGGAGTGCCAGACAGATTCTCTGGCAGCGGCTCCGGCACAGACTTCACCCTGACAATCAGCT
CCGTGCAGGCAGAGGACCTGGCAGATTATTTCTGCCAGCAGCACTACGATACCCCCTATACA
TTTGGCGGCGGCACCAAGCTGGAGATCAAG
Amino acid sequence of 19F3L1: (SEQ ID NO: 95)
DIVMTQ SPS SLA MS VGERVTMS CKS S QSLLNS SNQKNYLA WYQQKP GQA PKLLVYFA STRESG
VPDRFSGSGSGTDFTLTIS SVQAEDLADYFCQQHYDTPYTFGGGTKLEIK
Amino acid of 19F3L2 light chain (full length) (SEQ ID NO: 96, with non-
variable region sequences
underlined)
DIVMTQ SP S S LA VSVGERVTIS CKS SQSLLNSSNQKNYLAWYQQKPGQAPKLLIYFA STRESGVP
DRFSGSGSGTDFTLTISSVQAEDVADYYCQQHYDTPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQL
KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE
VTHQGLSSPVTKSFNRGEC
Amino acid sequence of 19F3H2 heavy chain variable region with CDR sequences
underlined:
(SEQ ID NO: 97)
QVQLVQ S GA EVVKPGA SVKVSCKA SGYSFTGYTMNWVRQAPGQNLEWIGLINPYNA GT SYNQ
KF QGKVTLTVDKS T S TA YMEL S S LRSED TA VYYCA RS EYRYGGDYFDYWGQGT TLTVS S
Amino acid sequence of 19F3L2 heavy chain variable region with CDR sequences
underlined:
(SEQ ID NO: 98)
DIVMTQ SP S S LA VSVGERVTIS CKS SQSLLNSSNQKNYLAWYQQKPGQAPKLLIYFA STRESGVP
DRFSGSGSGTDFTLTISSVQAEDVADYYCQQHYDTPYTFGGGTKLEIK
Amino acid sequence of 19F3L3 heavy chain variable region with CDR sequences
underlined:
(SEQ ID NO: 99)
DIVMTQ SP S S LA VSVGERVTIS CKS SQSLLNSSNQKNYLAWYQQKPGQAPKLLIYFA STRESGVP
DRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYDTPYTFGGGTKLEIK
Nucleotide sequence of 19F3L2 light chain (full length) (SEQ ID NO: 100)
GACATCGTGATGACCCAGTCCCCAAGCTCCCTGGCCGTGTCTGTGGGAGAGCGGGTGACAATCTCCTGTA
AGTCTAGCCAGTCTCTGCTGAACTCCTCTAATCAGAAGAACTACCTGGCCTGGTATCAGCAGAAGCCCGG
CCAGGCCCCTAAGCTGCTGATCTACTTCGCCTCTACCAGGGAGAGCGGAGTGCCAGACAGATTCTCTGGC
AGCGGCTCCGGCACAGACTTCACCCTGACAATCAGCTCCGTGCAGGCAGAGGACGTGGCAGATTACTATT
GCCAGCAGCACTACGATACCCCCTATACATTTGGCGGCGGCACCAAGCTGGAGATCAAGCGTACGGTGGC
AGCCCCATCTGTCTTCATTTTTCCCCCTAGTGACGAGCAGCTGAAATCCGGAACAGCCTCTGTGGTCTGT
CTGCTGAACAATTTCTACCCTCGCGAAGCCAAGGTGCAGTGGAAAGTCGATAACGCTCTGCAGAGTGGCA
ATTCACAGGAGAGCGTGACTGAACAGGACTCCAAGGATTCTACCTATAGTCTGAGCTCCACTCTGACCCT
GTCCAAAGCAGATTACGAAAAGCACAAAGTGTATGCCTGTGAGGTCACCCACCAGGGGCTGAGTTCTCCA
GTCACCAAATCCTTCAACAGAGGCGAATGT
93
CA 03176321 2022- 10- 20
